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Abstract 
This quantitative study assessed the association of the design methods used for early 
phase oncology studies (adaptive versus traditional) and the outcome of late stage clinical 
trials. Differences by cancer type and by drug classification were also assessed. The 
theoretical and conceptual frameworks used were the general systems theory and the 
design and evaluation of complex interventions, respectively. Units of analysis were 
individual oncology studies in the ClinicalTrials.gov database and Bayesian logistic 
modeling was applied on a random sample of 381 studies initiated after November 1999 
to December 2016. When assessing study design and outcome, there were lower odds of 
a positive outcome when adaptive methods were used though this association was not 
statistically significant (OR [95% highest posterior density (HPD)]:0.66 [0.20, 1.21]). 
Among the different drug types, using adaptive compared to traditional methods was 
associated with significantly higher odds of a positive outcome for taxanes, OR: 2.75, 
95% HPD: 1.01, 5.16) and other, OR: 3.23, 95% HPD: 1.58, 5.46) but no association 
among studies of monoclonal antibodies or protein kinase inhibitors.  Also, there were no 
significant associations between early phase study design and outcome in late phase 
studies by cancer type (lung, breast, other). Further research should be conducted using 
all completed oncology clinical trials in the database to more precisely determine the 
relationship between adaptive study design in early phase oncology studies and outcomes 
in late stage studies. Social change can occur through increased uptake of adaptive design 
methods, which may lead to more efficacious cancer treatment options. 
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Chapter 1: Introduction to the Study 
Cancer rates are increasing in the United States and across the globe (Centers for 
Disease Control and Prevention, 2017). While cancer has been reported as a single 
disease with a single treatment, cancer can originate from a variety of locations in the 
body (National Cancer Institute, 2015), be diagnosed at multiple stages of development 
and have varying genetic markers that can impact treatment response, leading to the 
complexity in treatment development. However, treatment development and approval 
have stagnated over the years, while costs have increased and the success rates of clinical 
trials have reduced (Berry, 2012; Christopher S. Coffey, 2017; Prasad & Mailankody, 
2017). Oncology treatments have poor regulatory approval rates with failure rates as high 
as 66% in results reported from 2003 to 2010 (Berry, 2011). In comparison to other 
diseases, oncology studies have been reported to have the lowest likelihood of regulatory 
approval (Biotechnology Innovation Organization [BIO], 2016). With more than 30% of 
the treatments in development, approval for oncology drugs progressing through the 
clinical trial process was reported to be only 5.1%. The Food and Drug Administration 
has also been trying to encourage innovation to improve treatment approval through the 
Critical Path Initiative (U.S. Food and Drug Administration, 2004). Improved and 
innovative design methods adopted in clinical trials should lead to improved and 
increased treatment options for patients with cancer. 
In this chapter, I provide background information with respect to the burden of 
cancer and the need for innovative methods given the limited success in cancer clinical 
trials with increasing costs. I also present an overview of the purpose of the study, the 
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study design, research questions and hypotheses. The components of the study are 
constructed in the theoretical foundation and conceptual framework. The assumptions of 
the study, analysis methods, as well as limitations, are also discussed. 
Background 
In comparison to other modalities, cancer clinical trials are the most frequent in 
clinical research, however, the success rate is quite poor (Biotechnology Innovation 
Organization [BIO], 2016). While the costs of oncology research continue to increase, 
researchers have noted that the oncology clinical trial failure rate is 66% for clinical trials 
reported from 2003 to 2010 (Berry, 2012; S.-C. Chow & Chang, 2008). Traditional 
methods developed in the 1940s continue to be used in the majority of early phase 
oncology studies (Hansen, Graham, Pond, & Siu, 2014). However, the efficacy 
associated with these traditional methods need to be assessed in order to improve 
treatment options for oncology patients. In addition, the traditional methods continue to 
be utilized even when the underlying monotonic dose-toxicity assumption is not held 
(Hansen et al., 2014).The limitations of the traditional methods need to be addressed as 
patients are exposed to sub-therapeutic doses due to the conservative methods 
(Butterfield, Disis, Khleif, Balwit, & Marincola, 2010; Hansen et al., 2014; Le Tourneau, 
2009). The traditional methods also identify the appropriate dose level only 30% of the 
time (Rogatko et al., 2007). With these limitations on traditional design options, 
innovative methods need to be developed, adopted and assessed.  
Barker et al. (2009) found that adaptive methods that use predictive models of 
therapeutic responses can be utilized to increase the speed of drug development. 
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Specifically, the I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic 
Response With Imaging and moLecular Analysis 2) study includes innovative, adaptive 
design methods and is supported by academic and regulatory bodies, has been prolific 
with respect to drug development in breast cancer. The study includes continuous 
enrollment and rolling treatment assessments, both of which can be aspects of adaptive 
design and integrates learning across and within included treatment components, but does 
not compare study design methods and outcomes. Researchers noted the need for 
innovative methods and improved study design in clinical trials to increase safety, 
efficacy and quality of drug development leading to improved treatment patient profiles 
and treatment options for patients. In order to improve study outcomes, innovative 
methods need to be better understood and utilized (Parekh et al., 2015). 
Berry (2012) noted that the costs associated with oncology drug development 
have been increasing over the years without the corresponding trial success, thus the need 
for improved and innovative studies. With the increasing cost of treatment development, 
more efficient and innovative study design methods need to be developed, assessed and 
utilized (Berry, 2012). However, barriers related to the ease of the innovative methods 
adoption have been identified regardless of the methods assets. The researchers noted the 
current barriers related to infrastructure, such as access to software, method 
understanding, knowledge and ease of use have led to a lower rate of adaptive design 
method adoption (Kairalla, Coffey, Thomann, & Muller, 2012; J. Quinlan, Gaydos, 
Maca, & Krams, 2010). More studies need to be conducted comparing operating 
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characteristics of traditional versus adaptive methods as well as adaptive design case 
studies to increase the knowledge base.  
Berry (2011) noted that both traditional and adaptive methods could be utilized in 
different settings using the strengths of each of the design methods. However, researchers 
need to understand the strengths and the operational characteristics of each method so 
they can be appropriately utilized when developing a clinical trial. Hatfield et al. (2016) 
assessed adaptive studies reported in CT.gov (2000 to 2014) and found that there has 
been a threefold increase in adaptive method use particularly in oncology of the study 
period. However, studies including adaptive design methods are approximately 25% (143 
of 573 studies) of the total number of clinical trials of phase II or higher. Recently 
researchers also used the ClinicalTrials.gov (CT.gov) database and found that 
approximately 20% of oncology clinical trials of phase II or higher used adaptive 
methods (Bothwell et al., 2018). While Bothwell et al. (2018) noted that 49% of the 
adaptive studies were deemed effective, neither Hatfield et al. (2016) nor Bothwell et al. 
(2018) compared the adaptive versus traditional designed clinical trial results or their 
downstream impact. More studies need to be conducted comparing operating 
characteristics of traditional versus adaptive studies. 
Problem Statement 
Cancer is the second leading cause of death for men and women in the United 
States (Centers for Disease Control and Prevention, 2017). The most commonly 
diagnosed cancers in 2017 were projected to be breast, lung, bronchus, prostate and colon 
cancer (National Cancer Institute, 2017). More than 1.6 million cases of cancer were 
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estimated to be diagnosed in the United States and over a half million individuals were 
reported to have died from the disease in 2016 (National Cancer Institute, 2017). With the 
increasing demands of cancer, treatment and care of cancer patients in the United States, 
effective treatments need to be developed through clinical trials with therapeutic dose 
levels and targeted populations.  
Using carefully planned safety, efficacy assessments, targeted cancer type and 
appropriate biomarker risk factors, effective treatments can be identified using efficient 
accrual and study design methods (Barker et al., 2009). Oncology treatment 
characteristics, specifically drug classifications including related biomarkers and tumor 
types, must be considered in study development (Barabási, Gulbahce, & Loscalzo, 2011; 
U. S. Food and Drug Administration, n.d.-b; Siddiqui & Rajkumar, 2012). Cancers are 
diverse in their location of development; treatment paths and biomarkers aid in learning 
about the target population and possible future standard of care (Ardies, 2014; Barker et 
al., 2009; Berry, 2012). Studies using biomarkers have also been shown to have increased 
likelihood of approval in comparison to studies without (Biotechnology Innovation 
Organization [BIO], 2016). Strengthening study design components should be addressed 
for improved clinical research. Unreliable surrogate endpoints (Fleming, 1996), 
limitations in disease response measurement techniques (Weber, 2009), inadequate 
animal models (Ananthakrishnan et al., 2017; Butterfield et al., 2010), bias introduced 
with historical comparators as well as limited clinical biomarkers (Butterfield et al., 2010; 
U. S. Food and Drug Administration, 2017) may lead to false positive or false negative 
results in early phase studies. Innovative study design methods that overcome some of 
  
6 
these limitations also need to be developed, assessed and adopted in early phase oncology 
studies.  
Within the field of oncology clinical trials, while early phase studies (Phase 0, 1 
and 2) show promising results, more than 66% of late stage (Phase 3) studies reported 
from 2003 to 2010 do not lead to statistical significance or positive results for the patient 
population (Berry, 2012). Additional research was conducted assessing the success of 
oncology studies from 2006 to 2015 and similar results were reported (Biotechnology 
Innovation Organization [BIO], 2016). The low rate of success in clinical research is a 
concern that needs to be addressed. 
Often traditional or fixed design methods are being used in early phase studies, as 
the methods have been historically accepted. The most common design method used in 
early phase clinical trials is the 3+3 design (Hansen et al., 2014). The 3+3 design enrolls 
patients by group (usually groups of three) with respect to protocol defined treatment 
dose level. In the initial set of patients, the individuals are assessed for dose limiting 
toxicities (DLT) in the DLT assessment period (e.g. one cycle of treatment). If fewer than 
a prespecified number of patients experience a DLT, the next set of patients are enrolled 
at the next highest dose. If the toxicity rate is higher than the planned rate, then additional 
patients may be enrolled at the same dose level or the study is stopped and the maximum 
tolerated dose (MTD) is the previous dose level. Unfortunately, initial doses in the 3+3 
design are often conservative as they usually start at a subclinical dose (Hansen et al., 
2014; Kairalla et al., 2012). Researchers have also found that these traditional design 
methods are often used in clinical trials with inappropriate drug classifications such as 
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molecularly targeted agents (MTAs). In traditional methods, there is an assumed dose-
toxicity monotonic relationship; as the dose increases, the probability of toxicity also 
increases (Ananthakrishnan et al., 2017). For MTAs and other recent oncology drugs that 
have been recently developed, the monotonic dose-toxicity relationship is not satisfied. In 
MTAs, toxicities are related to the accumulation of the drug, thus the assumed treatment-
dose relationship within a specific cycle is not satisfied (Hansen et al., 2014; Kairalla et 
al., 2012). However, the traditional methods continue to be utilized, in spite of the 
underlying assumptions of the design method not being met. 
Even with the research indicating the ineffectiveness of traditional methods, the 
adoption of innovative methods has been sporadic due to limited knowledge, time and 
infrastructure needs not consistently being met (Christopher S. Coffey, 2017; Hansen et 
al., 2014; Hatfield et al., 2016; Kairalla et al., 2012). Regulatory bodies including the 
Food and Drug Administration (FDA), Committee for Medicinal Products for Human 
Use (CHMP) to name a few, have noted the stagnation of innovation, a reduction in 
effective treatment identification, as well as challenges and opportunities in diseases such 
as cancer (Committee for Medicinal Products for Human Use [CHMP], 2006; U. S. Food 
and Drug Administration, 2006, n.d.-a). Innovative methods such as adaptive study 
designs may improve treatment development in oncology clinical research. Adaptive 
design clinical trials are defined to be studies with preplanned opportunities for 
modifications for one or more aspects included in the study design (Committee for 
Medicinal Products for Human Use [CHMP], 2006; U. S. Food and Drug Administration, 
2010). Design elements that can be modified within the adaptive plan include the sample 
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size, treatment assignment, population, dose level, among other study characteristics 
(Bornkamp et al., 2007). Any initial study characteristic can be adapted during a study, as 
long as the adaption is prespecified. Oncology clinical trial design is an area in need of 
innovative method development, assessment and adoption, including adaptive methods. 
Purpose of the Study 
Although adaptive methods have been available since the 1970s and with 
appropriate computational support and knowledge since the 1990s (A. R. Brown et al., 
2016), researchers have been reluctant to utilize the methods. However, uptake of 
adaptive methods has been assertively accepted at some research institutions likely due to 
awareness, training, education, feasibility, expertise, computational and programming 
availability (S. C. Chow, Corey, & Lin, 2012; J. A. Quinlan & Krams, 2006; Viele & 
McGlothlin, 2017). Appropriate communication with the study team to increase comfort 
understanding and communication with regulatory bodies is also critical in the study 
development process (Kairalla et al., 2012; Viele & McGlothlin, 2017). Awareness, 
training and expertise need to be improved to allow for increased innovative methods.  
In this quantitative study, I investigated the potential association of early phase 
study design research outcomes that utilize traditional versus adaptive methods on late 
stage results in oncology clinical trials. By comparing traditional versus adaptive methods 
and the downstream clinical trial outcome, the benefits related to late stage study success 
may be determined. Success in late stage studies may lead to improved patient treatment 
options. As drug development and approval are based on cancer type, study phase and 
treatment classifications, these potential effect modifiers were included in the analysis 
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model (Barabási et al., 2011; U. S. Food and Drug Administration, n.d.-b; Siddiqui & 
Rajkumar, 2012), to determine whether the association between use of adaptive versus 
traditional methods (e.g.. 3+3) in early phase studies and the results outcome of the late 
stage study, was found to be different in subgroups defined according to levels of these 
factors. 
Analysis Model 
The variables included in the analysis model are defined in Table 1. The analysis 
model is: Late phase study results (favorable/unfavorable) = early phase design 
(adaptive/traditional) + early phase + experimental treatment classification + type of 
cancer + drug classification + duration between early and late phase studies (months) + 
study funding 
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Table 1 
Analysis Model Variables, Description and Possible Values 
Variable Definition CT.gov format Values 
Dependent 
variable 
   
Outcome of 
late-phase 
study 
Late-stage study results. Results are 
based on the original study operation 
characteristics and statistical 
significance.  
 
The statistical outcome of the late-phase 
study (favorable = experimental 
treatment statistically better than 
comparison; equivalent = experiment and 
comparison are statistically equivalent; 
nonfavorable = experimental treatment is 
found to be better than the comparison 
treatment). For studies that are not driven 
by statistical significance, clinical 
relevance (effect size) will determine the 
outcome classification. 
Free text, 
categorized for 
variable values. 
Endpoint: favorable, 
equivalent, unfavorable 
 
Independent 
variables 
   
Design 
classification 
 
Adaptive studies are defined to be 
clinical study designs that use 
accumulated information or data of the 
study to modify aspects of the study as it 
continues (Christopher S Coffey et al., 
2012). The adaptations in these designs 
are predefined. Traditional studies will 
be defined to be nonadaptive studies. 
 
Free text Adaptive, traditional 
Early phase Phase of early-stage study Same as value Categorical: 0, 1a, 1b, 1, 
2, 2a, 2b 
 
Experimental 
treatment 
classification 
Interventional treatment classification Categorical Drug 
Device 
Biological/vaccine, 
Procedure/surgery 
Radiation 
Combination 
Other 
 
Cancer type The cancer site or type that is being 
researched in the early- and late-stage 
study. 
Same as reported 
value 
Breast, lung, pancreatic, 
bone etc. 
(continued)
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Table 1 Continued 
Variable Definition CT.gov format Values 
Experimental 
drug 
classification 
WHO drug classification 
 
Categorical 
variable 
EGFR or VEGF 
inhibitors, monoclonal 
antibody, proteasome 
inhibitor, 
immunotherapy, etc.  
Duration 
between 
studies 
(months) 
 
Time between the end of the early-stage 
study and the beginning of the late-stage 
study 
Dates; will take 
difference for 
duration 
Time in months 
Study funding 
source  
Who is sponsoring the early-stage 
study? 
Reported funding 
(grant, other) 
Private or public 
funding  
Sensitivity 
analysis 
variables 
   
    
Type of 
endpoint 
Type of endpoint used. Any endpoint 
that is not overall survival such as 
progression free survival or objective 
response will be considered a surrogate. 
 
Free text Surrogate, clinical, or 
both 
Sample size The number of patients planned to be 
enrolled in the early-phase studies. 
 
Numeric Numeric 
Biomarker Did the study include a biomarker as an 
endpoint in the study or not? 
 
Categorical Binomial (yes, no) 
Adaptive 
classification 
For those studies that are adaptive, are 
they are classified as well-understood or 
less well-understood designs as defined 
by the FDA (2010). 
Categorical Well-understood, less 
well-understood, not 
adaptive 
 
Research Questions and Hypotheses 
RQ1: To what extent is there an association between design methods used for 
early phase oncology studies (adaptive versus traditional) and the outcome of late stage 
clinical trials? 
Ho1: There is no association between early phase oncology studies (adaptive 
versus traditional) and the late stage clinical trial outcomes. 
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Ha1: There is an association between early phase oncology studies (adaptive 
versus traditional) and the late stage clinical trial outcomes. 
RQ2: In specific cancer types (e.g., breast cancer, lung cancer etc.), what is the 
association between the design methods used for early phase oncology studies (adaptive 
versus traditional) and the outcome of the late stage clinical trials? 
Ho2: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does not differ between 
specific cancer types. 
Ha2: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials differs between specific 
cancer types. 
RQ3: How does the treatment classification modify the relationship between the 
design methods used for early phase oncology studies (adaptive versus traditional) and 
the outcome of the late stage clinical trials? 
Ho3: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does not differ between 
specific treatment classification (e.g. surgical, adjuvant, radiation, etc.).  
Ha3: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does differ between 
specific treatment classification (e.g. surgical, adjuvant, radiation, etc.). 
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Theoretical Framework 
The general systems theory developed by Kenneth Boulding in 1956 is the study 
of systems and how the interrelated and interdependent parts interact with each other 
(Boulding, 1956). The underlying assumption of the theory is that as one component of 
the system changes, this change will affect other components of the system. In this study, 
I assessed the association between early phase design methods, specifically traditional 
versus adaptive and how the design method is associated with the late stage study 
outcome (favorable, equivalent or nonfavorable). The underlying hypothesis was that 
when adaptive methods are used, increased and high-quality information is gained and 
used in the design of late stage studies, leading to improved results in late stage studies. 
Adaptive methods may not be as effective in every type of cancer, treatment 
classification, or experimental drug classification, but the impact of the study 
characteristics will be assessed when adaptive methods are used versus not. Within 
systems theory, changing or altering one component can impact another (Boulding, 
1956). The change of one study characteristic and the impact in other components is 
evident in clinical trial development.  
For example, changing one classification, say target population, will likely impact 
the type of treatment as well as drug classification, as cancer is a diverse number of 
diseases with a variety of treatment paths due to a variety of cell proliferation paths 
(Ardies, 2014; Lonial & Nooka, 2016; National Cancer Institute, 2015). In addition, 
using the same treatment in different target populations can impact the outcome of the 
study, as not all treatments are effective in every population. The hypothesis of this study 
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was that the component design method (adaptive or traditional) is associated with the 
downstream results of the later stage study. The hypothesis is based on the idea that using 
the innovative design methods, the late stage outcomes may be improved due to the 
quality and increased quantity of gained information. 
Conceptual Framework 
The Framework for Design and Evaluation of Complex Interventions (DECI) 
provides guidance on the integrated evaluation of complex interventions (Campbell et al., 
2000). The framework was developed to assess complex research interventions with 
various interconnected components. The information gained within a study as well as the 
study results are integrated within and across every phase in an iterative fashion 
(Campbell et al., 2000). Due to the complexity of treatment and interventions in clinical 
trials, learning across and within studies is critical to continue learning and improving 
clinical trial outcome as well as assessing unexplored endpoints (Geifman & Butte, 
2016). Further learning in and across studies with positive as well as negative findings 
may aid in advancing the field (Butterfield et al., 2010). 
Researchers have noted the need for well-designed and implemented studies as 
well as the evaluation of the studies through meta-analysis and long-term programs, 
utilizing the DECI methods of systematic review and iterative information gain (Grol, 
2001). Due to the sequential nature of oncology clinical research, an iterative approach 
should be consistently applied and interventions re-examined as needed information is 
collected (Campbell et al., 2000; Geifman & Butte, 2016). Thus, the early phase studies 
are not just providing guidance for late stage studies but are also providing input in 
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combination with other research used for other ongoing and future early phase studies 
that use the treatment or directed toward the indication. Using adaptive methods may lead 
to better designed studies and improved target population information that can be used 
for integration into other studies. In addition, systematic reviews of clinical trials and 
health related data are critical for improving methods as well as treatment for the targeted 
populations (Griffiths, Lindenmeyer, Powell, Lowe, & Thorogood, 2006; Grol, 2001; 
Kroeze, Werkman, & Brug, 2006; Steinert et al., 2006). This research included oncology 
studies randomly identified in the ClinicalTrials.gov database. The focus of this research 
was to quantitatively assess adaptive methods versus traditional methods used in 
oncology clinical trials. I used early clinical study research, which is used to develop late 
stage clinical studies. The interrelationship of the phase of treatment is a key component 
of DECI. 
Nature of the Study 
In this study, I used a quantitative methods approach. Because I assessed the 
association of early phase design methods and the downstream influence on late stage 
clinical trials results in oncology numerically, a quantitative assessment of the outcome 
was appropriate. I extracted data from the National Institutes of Health (NIH) Clinical 
Trials registry and results database (National Institute of Health, 2017a). If not provided, 
the experimental treatment was classified as needed using World Health Organization 
(WHO) drug classification (World Health Organization Collaboration Centre, n.d.).  
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The phase of the study, the date associated with the results (to ensure sequential 
studies) and the design methods (adaptive versus not) were utilized in the model to 
determine if there is a relationship between early stage design methods and late stage 
results in oncology studies. Experimental treatment classification, drug classification and 
type of cancer were also included in the model. While there are strengths of traditional 
and adaptive methods, researchers need to be able to utilize the appropriate methods, 
such as drug classification and type of cancer as well as understand the operating 
characteristics of the study methods (Berry, 2011). This study may aid in identifying 
oncology populations and treatment classifications where adaptive methods are more 
effective leading to improved study outcomes in late stage studies. Additional sensitivity 
analyses were conducted including whether the study included a surrogate endpoint or 
not, planned sample size as well as adaptive method classification. 
The data used for this analysis was extracted from the National Institutes of 
Health Clinical Trials registry and results database (National Institute of Health, 2018). 
The database was established in 2008 where study characteristics and results are required 
for specific clinical trials, including oncology studies. Data in the database includes 
aggregate participant information, baseline characteristics, primary outcome measures, 
statistical analyses as well as adverse event information. Individual studies were the units 
of analysis. Participant level information is not available in this database, thus was not 
used as the unit of analysis for this research study. WHO Drug classification as well as 
study classification (adaptive versus traditional) was added to the dataset based on 
treatment and study design information provided in the database or using supplemental 
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publications. As researcher contact was included in the database, study characteristics or 
results that were unclear were clarified through contacting the study researchers. 
Operational Definitions of Terms 
Adaptive or traditional studies: Clinical study designs that used accumulated 
information or data of the study to modify aspects of the study as it continues 
(Christopher S Coffey et al., 2012). The adjustments are predefined. This definition is 
consistent with the Pharmaceutical Research and Manufacturers of America (PhRMA) 
Working Group (Gallo et al., 2006). Traditional studies were studies that were not 
classified as adaptive.  
Cancer type: The sub-population of cancer or cancers treated in the reported 
study.  
Duration between studies: The difference between the date reported in the 
ClinicalTrial.gov database for the late stage and early stage study. Only positive time 
differences (and their associated studies) were included in the analysis indicating that the 
early stage study occurred before the late stage study.  
Experimental drug classification: Based on the World Health Organization 
(WHO) Drug Dictionary which was based on the Anatomical-Therapeutic-Chemical 
(ATC) classification system (World Health Organization Collaboration Centre, n.d.). For 
example, anti-cancer drug bevacizumab was classified as “Monoclonal antibodies 
(L01XC)” within “Other antineoplastic agents (L01X)” using the WHO drug 
classification dictionary.  
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Experimental treatment classification: Based on the study treatment defined in the 
study such as surgery and radiation to name a few.  
Late stage results: Definitions of late stage study outcome followed a similar 
definition utilized by Rasmussen et al. (2009). Late stage studies that were considered 
favorable were those reported in the clinicaltrials.gov database that were statistically 
significant based on original study criteria (e.g. p < 0.05) in favor of the experimental 
treatment (Rasmussen, Lee, & Bero, 2009). For studies that were not driven by statistical 
significance, clinical relevance (effect size) was used for the outcome classification. 
Unfavorable studies were defined to be studies where the results were statistically 
significant in favor of the comparator treatment or did not meet the definition of 
favorable. For this study, equivalent studies were defined to be studies where the results 
were deemed equivalent (favorable). 
Less well-understood adaptive methods: methods that are not frequently utilized 
thus there are less experiences with the methods (U. S. Food and Drug Administration, 
2010).  
Phase of the study: The clinical research phase reported by the study researchers. 
Early phase studies were defined to be phase 0, I, Ia, Ib, II or any combination (phase 2 or 
less). Late phase studies were defined to be phase III, IIIa, IIIb or phase IV studies (phase 
3 or higher). 
Study funding source: The primary source of funding of the research. An example 
of private funding would be a pharmaceutical company. An example of public funding 
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would be the National Cancer Institute. A study could have multiple funding sources and 
were included in the model to reflect the multiple sources.  
Type of endpoint: Sensitivity analyses included the type of endpoint of the early 
phase study. Overall survival is considered the gold standard in oncology studies. Any 
other endpoint was considered a surrogate for this analysis. If the endpoint was a measure 
of the disease or a laboratory abnormality, the endpoint was classified as clinical. 
Endpoints were classified as clinical, surrogate or both. Similar definitions of endpoints 
were used by the researchers, Bothwell et al. (2018).  
Well-understood adaptive designs: These designs are frequently used adaptive 
methods and include group sequential methods with unblinded interim data review and 
controlled Type I error. 
Assumptions 
For this study, I assumed that the clinicaltrials.gov database was representative of 
all oncology clinical trials. Applicable studies that were initiated after January 1, 2000 
should be registered within the database according to federal guidelines for United States 
enrolling studies (National Institute of Health, 2017b). All phases of studies with one or 
more sites in the United States and all intervention types should be included in the 
database. Applicable studies include FDA-regulated drugs, biological products or devices 
that meet one of the following conditions: trial conducted under an FDA investigational 
new drug application or investigational device exemption or the trial involves a drug, 
biologic or device that is manufactured in the United States or its territories and is 
exported for research. Registering within a public database before patients begin 
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enrolling is also required by most medical journals in order for articles to be accepted for 
publication (International Committee of Medical Journal Editors, 2017). In addition, 
National Institutes of Health (NIH) supported trials are also encouraged to register. The 
Declaration of Helsinki also states that all research studies involving human subjects 
must be registered and researchers have the responsibility to make the research publicly 
available (National Institute of Health, 2015b). As a result of these regulations, 
requirements and guidance, the clinicaltrials.gov database registry and results should be 
representative of oncology clinical research studies.  
This study also assumed that the results database was up to date with results that 
were included in the analysis and that there was no systematic pattern (Missing at 
random, missing completely at random) of delayed reporting and the study outcome. 
Based on the requirements for the Clinical Trials database, most studies have one year 
from primary endpoint completion (National Institute of Health, 2017a) to have their 
results entered in the database, which should result in a reduction in delayed results 
reporting. 
Scope and Delimitations 
The scope of this study assessed the association with early phase oncology design 
methods and the outcome of late stage outcome results. This study was delimited to 
include oncology studies and human interventions only. In addition, this research only 
included late stage studies that have results in the Clinical Trials database. The research 
was delimited to include phase, experimental treatment classification, cancer type, 
experimental drug classification, duration between studies and study funding source. Late 
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stage studies were also not included as independent variables in the model even though 
they likely provide information for target population and effective treatment 
identification for future studies.  
Limitations 
For any research conducted, limitations of the research may be identified. A 
limitation of this research was the possible accuracy of the database. Researchers have 
noted that errors have been found in the Clinical Trials database (Hartung et al., 2014). 
However systematic errors have not been identified related to the type of study such as 
adaptive designs versus traditional studies. Early database entry studies likely have a 
higher error rate (Hartung et al., 2014). As such 10% of the studies’ results included in 
the analysis were confirmed through publication review as well as reaching out to the 
researchers to confirm the data reported in the clinical trials database.  
While a programmatic identification of adaptive studies was utilized, with limited 
structure related to adaptive classification and the frequency of free text utilization within 
the Clinical Trials database, likely not all adaptive studies were identified. In addition, 
with the ambiguity and changing classification of adaptive design methods, this likely 
lead to a limitation of systematically identifying adaptive studies. Other researchers have 
also identified the database structure and adaptive design definition a limitation in 
utilization of the Clinical Trials database (Bothwell et al., 2018; Hatfield et al., 2016). 
Once again, 10% of studies included in this analysis were manually reviewed and design 
classifications were compared to publication results or confirmed with Clinical Trials 
study researchers.  
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Significance 
Researchers have noted that drug development and approval has been stagnating 
even though the cost of development has been increasing (Barker et al., 2009; Berry, 
2011, 2012; U. S. Food and Drug Administration, n.d.-a). The results of this study may 
aid in the understanding of the influence of adaptive methods and late stage clinical trial 
outcomes as well as the influence of treatment populations and drug classification. While 
adaptive design methods in clinical trials have increased in use threefold since 2001, the 
methods are used in less than 30% of studies (A. R. Brown et al., 2016; Hatfield et al., 
2016). This research project may inform researchers on the importance of innovative 
study design methods due to the current low success rate of studies using traditional 
methods (Hansen et al., 2014; Rogatko et al., 2007). This study may increase knowledge 
related to adaptive methods and scenarios where the methods seem to provide improved 
results, reducing the barriers related to method utilization (Hatfield et al., 2016; Kairalla 
et al., 2012; Rogatko et al., 2007). The results of this study may aid in reducing the 
identified barriers with respect to the acceptance and utilization of adaptive design 
methods in oncology clinical trials. Inference from this study may inform researchers on 
the need for infrastructure, education and knowledge with respect to adaptive study 
designs leading to increased usage of the methods. Ultimately, this study may contribute 
to the identification of more effective treatments, as well as earlier identification of 
ineffective treatments, thus improving oncology patient care and outcome. The efficacy 
of adaptive methods are often shown in simulations, but have not been assessed in real 
clinical trials (Ananthakrishnan et al., 2017). Advances in oncology research are needed 
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and innovative methods such as adaptive design may improve treatment options for 
cancer patients. 
Summary 
With the increasing rate of cancer diagnosis, effective treatments need to be 
identified and developed. Further, patients need to be limited to the exposure of 
ineffective or sub-therapeutic treatment doses. Also with the increasing cost of drug 
development and stagnate results, innovative designs are needed to be assessed and 
adopted. While traditional methods are most frequently utilized in early phase studies, 
adaptive methods should be adopted as simulations studies indicate that these methods 
are more efficient at identifying effective and ineffective treatments. This study assessed 
the association of early phase design methods and late stage outcome results in oncology 
clinical trials. 
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Chapter 2: Literature Review 
Often traditional or fixed methods are being used in early phase studies, as the 
methods have been historically accepted. The most common design method used in early 
phase clinical trials is the 3+3 design with utilization rates as high as 98% (Hansen et al., 
2014; Rogatko et al., 2007). The traditional 3+3 design was introduced in the 1940s as a 
method to systematically escalate dose and monitor treatment safety (Bauer & Einfalt, 
2006; Dimairo, Boote, Julious, Nicholl, & Todd, 2015; Hatfield et al., 2016). The 3+3 
design enrolls patients by group (usually in groups of three) and protocol defined 
treatment dose level. At each treatment level, dose limiting toxicities (DLT) are assessed 
and based on the rate of toxicities, the dose level is increased, additional patients are 
accrued at the same dose, or the study ends. Treatment is assigned based on prespecified 
rules and dose escalation can only occur if there are fewer DLTs than planned or 
expected (Le Tourneau, 2009).  
Initial doses in the 3+3 design tend to be conservative due to subclinical dose 
levels (Hansen et al., 2014; Kairalla et al., 2012). In addition, the traditional methods 
have been shown to identify the appropriate dose or treatment approximately 30% of the 
time (Simon et al., 1997). In traditional methods, there is an assumed dose-toxicity 
monotonic relationship; as the dose increases, the probability of toxicity also increases. 
However, the assumption may not always be met in newer treatments as toxicity may be 
related to dose accumulation rather than dose intensity (Ananthakrishnan et al., 2017; 
Butterfield et al., 2010; Kairalla et al., 2012). 
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Traditional methods continue to be used in oncology studies even though newer, 
more innovative, efficient and effective design methods are available. Innovative 
methods such as adaptive methods use information learned from within the studies in 
order to adjust the underlying assumptions within the study itself. A guidance document 
for adaptive trials was released in 2010 by the Center for Drug Evaluation and Research 
(CDER), the Center for Biologics Evaluation and Research (CBER) and the Food and 
Drug Administration (FDA). As a result of these initiatives, adaptive approaches have 
been increasingly utilized. Through grants and educational opportunities, researchers 
have attempted to overcome the slow acceptance and utilization of innovative methods. 
(Berry, 2012). 
This chapter includes a discussion of the issues related to clinical research 
development in oncology and the decision making related to study design methods. Many 
factors impact the development of cancer treatment, including the type of cancer, subtype 
and related risk factors. All of these components are considered when developing a 
clinical trial and addressed during study design selection and development. Clinical trials 
go through prespecified phases of development, of which the earlier studies lead to the 
underlying assumptions and operating characteristics that are used in the late stage 
studies. While there may be advantages to traditional and adaptive methods, 
disadvantages of both design methods will be discussed. With the adoption of innovative 
design methods, there are barriers that also need to be identified, addressed and overcome 
with reasonable solutions. With the dismal results of oncology clinical trials with a failure 
rate as high as 66% for studies reported from 2003 to 2010 (Berry, 2011), all aspects of 
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research should be considered for improvement, including composite and innovative 
endpoints. The aim of conducting this research was to find the potential influence of early 
phase study design research outcomes that utilize traditional versus adaptive methods on 
late stage results in oncology clinical trials. 
Literature Search Strategy 
In this literature review, I will provide a summary of current adaptive design 
research as well as the state of clinical research in oncology. Oncology related summaries 
specifically treatment, risk factors and trial results were included in the review. Search 
terms included: adaptive design oncology trial success, clinical trial phase of treatment, 
clinical trial, oncology risk factors, oncology, surrogate endpoints, 3+3 and adaptive 
clinical trials. Specific design methods were also used in the search strategy such as 
Continual Reassessment Method (CRM), Sample Size Reassessment (SSR) and 
accelerated 3+3. Leaders in the field of adaptive methods including Peter Bauer, Scott 
and Don Berry, Christopher Coffey and Y.H. Joshua Chen were also included in my 
literature search. 
I searched for references within all Walden databases including ProQuest and 
PubMed databases as well as Google Scholar. Peer reviewed technical articles published 
after January 1, 2009, were included in my search, unless the work was considered 
critical and referenced frequently by authors or sources. Clinical trial results published 
after January 1, 2013, were also included in my search. Seminal publications, regulatory 
guidelines and authoritative websites were included in the literature review. Additional 
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publications were identified, by reviewing the citations within identified articles. 
Abstracts, methods and possible relevant target populations were also reviewed. 
Theoretical Foundation 
The quantitative theoretical framework is a set of constructs that indicate the 
relationship between the variables included in the study hypothesis or hypotheses 
(Creswell & Creswell, 2014). The variable relationship and how they interact with each 
other can be described using a theoretical framework, where the theory will provide a 
possible explanation of the relation of the variables of interest. The system could be 
considered an organism where there are a finite number of interacting variables rather 
than isolated parts. The general systems theory developed by Kenneth Boulding in 1956 
is the study of systems and how the interrelated and interdependent parts interact with 
each other (Boulding, 1956). The underlying assumption of the theory is that as one 
component of the system changes, this change will affect other components of the 
system.  
Systems theory has been used in a variety of fields including social work (Forder; 
Warren, 1998), career development (Patton & McMahon, 1999, 2006), business 
management (Chikere & Nwoka, 2015; Mele, Pels, & Polese, 2010), language learning 
(De Bot, Lowie, & Verspoor, 2007; X. Huang, Acero, Hon, & Reddy, 2001) family 
systems therapy (Becvar & Becvar, 2017; Knudson-Martin, 1994) and community 
development (Lerner, Almerigi, Theokas, & Lerner, 2005). In each field of research, the 
theory provides structure as to how the components impact each other and when one 
aspect changes, the change can impact the entire system. For example, in social work, 
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systems theory can help explain an individual’s behavior based on a multitude of 
interrelated components. An individual’s family life, community, social structure and the 
individual themselves all impact how the individual may respond to a situation. In the 
research that uses systems theory, there is a system of components that are interrelated 
and dependent on each other. An alteration of one component can positively or negatively 
change the other components of the system. 
In this study, I assessed the association between early phase design methods, 
specifically traditional versus adaptive and how the design method was associated with 
the late stage study outcome (positive, equivalent or negative). The underlying hypothesis 
is that when adaptive methods are used, increased and high-quality information is gained, 
leading to improved results in late stage studies. Adaptive methods may not be as 
effective in every type of cancer, treatment classification, or experimental drug 
classification, but the impact of the study characteristics were assessed when adaptive 
methods are used versus not.  
Within systems theory, changing or altering one component can impact another 
(Boulding, 1956). This characteristic is true in clinical trial development. For example, 
changing one classification, such as target population, will likely impact the type of 
treatment as well as drug classification, as cancer is a diverse number of diseases with a 
variety of treatment paths due to a variety of cell proliferation paths (Ardies, 2014; Lonial 
& Nooka, 2016; National Cancer Institute, 2015). 
Within systems theory there is a feedback loop, which is a process in which the 
system uses information generated within the system (Boulding, 1956). The process of 
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clinical research development uses early phase study results to provide input on future 
study development. Further, late stage study results can also impact future early phase 
studies, as the experimental treatment may be assessed in other indications or cancer 
subgroups. However, the time between the studies also needs to be considered. For 
example, studies conducted 20 years ago may have minimal impact on current studies 
due to changes in standard of care as well as differences in the target population over 
time. In contrast, an ongoing study may not be impacted by a study that has just reached 
completion due to the proximity in time. However, the ongoing study may be 
dramatically impacted by the recently released results due to shared study characteristics, 
such as similar treatment or targeted population. If the results of the recent study are 
negative and the shared study characteristic is target population and treatment, the 
ongoing study may be stopped for ethical reasons. This aspect of systems theory is 
considered to be self-correcting as the components of the system react from information 
provided by other components of the system(Boulding, 1956).  
The hypothesis of this study was that the component design method (adaptive or 
traditional) may be associated with the downstream results of the later stage study. The 
hypothesis was based on the idea that by using the innovative design methods, the late 
stage outcomes may be improved due to the quality and increased quantity of the 
information gained. Figure 1 provides an outline of systems theory and how the theory 
relates to clinical research and the assessment of adaptive and traditional methods. 
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Figure 1. Systems theory applied to oncology clinical trial research and the association of 
early stage design methods to late stage outcome results. 
Conceptual Framework 
Researchers have noted that while randomized clinical trials (RCTs) are the gold 
standard of treatment development, outcomes of complex interventions need to be 
systematically, interactively developed and assessed (Campbell et al., 2000). The 
Framework for Design and Evaluation of Complex Interventions (DECI) provides 
guidance on the integrated evaluation of complex interventions (Campbell et al., 2000). 
The framework was developed to assess complex research interventions with various 
interconnected components. The information gained within a study as well as the study 
results are integrated within and across every phase in an iterative fashion (Campbell et 
al., 2000). Due to the complexity of treatment and interventions in clinical trials, learning 
across and within studies is critical to continue learning and improving clinical trial 
Phase	0 Study	Outcome Phase	3 
Phase	1 
Phase	4 
Phase	2 
Biomarker	Use Design	Method	(Adaptive,	Traditional) Duration	between	Studies 
Drug	Classification Treatment	Classification 
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outcome as well as assessing unexplored endpoints (Geifman & Butte, 2016). Further 
learning in and across studies with positive and negative findings will aid in advancing 
the field (Butterfield et al., 2010). 
The variables included in the model indicate the complexities related to the 
diverse interventions, specifically the treatment of cancer in clinical trials. Important 
factors to consider in oncology clinical research include target population, treatment and 
drug classification, study sponsor as well as the duration between early and late stage 
study. The phases of my study (early phase: 0, I and II) are indicated in Figure 1 and 
Figure 2. The late stage studies (phase III and IV) are also included in Figure 2. The 
variables in the model and the quality of the results are being used to improve the study 
development of quality late stage studies. In each of the research questions and associated 
hypotheses for this study, I assessed whether the quality of the results and information 
was improved if adaptive methods are used.  
While the authors of the conceptual framework indicate that a single intervention 
such as a drug is not complex (Campbell et al., 2000)., I assessed multiple drugs for 
multiple indications, which is indeed complex One factor that makes oncology research 
complex is in multicountry studies, standard of care (SOC) and best supportive care may 
not be standard across locations thus integrated analyses should be carefully conducted 
(Organisation for Economic Co-operation and Development [OECD], 2013). In addition, 
standard of care is likely to change over time or during a study; thus, differences with 
respect to historical controls in randomized studies may be attributed to the SOC rather 
than the treatment of interest, leading to biased estimates or improvements not 
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attributable to the experiment treatment (Viele et al., 2014). While these variables were 
not included in my analysis, researchers should consider these aspects when integrating 
results of clinical research. 
Complex interventions that utilize the DECI framework are provided by the 
authors, such as service delivery and organization for stroke units as well as community 
based programs to prevent heart disease (Campbell et al., 2000). Researchers have noted 
the need for well-designed and implemented studies, as well as the evaluation of the 
studies through meta-analysis and long-term programs, utilizing the DECI methods of 
systematic review and iterative information gain (Grol, 2001). Researchers using adaptive 
methods may lead to better designed studies leading to improved information that can be 
used for integration into other studies. In addition, systematic reviews of clinical trials 
and health related data are critical for improving methods as well as treatment for the 
targeted populations (Griffiths et al., 2006; Grol, 2001; Kroeze et al., 2006; Steinert et al., 
2006). This research included oncology studies randomly identified in the 
ClinicalTrials.gov database. A stratified random identification of studies was conducted 
to allow for increased power for sub-population comparisons. The study was developed 
to assess the association of quantitative methods related to study design and the results of 
late stage studies.  
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Figure 2. The iterative process of the Framework for Design and Evaluation of Complex 
Interventions (DECI). Reprinted with permission from “Framework for design and 
evaluation of complex interventions to improve health” by M. Campbell et al., BMJ: 
British Medical Journal, 321(7262), 694-696. 
Due to the sequential nature of oncology clinical research, an iterative approach 
should be consistently applied and interventions re-examined as needed information is 
collected (Campbell et al., 2000; Geifman & Butte, 2016). Thus, the early phase studies 
are not just providing guidance for late stage studies, but are also providing input for 
other ongoing and future early phase studies, that use the same treatment or is directed 
toward the cancer indication. The development of clinical research is iterative to ensure 
that new information is captured and utilized for the development of early and late stage 
studies. My research does not include the qualitative methods that are mentioned in 
DECI, however, the qualitative component of the research could be conducted in the 
future and is included in the future research section of my dissertation. Consideration of a 
survey to assess the resistance to the adoption of adaptive methods and sent to oncology 
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researchers could be conducted in the future to assess qualitative aspects related to 
adaptive methods. 
The focus of this research was to quantitatively assess adaptive methods versus 
traditional methods used in oncology clinical trials. My dissertation used early study 
research, which is then used to develop late stage studies. The interrelationship of the 
phase of treatment is a key component of DECI. 
Literature Review 
Cancer – Epidemiology and Heterogeneity 
Cancer is defined to be the uncontrolled division of cells that may lead to the 
invasion of nearby or distal tissue (National Cancer Institute, n.d.). Cancer is the second 
leading cause of death for men and women in the United States (Centers for Disease 
Control and Prevention, 2017), with the most commonly diagnosed cancers in 2017 
projected to be breast cancer, lung and bronchus cancer, prostate cancer and colon cancer 
(National Cancer Institute, 2017). More than 1.6 million cases of cancer were estimated 
to be diagnosed in the United States and over a half million individuals were reported to 
have died from the disease in 2016 (National Cancer Institute, 2017). While deaths from 
cancer have decreased, diagnoses of some cancers have stabilized and the incidence of 
most cancers continue to increase (National Cancer Institute, 2017). Further, individuals 
that are living beyond the cancer diagnosis are expected to continue to rise (National 
Cancer Institute, 2017), thus the need for treatment development that reduce the long 
term impact on quality of life. Even with reductions in smoking rates, cancer rates 
continue to increase in the United States as well as across the globe as a result of a variety 
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of factors including an aging population (Centers for Disease Control and Prevention, 
2017). With the increasing demands on healthcare and treatment related to cancer in the 
United States, effective and safe treatments need to be developed and identified through 
clinical trials with therapeutic dose levels and targeted populations.  
Cancer can originate in the bone, internal organs, central nervous system, blood or 
bone marrow and can spread through the body via the blood or lymphatic system 
(National Cancer Institute, n.d.). Due to the variety of origination of disease as well as the 
stage of disease at diagnosis and the risk factors associated with the individual diagnosed 
such as age, environment, or genetic biomarker, cancer is not one disease; but a 
constellation of diseases (Ardies, 2014; Lonial & Nooka, 2016). As a result of different 
cell proliferation mechanisms related to cancer, drug treatment has to be developed to 
address the cancer disease diversity. Due to the diversity of the diseases as well as 
treatment development, target populations also need to be considered and identified in 
protocol development. 
Though cancer has been reported to be a single disease, cancer is actually a 
complex set of diseases (Butterfield et al., 2010). Often the reporting of the cure for 
cancer is reported in the news. However, researchers know that cancer is not a single 
disease, but a classification of hundreds of diseases (American Association for Cancer 
Research [AACR], n.d.). Cancer is a multitude of diseases with different mechanisms 
leading to cell proliferation (National Cancer Institute, 2015). As a result, treatment for 
each cancer likely needs a different plan of action to address the complexity of the 
diseases (National Cancer Institute, 2015).  
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The same cancer in children, young adults versus elderly may have different 
characteristics leading to different modes of treatment (Boissel et al., 2003; DeAngelo et 
al., 2015). Within a single type of cancer, there are a variety of disease characteristics that 
lead to variation of treatment effectiveness and response (Carey, Winer, Viale, Cameron, 
& Gianni, 2010; Kim, Ueda, Naka, & Enomoto, 2012; Lonial & Nooka, 2016). Due to 
the disease variation, to date, there is no single treatment that has been found to be 
effective on all cancers. A treatment found to be effective in breast cancer, may not be 
effective in pancreatic cancer. A treatment found to be effective in HER2+ breast cancer, 
may be ineffective in HER2- breast cancer. Due to the complexity of a single type of 
cancer as well as the diversity of treatment response across cancers, a variety of treatment 
options need to be developed and assessed (Barker et al., 2009). Cancer treatments need 
to continue to be developed in an effective manner to determine efficacy and safety, as 
well as identify the appropriate target population based on the treatment mechanisms and 
patient characteristics. Adaptive studies can aid in identifying target populations early in 
the process (Scher, Nasso, Rubin, & Simon, 2011). The complexity of cancer needs to be 
addressed in study design. 
Cancer Risk Factors 
As the disease itself varies, there is some consistency in risk factors related to 
cancer such as diet and obesity (Burger et al., 2013; Kampman, Vrieling, van 
Duijnhoven, & Winkels, 2012; Ross, 2010; Vera-Ramirez et al., 2013), tobacco use 
(Burger et al., 2013; Gillison et al., 2012; Maxwell et al., 2010; Warren & Cummings, 
2013) and exposure to other chemicals such as asbestos or particle pollutions (Berman & 
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Crump, 2008; O'Reilly, Mclaughlin, Beckett, & Sime, 2007). Occupational exposures to 
chemicals and particulates have been found to be related to increasing cancer rates 
(Alavanja, Hoppin, & Kamel, 2004; Burger et al., 2013; Purdue, Hoppin, Blair, 
Dosemeci, & Alavanja, 2007). While an individual’s behavior can impact their risk of 
cancer, increasing age (A. Y. Chen, Jemal, & Ward, 2009; Jemal, Siegel, Xu, & Ward, 
2010), as well as hormones and genetics (Burger et al., 2013; Vera-Ramirez et al., 2013) 
have been shown to increase the risk of certain cancers. Biomarkers can also indicate the 
aggressiveness of the cancer (Gravdal, Halvorsen, Haukaas, & Akslen, 2007; Lim et al., 
2009), as well as the appropriate treatment path that the medical staff and patient should 
take for their disease (Barker et al., 2009).  
Researchers continue to identify mechanisms of cancers in order to develop 
treatments to impact the disease path (Barker et al., 2009; Gravdal et al., 2007). Further, 
researchers also address risk factors in clinical trials through stratification factors, in an 
attempt to balance the population across the randomized treatments as well as classify 
patient baseline characteristics (Barker et al., 2009). This classification allows for better 
understanding of the patient population as well as the assessment of the impact of the 
treatments on a specific population. Once again, the complexity of cancer is addressed 
through the identification of risk factors and the appropriate treatment is prescribed. 
Treatment Development and Funding for Cancer 
All cancer clinical trial development, progresses through a similar process called 
phases of treatment development, regardless of the cancer type. After the pre-clinical 
assessments including animal models, there are, in general, three phases of studies that 
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are conducted on human beings; phase I, phase II and phase III. Each phase of 
development has specific and detailed objectives as well as sample size and provides 
information for later phase studies or studies in other target populations. 
Phase I studies are conducted on humans where the objective is to assess safety as 
well as determine the maximum tolerated dose (National Institute of Health, 2016). 
Unlike other nononcologic indications, cancer patients rather than healthy volunteers are 
often used in phase I cancer clinical trials due to limited treatment options for those with 
the disease (Salzberg, 2012). Phase I cancer trial sample sizes have increased over the 
years, with the median number of patients (Q1, Q3) estimated to be approximately 55 
patients (36, 80) (Dahlberg, Shapiro, Clark, & Johnson, 2014). The objective of cancer 
phase I studies is to assess safety and pharmacokinetics (the study of the movement of the 
drug in the body) and pharmacodynamics (the study of the effects and mechanisms of 
drug action) related to the specified dose can also be assessed (National Institute of 
Health, 2016). Efficacy is also usually estimated with a short time framed endpoint, such 
as treatment response.  
Phase II studies are usually larger than Phase I studies with a continued focus on 
safety, however, efficacy is more formally assessed. (National Institute of Health, 2016). 
There may be multiple efficacy endpoints, of which, the primary is likely a short-termed 
endpoint once again. While the sample size can vary, sample sizes of less than 100 
patients are most common (J.-H. Huang et al., 2015). These studies also may be 
randomized, but not necessarily comparative. 
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Phase III studies tend to be larger in sample size allowing for the comparison of 
multiple treatments (National Institute of Health, 2016). Phase III studies are often 
randomized studies to allow for the comparison of the new treatment versus the standard 
treatment of which the sample size can vary from approximately 100 patients to 
thousands (Salzberg, 2012). Phase III studies tend to focus on efficacy and likely includes 
other secondary objectives including safety and patient reported outcomes while 
controlling operational characteristics such as Type I and Type II errors (Ioannidis, Hozo, 
& Djulbegovic, 2013; National Institute of Health, 2016). Combined studies, otherwise 
known as seamless designs such as phase I/II or phase II/III can also be developed with 
the objective of attaining the study answers and treatment development more quickly 
(National Institute of Health, 2016).  
Phase 0 and Phase IV are less common studies that can be incorporated into 
treatment development. Phase 0 studies are considered exploratory and allow for the 
exploration of agents to be assessed in phase I studies (Doroshow & Parchment, 2008). 
Phase IV studies are also less common, but are conducted to assess long term safety and 
efficacy after treatment regulatory approval (National Institute of Health, 2016). 
Information gained at each phase of treatment provides guidance for the related studies 
conducted subsequently. Multiple phases can also be combined in a single study. 
The report developed through BioMedTracker tracks the clinical development and 
regulatory history of investigational drugs. The researchers found the probability of 
success going from phase I to phase II is 63.2% and from phase II to phase III is 30.7% 
for all modalities (Biotechnology Innovation Organization [BIO], 2016). While the 
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researchers assessed fourteen different modalities, oncology had the lowest likelihood of 
regulatory approval starting from phase I studies with 5.1%, even though almost 31% of 
the drug development program transitions were in oncology. Innovative methods need to 
be adopted in oncology to combat low clinical research success. 
The cost and time consumption of oncology drug development has increased over 
the years, without a corresponding treatment success rate (Berry, 2012; S.-C. Chow & 
Chang, 2008; Christopher S. Coffey, 2017). Researchers assessed the cost of ten recently 
approved cancer drugs and the median cost for development of the single drug was 
approximately $648 million (Prasad & Mailankody, 2017). The time from development 
to approval is also lengthy with medians ranging from 58.8 to 93.5 months dependent on 
submission types (Jardim, Schwaederle, Hong, & Kurzrock, 2016). With the multi-phase 
process, time and finance invested in clinical trials as well as the impact to current and 
future patients, improved methods including study design may lead to a higher success 
rates. 
Adaptive and Traditional Design Characteristics 
Ambiguity of adaptive design definition. Each phase of oncology studies has a 
specific objective or objectives likely related to efficacy or safety. In phase I studies, the 
focus tends to be safety, specifically determining the maximum tolerated dose (MTD) 
that will be used for the recommended phase two dose (RP2D). While confirmatory 
adaptive designs have been researched for over 25 years (Bauer, Bretz, Dragalin, König, 
& Wassmer, 2016), the methods became more widely known and utilized five years later 
(Bauer et al., 2016). During this time period however, the definition of adaptive designs 
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has been less clear. The ambiguity of the definition of adaptive designs has been a 
significant barrier with respect to the method adoption (Christopher S Coffey et al., 2012; 
Dimairo et al., 2015). 
Definition of adaptive design. Adaptive designs, for the purpose of this analysis 
is clinical study designs that use accumulated information (data) of the study, to modify 
aspects of the study as the study continues (Christopher S Coffey et al., 2012). Examples 
of adjustment include underlying assumptions include the mean, variance or the sample 
size. The most common adaptations in oncology include stopping for futility or safety, 
adjustments in dosing or treatment assignments, identifying a target population with an 
effective treatment response or seamless multi-phase studies (Berry, 2012; Reitsma, 
2015). In adaptive designs, the adjustments to the study are pre-defined, thus are not 
made on an ad hoc basis. The changes are not the result of inadequate planning, but are 
preplanned components of the design (Kairalla et al., 2012).The adaptations can be 
utilized on a single endpoint or a combination of endpoints that have been identified as 
predictive in nature (Berry, 2012). Studies can also be adapted on nonprimary endpoints 
such as survival post progression (SPP), progression free survival (PFS) for a study with 
overall survival (OS) as the primary endpoint (Berry, 2012). The adaptive design 
definition used for this study is consistent with the Pharmaceutical Research and 
Manufacturers of America (PhRMA) Working Group (Gallo et al., 2006) 
Traditional design characteristics. For this study, traditional study designs will 
be prespecified rule-based designs such as the 3+3 design. The 3+3 design methods were 
introduced in the 1940s as a method to systematically escalate the treatment dose while 
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monitoring the safety of the treatment (Hansen et al., 2014). In general, the initial set up 
patients (usually three) are enrolled at a subclinical treatment dose and are assessed for 
dose limiting toxicities (DLT) for the first cycle of treatment. If less than a prespecified 
number of patients experience a DLT, the next set of patients, usually three patients, are 
enrolled at the next highest dose. If once again, a prespecified number of patients 
experience a dose limiting toxicity, then an additional set up patients, usually three, are 
enrolled at the current dose. Dose escalation can only occur if there are less DLTs than 
expected. The dose escalation is often predefined and frequently based on Fibonacci 
series so that dose increments are smaller at higher doses. 
Limitation of traditional design. However, the maximum tolerated dose (MTD) 
may not be attained due to a lack of adverse events defined as DLTs being reported. For 
treatments that are cytostatic rather than cytotoxic, the toxicity rate may increase based 
on drug accumulation rather than the incremental increase of the dose level. Researchers 
have noted that the MTD is only identified in approximately 30% of trials 
(Ananthakrishnan et al., 2017; Hansen et al., 2014). By design, there are excessive dose 
escalations and pauses between steps, leading to longer study duration (Le Tourneau, 
2009). Due to the escalation design and the conservative methods, a high proportion of 
patients may be treated at suboptimal effective dose levels. Unfortunately, the 3+3 
methods have not been statistically supported and have been shown to be ineffective 
through simulations and oncology clinical results (Christopher S Coffey et al., 2012; U. 
S. Food and Drug Administration, 2011; Hansen et al., 2014). As such, the recommended 
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treatment dose may be erroneous impacting the treatment of future patients. Improved 
study design methods need to be developed and adopted. 
Traditional versus adaptive design assumptions and operating 
characteristics. When using the 3+3 design, there are underlying assumptions based on 
the dose and the response. Specifically, the 3+3 design assumes that as the dose 
increases, the related toxicities also increase. Researchers have noted that even in drugs 
where the assumed dose-toxicity relationship does not hold, the design methods are still 
utilized 60% of the time (Hansen et al., 2014). These methods are often used in early 
stage oncology studies and perhaps may be the result of the poor treatment approval with 
a failure rate as high as 66% in results reported from 2003 to 2010 (Berry, 2011). 
Researchers recommend including simulations of dose-toxicity operational characteristics 
when fixed designs are being used. This may improve understanding of assumptions 
related to the traditional design method use (Bornkamp et al., 2007).  
Using traditional methods, the success of the study is dependent on the original 
underlying assumptions. Unlike traditional methods, adaptive designs provide a path to 
address uncertainty during the original design phase. Adaptive design methods use 
information already accumulated on the trial allowing flexibility, which may increase the 
success of the study. In traditional designs, underlying assumptions are often based on 
historical studies which are used to determine the sample size (C. H. Brown et al., 2009). 
However, when using adaptive methods, the initial design may utilize the same 
assumptions as the traditional design, but during the study, the underlying assumptions 
can be assessed in a blinded or unblinded fashion and adjustments to the design can be 
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made. For example, when using the adaptive methods such as sample size re-estimation, 
the underlying assumptions such as endpoint variability can be assessed during an interim 
review and the sample size adjusted accordingly (Chuang-Stein anderson, Gallo, & 
Collins, 2006). 
Reluctance to adopt adaptive methods. With the introduction of the adaptive 
methods and the indication that they are more effective than traditional methods (Berry, 
2011; Christopher S. Coffey, 2017), researchers unfortunately continue to be reluctant to 
adopt the methods. Reasons for reluctance are diverse but include a lack of understanding 
of the methods (Kairalla et al., 2012), lack of education and access to case studies 
(Dimairo et al., 2015), increased time for planning (Collinson et al., 2012; Dimairo et al., 
2015) and the need for additional software and infrastructure (Kairalla et al., 2012). 
Researchers also note the limitations of access to off the shelf packages identified as 
another barrier of adoption (Bornkamp et al., 2007). When the adaptive methods are 
used, they are most commonly used in phase II studies (Hatfield et al., 2016). Expansion 
of their use should be considered for phase I studies. 
Researchers have found that studies initiated from 1991 to 2006, 98% were 
designed using traditional methods (Rogatko et al., 2007). In studies initiated between the 
years 2000 and 2014, while adaptive methods have been increasing in use, a dramatic 
uptake in use of methods was not observed (Hatfield et al., 2016). During this time 
period, in all clinical trials, only 143 of 573 (25.0% of total studies identified) nonphase I 
adaptive studies were included in their analysis (Hatfield et al., 2016). Barriers related to 
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the adoption of adaptive methods need to continue to be identified and addressed for 
future as well as current researchers. 
Advantages and disadvantages of traditional methods. While traditional 
methods have limitations, there are some advantages to the methods as well. Researchers 
have noted that the traditional design methods are simple to use and understand leading to 
their continued use (Ananthakrishnan et al., 2017; Buoen, Bjerrum, & Thomsen, 2005; 
Le Tourneau, 2009). While the methods may not have clinical success or statistical 
justification (Bornkamp et al., 2007; Buoen et al., 2005), the methods are commonly used 
due to preference, habit and conservative dosing (Buoen et al., 2005). Based on the 
dismal success rate of studies in oncology, however, a shift in the clinical research 
development process needs to occur.  
The failure rate of oncology studies, submitted between 2003 to 2010 was 66% 
(Berry, 2011), indicating that innovative methods need to be developed and adopted in 
clinical trials (Berry, 2012; S.-C. Chow & Chang, 2008; Christopher S. Coffey, 2017). 
The traditional methods also fail to identify the maximum tolerated dose in 
approximately 30% of trials (Ananthakrishnan et al., 2017), which may be due to the 
methods being underpowered (Butterfield et al., 2010). In addition, the dose response 
curves are usually not estimable due to the low sample size and the study being 
underpowered once again (Kairalla et al., 2012). The traditional methods also have a 
conservative dosing trend, thus excessive patients tend to receive sub-therapeutic doses 
without the opportunity for intra-patient dose escalation (Ananthakrishnan et al., 2017; 
Butterfield et al., 2010; Hansen et al., 2014; Le Tourneau, 2009). Historical controls for 
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parallel designs also have limitation due to population and standard of care changes over 
time that cannot be controlled within study parameters (C. H. Brown et al., 2009). While 
traditional methods are simple to understand, their inaccuracies and limitations are a 
detriment to current and future patients that need to be addressed. 
Often in early stage traditional studies, clinical decisions to continue the treatment 
development are based on toxicity alone (phase I) or rapid response efficacy data (phase 
II) (Butterfield et al., 2010). Decisions to continue or stop the study are based on the 
current dose only and not the accumulative information of all treatment doses assessed in 
the study (C. H. Brown et al., 2009). The accumulation of information in the adaptive 
trial, guide the flexibility of the design, which may contribute to the success of the 
studies. The additional information gained is leveraged for improved study operating 
characteristics (Kairalla et al., 2012; Reitsma, 2015). Unlike traditional designs, adaptive 
studies can use historical data for the initial design, but also use the current study 
information for adjustments to the underlying assumptions. 
Early phase studies assess the treatment for safety as well as identify the 
maximum tolerated dose. Efficacy is more thoroughly assessed in later stage studies. 
However, due to the early phase traditional designs being underpowered (Butterfield et 
al., 2010), the accuracy of these studies can lead to negative downstream impact on 
subsequent trials. Further, when the differences in the DLT rates are smaller, the accuracy 
of the MTD selection is reduced when traditional methods are utilized (Ananthakrishnan 
et al., 2017). Often when adaptive methods are utilized, simulations are conducted so the 
entire clinical team can understand the operating characteristics under a variety of 
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assumptions. However, when traditional methods are used, trial performance on 
identifying the correct dose are often not assessed (Bornkamp et al., 2007) but should be.  
Traditional designs use underlying assumptions from previous studies in order to 
develop the current study. While this may be the case for both traditional and adaptive 
designs, adaptive designs can modify prespecified characteristic(s) in order to reflect the 
cumulative data. While traditional studies depend on theoretical underlying behavior 
often assumed from other studies, adaptive studies rely heavily on simulations to increase 
knowledge of trial behavior, study characteristics and possible risks (Reitsma, 2015; 
Viele & McGlothlin, 2017). More simulations should be conducted when using 
traditional methods so that there is a greater understanding of study characteristics and 
possible outcomes as well (Reitsma, 2015; Viele & McGlothlin, 2017). If operating 
characteristics were assessed when traditional methods were being utilized, perhaps 
increased knowledge with respect to their limitations would be more understood.  
Additional knowledge with respect to the underlying assumptions of traditional 
methods, specifically the 3+3 also need to be addressed. The intended use of the 3+3 
assumes that toxicities increase with the dose. However, for biologics this assumption 
may not be valid (Le Tourneau, 2009). This trend was also found even in drug 
classifications of molecularly targeted agents (MTA) of which more novel design 
methods should be utilized due to the assumption related to dose and adverse events. In 
MTAs, toxicities tend to develop as the result of accumulation of drug rather than the 
actual dose. However, 60% of those studies utilized conventional 3+3 design methods 
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(Hansen et al., 2014). Once again, traditional operating characteristics as well as 
underlying assumptions should be assessed before the methods are adopted. 
Need for innovation. Learning from other studies is critical, but also using the 
maximum information from within a study is also important. Using updated design 
methods, such as adaptive designs, which are designed to use accumulative information 
within the study, rather than the single dose level data used in traditional designs. The 
adaptive methods have been shown to be more effective at identifying the appropriate 
treatment (Berry, 2011; Christopher S. Coffey, 2017; Christopher S Coffey et al., 2012; 
Dimairo et al., 2015; Hatfield et al., 2016), as well as more efficient with respect to 
precision, power and controlling the type I error level (Bornkamp et al., 2007). 
Researchers have also noted that adaptive design methods can more quickly identify 
ineffective treatments reducing the risk to the targeted patient population (Christopher S 
Coffey et al., 2012).  
When using traditional methods, one underlying assumption is that as the dose 
increases, so does the rate of toxicities. However, in newer noncytotoxic drugs such as 
molecular targeted agents and cytostatic drugs, the dose toxicity relation is not 
maintained. As such, researchers need to understand the characteristics of their study 
drug as well as the adopted design methods (Kairalla et al., 2012). Researchers also need 
to understand the benefit of using cumulative information within a study rather than only 
information from a specific dose. As a result of using the accumulated data, adaptive 
trials tend to eliminate failures earlier (Reitsma, 2015), thus patients are less likely to be 
exposed to sub-therapeutic doses. Once again, the positive impact of adaptive methods 
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can be seen in the early phase I-SPY2 (Investigation of Serial Studies to Predict Your 
Therapeutic Response with Imaging and moLecular Analysis 2) early phase program. 
The I-SPY2 studies that successfully proceed out of the phase I study, are expected to 
have an 85% success rates in confirmatory studies (Reitsma, 2015). The Critical Path 
Initiative was established to improve and facilitate innovative discussions (U. S. Food 
and Drug Administration, 2004). Biostatistics and associated methods are one of the 
initiatives with the objective of improving tools, methods and study designs for drug 
development. The studies, I-SPY1 and I-SPY2 were the result of these initiatives (Parekh 
et al., 2015). Innovative methods knowledge needs to continue to expand so that the 
methods are utilized appropriately and more frequently in clinical research. 
While learning from within a study is critical (S.-C. Chow & Chang, 2008; 
Kairalla et al., 2012), learning from outside the study is also important. Researchers have 
suggested that access to analysis code and output will help with the design of future 
studies (Dimairo et al., 2015). The I-SPY2 adaptive study is an excellent example of 
shared data and results from study to study as well as shared information within the study 
(Barker et al., 2009). Shared information of positive and negative results should occur 
more frequently to help improve oncology research results and reducing the chances of 
repeating failed research. The ClinicalTrials.gov database is a good start to assess shared 
design and initial results, however, improved data structure is necessary that reduces free 
text fields and collects additional response data as researchers have suggested (Hatfield et 
al., 2016). Unfortunately, the registry databases have not completely eliminated 
publication bias related to study results (Dwan, Gamble, Williamson, & Kirkham, 2013). 
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Sharing of information across studies, regardless of outcome will be a critical step 
forward in improving the results of clinical trials thus increasing effective treatment 
options for patients. 
Both traditional and adaptive methods can be utilized in adaptive clinical trials 
using strengths of each method. However, researchers need to understand the strengths 
and operational characteristics of each method so they can be appropriately utilized 
(Berry, 2011). Researchers have noted that while adaptive designs may not always be 
recommended (Korn & Freidlin, 2017), when studies include more than two treatment 
arms, adaptive methods do appear to be more efficient and effective (Berry, 2011). Of the 
drugs that were approved by the FDA from 1992-2008, 21 of 25 (84%) used the 3+3, 
where more than 50% had 6 or more dose levels (Le Tourneau, 2009). Early phase 
oncology studies are ideal for adaptive design methods as the determination of the 
maximum tolerated dose is critical, thus the emphasis on controlling type II errors (false 
positive) need to be considered (Kairalla et al., 2012). Type II errors can result in future 
patients receiving too low a dose, which likely will impact efficacy in the target 
population. When there are a high number of dose levels in determining the MTD within 
a study, researchers once again need to assess innovative design methods and determine 
if the methods are more appropriate for their study. 
Challenges for adaptive design adoption and overcoming barriers. Before 
adaptive design methods are adopted, a clear definition of adaptive methods needs to be 
established and understood. This has been a significant barrier related to the acceptance 
and adoption of adaptive designs (Christopher S Coffey & Kairalla, 2008; Christopher S 
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Coffey et al., 2012; Dimairo et al., 2015). Researchers have noted the ambiguity of what 
adaptive design really means and has been and continues to be a barrier for adaptive 
design method adoption for more than ten years. Even reviewing the ClinicalTrials.gov 
database, a traditional dose escalation design used the term ‘adaptive’ to describe the 
study design, though based on publication of the results, the study appears to be a 
traditional design (NCT02281786) (Panza et al., 2016). Further, unplanned changes to the 
design is not considered adaptive designs (Dimairo et al., 2015). Poor planning, leading 
to the need in the design change is not an adaptive design. 
Regulatory considerations related to innovative designs such as adaptive methods, 
need to be addressed before design methods are utilized. Researchers need to increase 
their knowledge in understanding the innovative methods as well as the regulatory 
requirements associated with adaptive methods (S. C. Chow et al., 2012; Christopher S 
Coffey & Kairalla, 2008; Dimairo et al., 2015). Knowledge associated with regulatory 
requirements appear to be growing, thus regulatory concerns are becoming a reduced 
limitation (Dimairo et al., 2015). Recommendations from regulatory agencies include 
satisfactory simulations reflecting multiple situations (Viele, 2017), in order to assess the 
operating characteristics of the design and the behavior under a variety of situations 
(Miller et al., 2017). Researchers have also published case studies, best practices and 
adaptive design characteristics to increase knowledge as well as increase and improve 
adaptive design use, particularly for less well-understood adaptive designs (Table 2) (He 
et al., 2017; Miller et al., 2017). Regulatory bodies as well as researchers have voiced 
their concerns on controlling alpha spending, confidence interval and p-value estimates 
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due to the study adaptations (S.-C. Chow & Chang, 2008), thus study operating 
characteristics should be reviewed by the clinical study team to increase understanding as 
well as provide documentation to regulatory bodies. The challenge recommendations for 
adaptive designs are similar to study conduct using traditional designs, though statistical 
methods may have been more recently developed. Like traditional methods, appropriate 
statistical analyses methods need to be utilized to reflect the study design to reduce the 
introduction of bias as well as control for type I and type II errors (He et al., 2016). 
Traditional methods have been used since at least the 1940s (Hansen et al., 2014) 
and are relatively simple to develop and utilize. There has however been an increase in 
use of adaptive methods over time (Bauer & Einfalt, 2006; Hatfield et al., 2016). To use 
adaptive methods, an increased amount of time for planning is needed and must be 
considered in the timelines prior to initiation of development (Dimairo et al., 2015; 
Kairalla et al., 2012). Funding of this additional time also needs to be considered and 
addressed prior to study development (Kairalla et al., 2012). Aside from additional initial 
funds, infrastructure including programming and randomization must be in place during 
protocol development (Christopher S. Coffey, 2017; Christopher S Coffey & Kairalla, 
2008; Hansen et al., 2014; Hatfield et al., 2016). While the FDA has allocated funds to 
facilitate innovative discussions and method utilization, in order to access the funds, the 
study must be designed before you can apply for the grant (Christopher S. Coffey, 2017).  
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Table 2 
Best Practices and Challenges for Less Well-Understood Adaptive Designs 
Challenge Best practice 
Type I error control Appropriate statistical techniques related to planned 
analysis as suggested by Wassmer & Dragalin (Wassmer 
& Dragalin, 2015), Chen, DeMets & Lan (Y. Chen, 
DeMets, & Gordon Lan, 2004) and Schmidli et 
al.(Schmidli, Bretz, Racine, & Maurer, 2006). 
 
Data Monitoring Committee (DMC) review 
process and the role of the DMC 
DMC members should have the expertise, experience to 
review according to the adaption plan. Also should 
restrict interim results knowledge to a small decision-
making group. 
 
Statistical bias related to treatment effects 
estimates 
Appropriate simulations to understand the potential for 
bias in specific situations. 
 
Subject heterogeneity across study stages Minimize protocol amendments. Enroll across regions or 
sites in similar timeframes. 
 
Potential for making decisions based on highly 
variable and unreliable interim results 
Appropriate timing of interim analysis (follow up and 
reducing variability). Targeting interim analysis to occur 
with 50 to 75% information or sample size. 
 
Potential for overrun of subjects being recruited Planning prior to analysis is critical including continual 
data cleaning, timing of interim analysis, programs and 
firewall ready. 
 
Issues with seamless phase II/III trials Consideration between accrual speed and endpoint 
assessment.  
Adapted from “Addressing challenges and opportunities of “less well-understood” adaptive designs. ” by 
He, W., Gallo, P., Miller, E., Jemiai, Y., Maca, J., Koury, K., ... & Lin, M., 2017, Therapeutic Innovation 
& Regulatory Science, 51(1), 60-68. 
Aside from adaptive design methods being adopted and understood, other clinical 
research areas of expertise are needed such as data management. Data management 
processes need to be addressed to reduce bias related to logistical challenges (Dimairo et 
al., 2015). For example, the timely reporting of data including dose exposure, treatment 
response and related adverse events are critical for the quality assessment of a dose level. 
Further, research institutions may need to have a dedicated team for the development of 
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adaptive studies, as researchers have indicated that an adaptive working group does 
appear to help with respect to expertise and knowledge dissemination (Morgan et al., 
2014). Funding gaps also need to be addressed, as there has been a lag in adaptive design 
adoption in publicly funded research (Dimairo et al., 2015; Hatfield et al., 2016).  
While there are barriers that need to be overcome to address the adoption of 
adaptive design methods, there are some simple solutions that researchers have 
suggested. Adaptive methods education in the universities is necessary but not just 
exclusively for statisticians (Dimairo et al., 2015). Education opportunities including 
hands-on experience, however, need to expand beyond the university to address the needs 
of current researchers. In addition, the justification and explanation of the trial options to 
the researchers to have a better understanding of traditional versus adaptive methods is 
critical (Viele & McGlothlin, 2017). The adoption gap between public and private funded 
research confirms the need for sharing of resources through cross funding working 
groups such as the Drug Information Association’s (DIA) Adaptive Design Scientific 
Working Group (ADSWG). Further, sharing of initial design related outputs could also 
increase expertise across the field (Morgan et al., 2014). 
Limitations of clinical research. Oncology clinical trials are developed in 
general sequential order to utilize information from the previous study. Using data from 
studies cumulatively is becoming more common through the use of meta-analyses, these 
methods should be utilized and adopted consistently across clinical research, phase and 
indication. Unfortunately, in clinical research, when a study fails, often results are not 
published (Hopewell, Loudon, Clarke, Oxman, & Dickersin, 2009). Only the researchers 
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involved in the study itself may fully understand and learn the reasons for the failed study 
due to the reduced likelihood of the results being published (Chapman et al., 2017; 
Gluud, 2006; Raghav et al., 2015). This knowledge can be applied to other internal 
studies, however, the information will not likely be publically shared with external 
researchers. Researchers have noted the phenomenon of publication bias where positive 
studies are more likely to be accepted for publication in comparison to negative studies 
(Gluud, 2006). While positive studies are critical for patient treatment, assessing the 
results and study design of negative studies is also critical in improving the treatment 
related to oncology. Researchers have noted that unplanned endpoints with positive 
results are more frequently reported than negative results in abstracts (Raghav et al., 
2015). Researchers have categorized negative trials and research no longer of interest in 
the same category for reasons not published (Chapman et al., 2017), which is a concern. 
Researcher assessment and information exchange of positive and negative studies will aid 
in advancing the field. 
Researchers have noted that appropriate endpoints need to be used and developed 
in clinical research (Collinson et al., 2012; Fleming, 1996). The appropriate endpoint also 
needs to be selected based on all study specific information such as treatment mechanism, 
type of cancer and planned follow up (Collinson et al., 2012). In oncology clinical 
research, overall survival is considered the gold standard, this endpoint may not be 
appropriate as it measures beyond the treatment being assessed (Driscoll & Rixe, 2009; 
Zhuang, Xiu, & Elsayed, 2009). Researchers have developed their own endpoint that may 
be appropriate for their research (Collinson et al., 2012), however, the comparison of 
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efficacy across treatments may become challenging as each endpoint is usually assessed 
independently. In adaptive studies, the adaptation can be based on a single endpoint or a 
combination of endpoints (Berry, 2012).  
Alternative outcomes have been considered to reduce the duration of trials thus 
decreasing cost and patient wait time. In oncology, using a surrogate endpoint may 
decrease the sample size by one third (Fleming, 1996). However, in surrogate endpoint 
selection, the true effect needs to be assessed while reducing possible noise (Fleming, 
1996). The possible overestimation of the effect needs to be considered. Surrogate 
endpoint selection needs to be considered with the expectation of predicting the true trial 
outcome using the surrogate outcome. For example, in oncology, treatment response is 
often used as a surrogate for overall survival. However, colorectal cancer researchers 
have found through meta-analysis that while there was a tumor response, there was 
virtually no evidence of improved survival (Fleming, 1996). Other researchers have also 
reported similar results when comparing the surrogate endpoint to survival (T. T. Chen, 
Chute, Feigal, Johnson, & Simon, 2000; Villaruz & Socinski, 2013). 
Often early phase studies are assessed on single endpoints such as toxicity, in 
order to identify the maximum tolerated dose (MTD). As a result pharmacodynamics (the 
study of the effects and mechanisms of drugs) or efficacy are not often considered at all 
or are not the primary consideration (Ananthakrishnan et al., 2017). Researchers report 
that in clinical research, consideration of alternative surrogate endpoints related to 
pharmacodynamics (the study of the effects and mechanisms of drug action) should be 
examined (Ananthakrishnan et al., 2017). Once again, simulations should be conducted to 
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assess the operating characteristics including accuracy to identify the MTD using the 
surrogate endpoint as well as efforts to reduce and acknowledge possible variability in 
the target population data as well as the endpoint itself (Ananthakrishnan et al., 2017; 
Fleming, 1996). As stated, consideration of data management logistics should be made 
when using pharmacokinetic (the study of the movement of the drug in the body) and 
pharmacodynamics endpoints. Sample collections related to study endpoints, such as 
pharmacodynamics will need to be conducted on an expedited timeframe to aid in 
decision making. 
Summary and Conclusions 
Based on the information presented, researchers appear to have difficulty in 
adopting innovative methods as they relate to oncology clinical research. Methods such 
as the 3+3 design continue to be used, even when they have been shown to be ineffective 
or are used erroneously. Increased knowledge of underlying assumptions related to 
traditional and adaptive methods is a barrier that needs to be overcome to improve cancer 
treatment development for the target population. While there may be a high learning 
curve for adaptive methods, shared knowledge as well as software development and 
access need to be addressed. The frequency and the operating characteristics through 
simulations of adaptive versus traditional methods, has been compared in clinical 
research. The real-world late stage outcome results have not been assessed in relation to 
the design method used in the early phase studies. The current study assessed the 
association between early stage design methods (adaptive versus traditional) and the 
association to late stage outcome results. 
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Chapter 3: Research Method 
Even though adaptive methods have been available since the 1970s with 
appropriate computational support and knowledge since the 1990s (A. R. Brown et al., 
2016), researchers have been reluctant to utilize the design methods. Uptake of adaptive 
methods, however, has been assertively accepted at some research institutions in 
comparison to others, likely due to awareness, training, education, feasibility, expertise, 
computational and programming availability (S.-C. Chow & Chang, 2008; J. A. Quinlan 
& Krams, 2006; Viele & McGlothlin, 2017). Appropriate communication with the study 
team to increase comfort, understanding, dissemination and collaboration with regulatory 
bodies is also critical in the study development process and to increase understanding and 
design acceptance (Kairalla et al., 2012; Viele & McGlothlin, 2017). Increased 
awareness, training and expertise need to be improved to allow for increased innovative 
methods utilization.  
I investigated potential associations of early phase study design research 
outcomes that utilize traditional versus adaptive methods on late stage results in oncology 
clinical trials. By comparing traditional versus adaptive methods in early phase studies 
and the downstream late stage clinical trial outcome, the possible benefits related to late 
stage study success leading to improved patient treatment options, were examined. As 
drug development and approval are based on cancer type (Barabási et al., 2011), study 
phase (U. S. Food and Drug Administration, n.d.-b) and treatment classifications 
(Siddiqui & Rajkumar, 2012), these potential effect modifiers were included in the 
analysis model. The study examined the potential effect modifiers including phase of 
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study, treatment classification and type of cancer, on the association between use of 
adaptive versus traditional methods (e.g. 3+3) in early phase studies and the results 
outcome of the late stage study. Additional variables such as surrogate endpoint and 
planned sample size used in the phase III study were assessed in sensitivity analyses. 
In this chapter, the research design, methodology and rationale with respect to the 
study is presented. The operational characteristics are summarized including sample size 
of the number of studies (the unit of analysis), inclusion and exclusion criteria and 
sampling procedure of the oncology studies in the Clinical Trials database. The research 
questions and hypotheses, as well as the related data analysis plan and key analysis 
variables and operational definitions were also included. Possible threats to validity and 
ethical procedures related to the Clinical Trials database and Internal Review Board 
(IRB) research requirements at Walden University, was also addressed. 
Research Design and Rationale 
This quantitative, nonexperimental, noninterventional, retrospective observational 
study was analyzed using a Bayesian logistic regression to assess the association between 
early phase design methods and late stage outcomes in oncology clinical trials. Data for 
this analysis was extracted from the National Institute of Health Clinical registry and 
results database (National Institute of Health, 2018). The data is extracted on a daily basis 
by the Clinical Trials Transformation Initiative (CTTI) Aggregate Analysis of 
ClinicalTrials.gov (AACT) (Clinical Trials Transformation Initiative, n.d.-a). In addition, 
researchers also have the option to extract the data independently. Individual studies were 
the units of the analysis. The Bayesian logistic regression methods were used for the 
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analysis as asymptotic approximations are not necessary (SAS, n.d.-c) like they are when 
using Frequentist methods, thus estimates should be more reflective of the data. In 
addition, when using Frequentist methods, the asymptotic distribution can break down 
leading to questionable results, which is not the case when Bayesian models are used 
(Modlin, 2018). Thus, to be expected, researchers have reported that Bayesian techniques 
have given more accurate results in comparison to classical methods (Guardia-Olmos, 
2008; Ogunsakin & Siaka, 2017; Yi, Kaklamani, & Pasche, 2011). The Bayesian analysis 
parameters and equivalent confidence intervals (credible intervals) also allow 
probabilities to be utilized and interpreted, a common error when interpreting 
Frequentist’s model estimates (Modlin, 2018). In addition, if a similar analysis related to 
the use of adaptive studies and their association to late stage outcomes is conducted in the 
future, the posterior estimates from this model can be used as priors for that analysis 
based on the Bayesian modeling conducted in this study. 
The categorical endpoint used in the analysis was based on the late stage results 
reported in the Clinical Trials database. If clarification was needed on the late stage 
results, I reviewed study related publications or study researchers were contacted. The 
endpoint categories were favorable, equivalent, or nonfavorable. The favorable category 
was utilized if the late stage clinical trials results reported in the database were 
statistically or clinically significant for the experimental treatment in comparison to the 
standard of care. The endpoint was classified as nonfavorable if the late stage clinical 
trials results were reported where the standard of care was reported to be statistically or 
clinically significantly better in comparison to the experimental treatment. For 
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bioequivalence or noninferiority studies and no significant endpoint differences were 
found, the study was coded as equivalent (favorable). A similar outcome result 
classification system was utilized by the researchers Rasmussen, Lee and Bero (2009).  
While the clinical trials results were reported in the database, the endpoint 
categories were identified where possible through statistical programming. The 
confirmation of the identified categories were manually reviewed by me, and a 
percentage were verified through the database, publication review, or researcher contact. 
Similarly, the covariate classifying the early stage design methods (adaptive versus 
traditional) was also extracted from the database, if available in the database study 
description. If the clinical trial design was not included in the database description, the 
design classification variable was captured via publications, or researcher contact. Once 
again, confirmation of the categories was manually reviewed and a percentage was 
verified through publication review as well as researcher confirmation as needed. The 
remaining variables included in the analysis were included in the database and are 
described in Table 4 below. 
The analysis model was: 
Late phase study results (favorable/unfavorable) = early phase design 
(adaptive/traditional) + early phase + experimental treatment classification + type of 
cancer + drug classification + duration between early and late phase studies (months) + 
study funding 
This study could aid in understanding the influence of adaptive design on cancer 
treatment development. In addition, this study could increase knowledge related to 
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adaptive design, which has been identified as being a barrier related to the adoption of the 
innovative methods (Kairalla et al., 2012). 
Methodology 
Population 
Aggregated study data reported in the publicly available Clinical Trials database 
were extracted in March 2018 from the related results database using the Clinical Trials 
Transformation Initiative (CTTI) Aggregate Analysis of ClinicalTrials.gov (AACT) 
(Clinical Trials Transformation Initiative, n.d.-a; National Institute of Health, 2018). The 
database is a cloud-based resource used by researchers, clinicians and patients to find 
information related to clinical studies for specific diseases and conditions (National 
Institute of Health, 2018). The registry of studies was established for all funded studies 
and was the result of the Food and Drug Administration Modernization Act of 1997 
(Food and Drug Administration, 1997). The database is a requirement of the specified 
legislation to be established and maintained by the United States Department of Health 
and Human Services (HHS). Studies for the treatment serious or life-threatening diseases 
or conditions are required to register in the database. Further the results database 
including study outcomes and adverse events were made available starting in 2008. The 
extracted data were aggregated by study which was the unit of analysis. No additional 
access or permission was needed to use the database information, as the data is publicly 
available and accessible. 
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Sampling and Sampling Procedures 
Stratified random sampling based on cancer type, treatment and drug 
classification was conducted to allow for appropriate sample size in order to increase 
possible power for comparisons in sub-populations. Within strata, clinical trial order was 
random and identified as adaptive or traditional. Random numbers were assigned to each 
study and ordered from lowest to highest. Studies were included in the sample in that 
order until the sample size was met within each design method. Table 3 provides an 
example of studies within cancer type and treatment type. 
Sampling Strategy 
Stratification variables were used to ensure that analysis within each cancer type, 
treatment classification, experimental drug classification and funding source could be 
conducted. Researchers have noted that within the Clinical Trials database, 
approximately 37% (158/428) to (Hatfield et al., 2016) 42% (142/336) (Bothwell et al., 
2018) of the Phase II to Phase III studies used adaptive methods. 
Table 3 
Random Study Order Identification Within Strata 
Cancer Type Treatment type 
Cancer type 1 Cancer type 2 Cancer type 3 Drug Radiation 
NCT_ XXXX1 NCT_ XXXX2  NCT_ XXXC1  
NCT_ XXXX3 NCT_ XXXX4  NCT_ XXXD1  
NCT_ XXXX7 NCT_ XXXX9 … NCT_ XXXC3  
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Inclusion Criteria 
Only studies for oncology intervention treatment were included. Intervention 
treatments include drug, biological, surgery, radiation and any combination. Combination 
treatments were also be eligible for the analysis and appropriately identified in the 
analysis model. Studies initiated between, January 1, 2000 to December 31, 2016 were 
included in the analysis. The latter cutoff date allowed enough time (approximately one 
to three years) for the studies to mature and results to be included in the database. 
Exclusion Criteria 
Early phase studies for healthy volunteers were excluded, as the studies cannot be 
considered interventional. Oncology related palliative care or noninterventional studies 
were excluded in the analysis. 
Archival Data 
Data from the National Institute of Health Clinical Trials registry and results 
database were used for this study (National Institute of Health, 2017a). The data was 
extracted by the Clinical Trials Transformation Initiative on a daily basis and available 
using the recommended software (Clinical Trials Transformation Initiative, n.d.-a, n.d.-
b). In 1997, the Food and Drug Modernization Act (FDAMA) was enacted requiring a 
registry for efficacy trials for serious and life-threatening conditions, including oncology 
studies (National Institute of Health, 2015b). The law was amended in 2007, (HR 3580, 
the FDA Amendments Act of 2007) where a legal requirement for the registration of the 
trials of drugs was implemented (National Institute of Health, 2017b). The clinical trials 
results database was initiated in 2008. 
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Researchers have reported that the average duration of Phase III oncology clinical 
trials is between 1 and 3 years (Pregelj, Verreynne, & Hine, 2015). Therefore, studies 
initiated in 2016 may be close to reaching maturity of the primary endpoint. Thus, 
oncology studies initiated prior to 2016 (up to December 31, 2015) were included in the 
analysis. 
In 2004, the International Committee of Medical Journal Editors required 
researchers to register in ClinicalTrials.gov or an equivalent registry prior to the first 
patient to be enrolled in their study (International Committee of Medical Journal Editors, 
2017). This criterion had to be met in order for the publication to be considered for 
acceptance into their journal. This committee is represented by most major journal 
publications; thus, there is increased motivation for the researchers to register their 
studies not just in the United States, but also across the globe. As a result of the FDA 
enactments as well as the International Committee of Medical Journal Editors, the 
clinical trials database should be representative of clinical trials being conducted in the 
United States and possibly around the world. Further, effective in January 2015, the 
National Cancer Institute (NCI) required that all NCI-supported intervention study results 
need to be reported publicly within 12 months of the study completion date (National 
Institute of Health, 2015a), thus improving cancer clinical trials results representation in 
the database. 
  
66 
Instrumentation and Operationalization of Constructs 
Independent Variable 
The categories of the study design were based on the early phase study design 
specifically adaptive or traditional (see Table 4 for definitions). As a result of the 
changing definition of adaptive studies, the ambiguous definition evolving over the years 
(Bothwell et al., 2018; Christopher S Coffey et al., 2012; Kairalla et al., 2012) and the 
self-reporting of study design methods categorization (Bothwell et al., 2018), I reviewed 
the database and related publications to provide clarity of the study description design. 
Adaptive studies were defined to be clinical study designs that use accumulated 
information or data of the study to modify aspects of the study as it continues 
(Christopher S Coffey et al., 2012). The adaptations in these designs are predefined. This 
definition is consistent with the Pharmaceutical Research and Manufacturers of America 
(PhRMA) Working Group (Gallo et al., 2006). Traditional studies were defined to be 
studies that did not satisfy the definition for adaptive. Adaptive methods that were 
defined to be less well-understood were designs that have not been frequently utilized 
thus there were less experiences with the methods (U. S. Food and Drug Administration, 
2010). Each study within the Clinical Trials database has a unique identification 
associated, thus confirming classification with publications and facilitating 
communication with researchers on specific studies is simplified. Classification of design 
methods was based on the Pharmaceutical Research and Manufacturers of American 
(PhRMA) Working Group definition (Gallo et al., 2006). Subdivision of adaptive designs 
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into well-understood versus less well understood was also be used based of FDA 
definitions (U. S. Food and Drug Administration, 2010). 
Operationalization of Variables 
Table 4 provides the variable information that was used for the analysis. Included 
in the table are the variable definitions, the format of the variables within the Clinical 
Trials database, as well as the value of the variables for the analyses. 
Table 4  
Analysis Model Variables, Description and Possible Values 
Variable Definition 
CT.gov 
format Values 
Dependent variable    
    
Outcome of late-
phase study 
Late-stage study results. Results are based on the 
original study operation characteristics and 
statistical significance.  
 
The statistical outcome of the late-phase study 
(favorable = experimental treatment statistically 
better than comparison; equivalent = experiment 
and comparison are statistically equivalent; 
nonfavorable = experimental treatment is found 
to be better than the comparison treatment). For 
studies that are not driven by statistical 
significance, clinical relevance (effect size) will 
determine the outcome classification. 
Free text, 
categorized 
for variable 
values. 
Endpoint: favorable, 
equivalent, 
unfavorable 
 
Independent 
variables 
 
   
Design 
classification 
 
Adaptive studies are defined to be clinical study 
designs that use accumulated information or data 
of the study to modify aspects of the study as it 
continues (Christopher S Coffey et al., 2012). 
The adaptations in these designs are predefined. 
Traditional studies will be defined to be 
nonadaptive studies. 
 
 Free text Adaptive, Traditional 
Early phase Phase of early-stage study Same as 
value 
Categorical: 0, 1a, 
1b, 1, 2, 2a, 2b 
(continued) 
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Variable Definition 
CT.gov 
format Values 
Experimental 
treatment 
classification 
Interventional treatment classification Categorical Drug 
Device 
Biological/vaccine, 
Procedure/Surgery 
Radiation 
Combination 
Other 
Cancer type The cancer site or type that is being researched 
in the early- and late-stage study. 
 
Same as 
reported 
value 
Breast, lung, 
pancreatic, bone etc. 
Experimental 
drug 
classification 
 
WHO drug classification 
 
Categorical 
variable 
EGFR or VEGF 
inhibitors, 
monoclonal antibody, 
proteasome inhibitor, 
immunotherapy etc.  
Duration 
between studies 
(months) 
Time between the end of the early-stage study 
and the beginning of the late-stage study 
Dates; will 
take 
difference for 
duration 
 
Time in months 
Study funding 
source  
Who is sponsoring the early stage study? Reported 
funding 
(grant, other) 
Private or public 
funding  
    
Sensitivity analysis 
variables 
   
    
Type of endpoint Type of endpoint used. Any endpoint that is not 
overall survival such as progression free survival 
or objective response will be considered a 
surrogate. 
 
 Free text Surrogate, clinical or 
both 
Sample size The number of patients planned to be enrolled in 
the early-phase studies. 
Numeric Numeric 
Biomarker Did the study include a biomarker as an 
endpoint in the study or not? 
Categorical Binomial (yes, no) 
Adaptive 
classification 
For those studies that are adaptive, are they are 
classified as well-understood or less well-
understood designs as defined by the FDA 
(2010). 
Categorical Well-understood, less 
well-understood, not 
adaptive 
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Data Analysis Plan 
All analyses were performed using SAS 9.4 or higher (SAS, n.d.-b). Data was 
downloaded from the CTTI AACT relational database, which included the study 
characteristics such as phase, type of intervention, population, sample size, among other 
variables in aggregate form. Target analysis variables were extracted, including study 
outcome, phase, treatment, cancer type, experimental drug classification and study related 
dates. CT.gov studies included in this analysis were assessed and reported for 
completeness.  
When studies are entered into the Clinical Trials database, records are reviewed 
for accuracy and content by the NIH database administrators (National Institute of 
Health, 2010). The database administrators also conduct programmatic and manual 
internal consistencies with respect to other study related information associated with the 
clinical trial (Zarin, Tse, Williams, Califf, & Ide, 2011). Once the results of the study 
have been reported, consistency within the record are assessed, as well as comparing 
information that is relevant to the appropriate field (National Institute of Health, 2009). 
Protocol and results data entry guidance is also provided by the database administrators 
to the researchers which should improve data quality (Tse, Williams, & Zarin, 2009; 
Zarin et al., 2011). 
For any clarification related to early phase design selection, late stage outcome 
results, study related researchers were contacted and/or publications were reviewed using 
the Clinical Trials unique study identifier for the search. Previous researchers (Hatfield et 
al., 2016) have also classified study designs (adaptive classifications) using the Clinical 
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Trials database. The Hatfield et al. (2016) analysis datasets, including study design 
classification variable, were publically available and were used for study design 
verification in this analysis. Bothwell et al. (2018) also conducted a study of adaptive 
study classifications using the Clinical Trials database. While the data for the Bothwell 
analysis was not publicly available, the researchers shared a list of adaptive classified 
studies that they included in their analysis. This data were also be used for validation of 
study classification in this study.  
In addition, an independent review and classification of 10% of the studies were 
conducted. A kappa statistic was used to measure the agreement between the independent 
data reviewers. If the discrepancy rate was greater than 15%, an additional 10% of study 
design classifications were reviewed. Prior to the analysis of this study, the two 
independent reviews were reconciled.  
Sample Size and Power Estimation 
As previously noted, the failure rates of oncology treatments are as high as 66% 
(Berry, 2011). Using these estimates, assuming a positive outcome rate of 37% for late 
stage studies where adaptive methods (nonadaptive: 22%) were used, there is 85% power 
with a sample size of 425 studies (adaptive=125; nonadaptive=300). Under these 
assumptions, as well as a polynomial endpoint (phase III study outcome: positive, 
equivalent, negative) and early phase study design method (adaptive or not), a two-sided 
alpha of 0.05 was used to estimate the sample size. Sample size estimates were computed 
using Nquery Advisor 8.0 (Statistics Solutions, n.d.).Table 5 provides power estimates if 
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the proportion of positive results within the traditional versus adaptive design methods 
was varied. 
 
Table 5 
 
Sample Size Under Assumptions of Proportion, Power and Type I Error for 
Target Population 
Power 
(%) 
Type 
I Proportion Sample Size 
  Traditional Adaptive Traditional  Adaptive 
85 0.05 0.22 0.37 300 125 
75 0.05 0.22 0.35 300 125 
65 0.05 0.25 0.37 300 125 
53 0.05 0.22 0.32 300 125 
48 0.05 0.27 0.37 300 125 
 
To allow for increased power to compare cancer types, treatment and drug 
classifications, a stratified identification of studies to be included in the analysis was 
used. The order of the possible studies included within each stratification variables was 
random. Clinical trials were included in the analysis in the randomization order until the 
target sample size was met.  
Table 6 provides additional power estimates for sub-populations under a variety 
of assumptions for power and proportion of positive results for late stage studies when 
traditional versus adaptive methods were used for the early stage studies. For example, 
assuming a two-sided type I error (the probability of falsely rejecting the null hypothesis) 
of 0.05 and 22% of positive outcomes of late stage studies where traditional methods 
were used and 46% where adaptive methods were used, there is 80% power if 150 studies 
(traditional=100, adaptive=50) were identified in the sub-population. In addition, if the 
  
72 
different rates of adaptive versus traditional were identified, alternate power estimates 
were provided.  
 Table 6 
 
Sample Size Under Assumptions of Proportions of Positive Outcomes, Power and Type II 
Error for Subpopulation 
Power 
(%) 
Type 
I Proportion positive outcome Sample size 
  Traditional Adaptive Traditional  Adaptive 
80 0.05 0.22 0.46 100 50 
60 0.05 0.30 0.50 100 50 
42 0.05 0.25 0.37 100 50 
81 0.05 0.22 0.32 75 30 
28 0.05 0.22 0.37 75 30 
 
Research Questions and Hypotheses 
RQ1: To what extent is there an association between design methods used for 
early phase oncology studies (adaptive versus traditional) and the outcome of late stage 
clinical trials? 
Ho1: There is no association between early phase oncology studies (adaptive 
versus traditional) and the late stage clinical trial outcomes. 
Ha1: There is an association between early phase oncology studies (adaptive 
versus traditional) and the late stage clinical trial outcomes. 
RQ2: In specific cancer types (e.g. breast cancer, lung cancer etc.), what is the 
association between the design methods used for early phase oncology studies (adaptive 
versus traditional) and the outcome of the late stage clinical trials? 
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Ho2: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does not differ between 
specific cancer types. 
Ha2: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials differs between specific 
cancer types. 
RQ3: How does the treatment classification modify the relationship between the 
design methods used for early phase oncology studies (adaptive versus traditional) and 
the outcome of the late stage clinical trials? 
Ho3: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does not differ between 
specific treatment classification (e.g. surgical, adjuvant, radiation, etc.).  
Ha3: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does differ between 
specific treatment classification (e.g. surgical, adjuvant, radiation, etc.). 
Analysis Plan 
Analysis Model 
A multivariable Bayesian logistical regression model was used for this study. The 
comparator covariate was the study identified design methods (adaptive versus 
traditional) used by the early phase studies. The outcome (or response) variable was the 
late stage outcome that had three categories (favorable, equivalent and nonfavorable). 
Favorable is when the late stage study outcome results were statistically significant or 
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clinically significant per study design and in favor of the experimental treatment. A study 
was deemed to be nonfavorable if the results did not reach statistical or clinical 
significance in favor of the experimental treatment. For bioequivalence or noninferiority 
studies and no significant endpoint differences were found as designed, the study was 
coded as equivalent (favorable). A similar classification system was utilized by the 
researchers, Rasmussen et al. (2009).  
Covariates included in the model were phase of study, treatment classification, 
cancer type, experimental drug classification (if applicable), duration between studies and 
study funding. As researchers have found that there is no single treatment for all cancers, 
the treatment classification, cancer type and experimental drug classification should be 
included in the model (Barker et al., 2009; Carey et al., 2010; Kim et al., 2012; Lonial & 
Nooka, 2016). Phase of treatment was included as it is unclear the impact of each 
development phase of study (phase 0, 1, 2) and the contribution of each phase with 
respect to the outcome of the late phase study results.  
Duration between the early phase study and the late stage study was also included 
as the shorter or longer lag time, were likely to have less influence on an ongoing study. 
As such a random forest analysis of the time between the early and late stage studies and 
outcome was used for categorical classification. The classification of the duration of time 
variable was included in the analysis model. The duration of time classification variable 
was not expected to be linear. If no significant classifications were identified using the 
random forest methods, the duration of response would be classified by quartiles. Study 
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funding, specifically private versus public, has been found to be associated with adaptive 
method design versus not (Kairalla et al., 2012). 
Frequentist Modeling Techniques 
Standard logistic regression analysis for univariate modeling with a logit link 
function and binomial distribution was used for univariate analyses. PROC LOGISTIC 
was used for the logistic modeling. Odds ratios and 95% confidence intervals were 
computed and presented. Type 3 p values will be used to assess the statistical significance 
of all variables including those classified as categorical. Type 3 p values assess the 
overall influence of the variable including all the categories within the variable as well as 
interaction terms, if applicable. For forward and backward stepwise modeling, 
HPGENSELECT was used with a binomial distribution and a logit link. Akaike 
Information Criteria corrected for bias (AICC) was used to determine which variable 
should be removed from the model. 
Bayesian Modeling Techniques 
A Bayesian logistic regression analysis for modeling with a logit link function and 
binomial distribution was used. PROC GENMOD was used for the logistic modeling 
with contrast statements of linear combinations of parameters included in the model, 
including interaction terms where specified. PROC PLM was used for post processing 
estimations of model estimates including the odds ratios and the corresponding credible 
intervals. The credible interval is an interval that the true but unobserved parameter falls 
within a specific probability based on quantiles (Stokes, Chen and Gunes, 2014). The 
95% highest posterior density (HPD), the minimum interval, was computed. The analysis 
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was conducted with outcome of the late stage study (favorable, equivalent and 
nonfavorable). The noninformative prior distribution with mean of zero and a large 
variance (1x10^6) for the independent parameters in the model was assumed to be 
multivariate normal. The burn-in period for the Markov Chain Monte Carlo was 2000 
samples with 20,000 simulations, which is the default setting in SAS and conventionally 
accepted as initial frequencies (Stokes, 2014). However, adjustments to the burn-in 
period or number of simulations were made based on the convergence and auto-
correlation model assessment statistics. The Markov chain techniques were used for 
sampling using the Gamerman algorithm (Gamerman, 1997). 
Assessment of the Model 
Convergence was assessed on all parameters using the trace plots. The trace 
should show good variability across the plot for good mixing and low autocorrelation 
across Markov chain samples. In addition, the posterior autocorrelation was assessed to 
determine if convergence has been attained. The burn-in period was extended if good 
mixing was not evident in trace plots through an equilibrium distribution or if 
convergence was not been attained. Convergence diagnostic tests was also utilized 
including Gelman-Rubin (1992), Geweke (1992), Heildelberger-Welch (1983) and, 
Raftery-Lewis (A. E. Raftery & Lewis, 1996; A. E. L. Raftery, S. M., 1992). Table 7 
below provides the description and measures of each convergence test. 
The Deviance Information Criterion (DIC) (Spiegelhalter, Best, Carlin, & van der 
Linde, 2003) is a Bayesian generalization of the Akaike information criteria (Akaike, 
2011) and was used to assess the overall model as well as the contribution of each 
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variable. Dispersion and heterogeneity were assessed and if needed, the covariance 
matrix was scaled. Table 7 provides details on convergence tests that were used to assess 
the model. 
Table 7 
 
Bayesian Model Convergence Tests, Description and Purpose 
Convergence test Description and purpose 
Gelman-Rubin Multiple Markov chains are assessed to determine if they converge to the 
same target distribution or not. If the test fails, a longer burn in period 
may be needed. A large test value indicates the null should be rejected. 
 
Geweke Compares means from early and late parts of the Markov chain to see 
whether convergence has been attained (Ho: µ1=µ2=….= µj)Assess 
whether the mean estimate of the Markov chain is stable over time. A 
large Z statistic (or small p-value) indicates rejection of the null. 
 
Heidelberger-Welch Consists of a two part test. The first part assesses the stationarity of the 
Markov chain (Ho: Chain comes from the covariance stationary process). 
The second part of the test is the half-width best checks where the 
Markov change is assessed as to whether or not the sample size is 
adequate to estimate the mean value accurately. This one sided test is 
rejected if the p-value is greater than 1-a. Also need to specify epsilon, 
but not sure where this fits into the test. 
 
Raftery-Lewis The posterior percentiles was used to summarize the parameter estimates, 
the R-L diagnostics assessed the accuracy of the estimated percentiles. 
The closer the ratio of sampled values of a parameter versus the sample 
number is to 1, the less correlated the samples are. Note that this test 
focuses on the percentiles and does not assess the convergence overall. 
This assessment will aid in determining whether the burn in period is 
appropriately sized or not. This test tends to be conservative in that, the 
statistic will suggest more iterations than necessarily needed. 
 
Effective Sample Size (ESS) ESS=n/tau where n is the total sample size and the autocorrelation time 
(tau) is basically the sum of the autocorrelation. A low ESS or high tau 
indicates a bad mixing of the Markov chain. This ESS assessment is an 
indicator of correlation between successive samples. The higher the 
correlation between successive samples, the less information gained. 
(SAS, n.d.-a; Stokes, 2014) 
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Model Interpretation 
Descriptive statistics including the mean, median and range for continuous 
variables were computed. For categorical variables, frequencies were computed. PROC 
GENMOD was utilized where the coefficients of each covariate was estimated, adjusted 
for the other variables in the model. The odds ratio along with the associated 95% 
credible interval will be computed. The posterior summaries and credible intervals were 
used to assess parameter significance. If the odds ratio was greater than one, then there 
were higher odds of a positive outcome with respect to the exposure (i.e. adaptive 
methods). Similarly, if the odds ratio is less than one, there are lower odds of a positive 
outcome with respect to the exposure. The expectation is that when adaptive methods are 
used, there will be higher odds of a positive late phase outcome. If the 95% credible 
intervals include the value one, then the results are not statistically significant. 
Multiple Comparisons 
Three hypotheses were evaluated, however, adjustments type I errors for multiple 
comparisons was not be employed. In order to test each hypothesis, the full model was 
assessed for significance along with the reduced parameter model (parameter of interest + 
design methods). The first hypothesis was to compare whether the early phase design 
method is related to the outcome of the late phase study. The statistical significance of 
this hypothesis was assessed using the credible intervals (equivalent to classical 
confidence intervals) in the logistic model. The Deviance Information Criterion (DIC) 
was compared across the full versus the reduced parameter model to assess variable 
contribution. For the second and third hypothesis, a similar test was conducted within 
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each cancer type as well as within each treatment classification. Subgroup analyses was 
conducted and assessed regardless of statistical significance. 
Threats to Validity 
For any analysis there can be threats to validity that should be acknowledged and 
countered to the extent possible. Often when multiple studies are combined, publication 
bias may be a concern. Publication bias is the result of more positive studies being 
published in journals, in comparison to results with negative studies. However, due to the 
FDAMA and FDAAA requirements of registry for efficacy trials for serious and life-
threatening conditions including oncology studies (National Institute of Health, 2015b, 
2017b), the Clinical Trials database should be representative of oncology clinical 
research occurring in the United States. The registry requirement for publication in major 
journals prior to patient enrollment (International Committee of Medical Journal Editors, 
2017) also improves the quality and representation of the database. 
Researchers have shown that the Clinical Trials database is of high quality with 
respect to publications as reported by Hartung et al. (2014). An independent review of a 
randomly extracted sample was conducted to assess discrepancies between the results 
reported in the Clinical Trials database and the related publications. Of the 110 trials that 
Hartung et al. (2014) randomly selected from the database, approximately 15% reported 
primary outcome descriptions and 20% reported primary outcome value inconsistencies. 
Any possible discrepancies identified for the current analysis were reported to the 
database administrators. 
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While the Clinical Trials database has a requirement that the results from studies 
be entered within one year of maturity for designated studies, researchers have noted that 
delays in reporting appears to be a consistent problem (Anderson et al., 2015). Increasing 
the time tolerance for reporting did improve the reporting percentage, however despite 
ethical and legal obligations as required by United States law, delays in reporting is 
prevalent (National Institute of Health, 2017a). Missingness within included studies were 
reported and assessed for possible bias and patterns. 
In addition, as noted by previous researchers, with the ambiguity of the definition 
of the classification of adaptive studies and self-reporting of classification (Bothwell et 
al., 2018) may negatively impact the results of the current study. However, as noted 
previously, 10% of the studies included in this analysis were independently verified and 
compared. If the discrepancy rate was noted to be greater than 15%, an additional 10% of 
study design classifications were reviewed. 
Ethical Procedures 
Ethical issues can arise during enrollment as well as data collection of any clinical 
trial (Creswell & Creswell, 2014). As this study uses archival data, ethical related issues 
through Internal Review Boards (IRB) or Central Review Boards (CRB) were addressed 
within each study and enrolling site, prior to the initiation of this study due to human 
subjects being enrolled and treated for their cancer (National Institute of Health, n.d.). 
Prior to enrolling in the Clinical Trials database, the researchers need to get review board 
approval before the Clinical Trials database status is changed to recruiting. 
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The data used for this analysis, collected between the years 2000 and 2016 in the 
Clinical Trials database is aggregated, thus there were no concerns for patient data 
identification, as the data includes no patient identifiers. No individual patient 
information is available in the database. Prior to my study initiation and data analysis, I 
obtained an IRB approval through Walden University. The data for the analysis is 
publicly available and can be downloaded directly from the Clinical Trials database 
website without permission. 
Summary 
This study was conducted to assess the relationship between early phase study 
design methods and the outcomes of late stage study results. The quantitative 
nonexperimental noninterventional retrospective observational study used a Bayesian 
logistic regression analysis using data from the Clinical Trials database. The unit of 
analysis was individual studies where the data is aggregated within the database. 
Additional covariates included in the model included experimental treatment 
classification, type of cancer, drug classification, study funding as well as the duration 
between the early and late phase study. This study could aid in understanding the 
influence of adaptive design on cancer treatment development and may also increase 
knowledge related to these innovative methods in cancer research. 
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Chapter 4: Results 
In this quantitative observational study, I investigated the potential association 
between early phase study design research that utilized traditional versus adaptive 
methods and late stage results in oncology clinical trials. By comparing traditional versus 
adaptive methods and the downstream clinical trial outcome, the association with late 
stage study outcome was assessed. As drug development and approval are based on 
cancer type, study phase and treatment classifications, these potential effect modifiers 
were included in the analysis model (Barabási et al., 2011; U. S. Food and Drug 
Administration, n.d.-b; Siddiqui & Rajkumar, 2012), to determine whether the 
association between use of adaptive versus traditional methods (i.e. 3+3) in early phase 
studies and the results outcome of the late stage study, is different in subgroups defined 
according to levels of these factors. 
The hypotheses that were tested include: 
Ho1: There is no association between early phase oncology studies (adaptive 
versus traditional) and the late stage clinical trial outcomes. 
Ha1: There is an association between early phase oncology studies (adaptive 
versus traditional) and the late stage clinical trial outcomes. 
Ho2: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does not differ between 
specific cancer types. 
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Ha2: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials differs between specific 
cancer types. 
Ho3: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does not differ within 
specific treatment classification (e.g. surgical, adjuvant, radiation, etc.).  
Ha3: The association between early phase oncology design methods (adaptive 
versus traditional) and the outcome of the late stage clinical trials does differ within 
specific treatment classification (e.g. surgical, adjuvant, radiation, etc.).  
The purpose of this chapter is to provide a description of the sample of data 
obtained from the ClinicalTrials.gov clinical trials database for oncology studies as well 
as provided a description of the results of the statistical analysis conducted. The results 
are described using tables and figures. Narratives are also provided to support 
assessments of the statistical significance of planned and sensitivity analyses. A summary 
of the findings with respect to the research questions is also provided. 
Source Data 
This retrospective study was an analysis of archival database including oncology 
clinical trials maintained by the National Institute of Health and aggregated by the 
Clinical Trials Transformation Initiative (CTTI) (Clinical Trials Transformation 
Initiative, n.d.-a; National Institute of Health, 2018). Summary variables were also added 
to the database by CTTI, such as number of treatment arms, device study, radiation, to 
name a few. The oncology studies included in the analysis were interventional for 
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patients with disease but excluding studies that accrued healthy volunteers that were 
initiated after November 1, 1999 to December 31, 2016. For studies included in the 
analysis, the results of the primary endpoint had to be reported in the database by the 
investigators at extraction. The data is publicly available and was extracted from the 
Clinical Trials database on March 26, 2018, which was prior to IRB approval. As the 
database is actively accruing data and no codebook with descriptive data were available, 
the first extract was planned to be used to identify variables of interest and get a better 
understanding of the database structure. The second extraction after IRB approval was 
planned however, due to challenges identified with the first extraction with the size of the 
database, hidden characters in the extracted datasets creating errors, the need for multiple 
database administrators’ assistance and no available codebook with summary statistics as 
the database is active, the original extraction was used for the analysis. However, as the 
data is archival, publicly available for extraction and aggregated with no individual 
patient identifiers, there continues to be no risk to patients. 
Data Analysis 
At data extraction there were 269,310 studies of which 3,040 oncology 
intervention studies that did not include healthy volunteers with the indicator that results 
were available. A summary of the Clinical trials database is found in Table 9. Oncology 
intervention clinical trials were included in this study. Studies were sorted by covariates 
(disease condition, treatment type and year initiated) and randomly assigned a number 
based on these covariates. Increased weights were assigned to more recent research as 
researchers have noted that adaptive methods have increased in use over the years 
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(Hatfield et al., 2016). Increasing the weights of recent studies, increases the probability 
of adaptive studies to be included in this study. Studies included in this research were 
randomly added and a sample size of 381 was attained (286 early phase, 95 late phase).  
Of the early phase studies, 220 (76.9%) were deemed traditional design and 66 
(23.1%) were classified as adaptive studies. Similarly, of the late phase studies, 56 
(58.9%) and 39 (41.0%) were classified as traditional and adaptive design respectively. 
The overall percentage of adaptive studies was 27.5% (N = 105).  
Studies that included the most frequent diseases, specifically breast, lung, 
pancreatic, sarcoma and multiple cancers, were included in the study to try to ensure 
frequencies of cancers were large enough for primary and sub-study comparisons. 
However, as previously noted, programmatic filtering of disease condition was not 100% 
accurate in identifying the correct disease type. In addition, studies that recruited multiple 
populations were included in the analysis, thus additional cancer types were included in 
the analysis dataset. Nonetheless, due to the random selection of studies, the sample 
should be representative of all oncology studies in the database. Table 8 includes a 
description of the database and studies included in the analysis. Table 9 includes a 
summary of the reason why studies were excluded from this analysis of which the 
primary reason was due to accrual problems (32.7%) leading to incomplete results. 
However the unreported reason for the incomplete results was also frequently noted 
(29.5%). Figure 3 includes a visualization of the studies in the database, reasons included 
and excluded as well as a description of the included studies. 
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Table 8 
Summary of Studies Within the Clinical Trials Database 
Total N, % 
Number of studies 269,310 
Number of studies excludeda 203,522 
Oncology intervention studies 3819 
With results 3040 
Random sample 537 
Excludeda 156 
Included in analysis 381 
Phase (adaptive, N)  
Early 286 (66) 
Late 95 (39) 
Design (%) % 
Adaptive 105 
Traditional 276 
a. See Table 9 for exclusion reasons. 
 
Table 9 
Reason Studies Were Excluded from the Analysis 
Exclusion reason n (%) 
Number of studies excluded 156 
Results outcome  
Incomplete 122 (78.2) 
Unknown 18 (11.5) 
Unknown design 4 (2.6) 
Reason unplanned study stoppage  
Accrual problems 51 (32.7) 
Administrative reasons 1 (0.6) 
Business decision 13 (8.3) 
Complete 2 (1.3) 
Drug availability 2 (1.3) 
Funding problem 7 (4.5) 
Futility or safety concerns 16 (10.3) 
Other reason 4 (2.6) 
PI logistics 14 (9.0) 
Unknown – not reported 46 (29.5) 
 
  
87 
Interrater Agreement 
Five hundred and thirty-seven studies were randomly selected from the clinical 
trials database. Ten percent (54 studies) of the sample was randomly selected to allow for 
an independent review of the study outcome and study design. The independent 
reviewer’s classifications were compared to the analysis dataset using the Kappa 
coefficients, which measures inter-rater agreement, are presented in Table 10. The inter-
rater agreement was greater than 94% for each variable with a Kappa coefficient of 
0.9206 and 0.8845 respectively indicating a good agreement across raters thus indicating 
that manual classifications included in the analysis were relatively accurate. As such, 
independent review of an additional 10% of the sample was not needed. 
Table 10 
Interrater Agreement for Study Design and Study Outcome Classification 
Study design classification  n (%)  
N 54 
Agreement 96.3% 
Conflict 3.7% 
  
Kappa coefficient (95% CI) 0.9206 (0.8126, 1.0000) 
Standard error 0.0551 
Two sided p value <0.0001 
  
Study outcome classification N (%)  
N 54 
Agreement 94.4% 
Conflict 5.56% 
  
Kappa coefficient (95% CI) 0.8845 (0.7592, 1.0000) 
Standard error 0.0639 
Two sided p value <0.0001 
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Figure 3. Exclusion and inclusion criteria for studies selected for analysis. 
Aggregate Participant Characteristics Within Studies 
Table 11 provides descriptive characteristics aggregated for participants within 
each study included in this analysis. The median sample size for early phase and late 
phase studies was 22 (Range: 1 to 343) and 158 (8 to 2091) patients respectively. Most 
early phase studies included only one participating country, primarily the United States 
(55.6%), whereas late phase studies had a median of 14 participating countries. Most 
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studies in either phase included adults (age greater than or equal to 18 years). The most 
common cancers included in early stage studies were lung (12.9%), colorectal (12.9%), 
breast neoplasms (12.3%) and multiple myeloma (12.6%). Multiple cancers were 
included in 8.0 percent of early phase studies. Similarly, the most common cancers 
included in the late stage studies were breast (25.7%), lung (19.9%) and multiple 
myeloma (12.3%), of which only 1.1% of studies included multiple disease conditions. 
Most studies in either stage category included both men and women (76.0% and 65.3%, 
respectively) with age greater than or equal to 18 (Early: 88.1%; Late 91.6%). Additional 
details of participant characteristics within studies can be found in Table 11. 
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Table 11 
Summary of Participant Characteristics Within Studies (Analysis Units)a 
  
Early phase 
[b] 
Late phase 
[b] Total 
Number of studies, N (%)  286 (75.1) 95 (24.9) 382 
Number of participants 
(actual) 
 
Median  
(min, max, STD, N) 
22  
(1, 343, 
47.9, 284) 
158  
(8, 2091, 
275.5, 94) 
36 
(1, 2091, 
167.5, 378) 
     
Number of participating 
countries 
 
Median  
(min, max, STD, N) 
1  
(1, 30, 4.7, 
278) 
14  
(1, 62, 12.4, 
92) 
1  
(1, 62, 8.9, 
370) 
     
Minimum age of study 
participantsc (years) 
(n, %) 
    
     
 > 2 years 1 (0.4) 0 1 (0.3) 
 > 15 1 (0.4) 0 1 (0.3) 
 > 16 2 (0.7) 1 (1.1) 3 (0.8) 
 > 18 252 (88.1) 87 (91.6) 339 (89.0) 
 > 19 3 (1.1) 0 3 (0.8) 
 > 20 18 (6.3) 4 (4.2) 22 (5.8) 
 > 21 2 (0.7) 2 (2.1) 4 (1.1) 
 > 25 1 (0.4) 0 1 (0.3) 
 > 30 1 (0.4) 0 1 (0.3) 
 > 40 1 (0.4) 1 (1.1) 2 (0.5) 
 > 45 1 (0.4) 0 1 (0.3) 
 > 60 1 (0.4) 0 1 (0.3) 
 > 65 2 (0.7) 0 2 (0.5) 
     
Maximum age of study 
participantsc (years) 
(n, %) 
    
 < 18 only 1 (0.4) 0 1 (0.3) 
 ≥ 65 38 (13.3) 14 (14.7) 52 (13.7) 
 Not specified 247 (86.4) 81 (85.3) 328 (88.1) 
     
     
Cancer typed, N (%) 
 
    
 Breast neoplasms 79 (12.3) 44 (25.7) 123 (15.1) 
 Lung neoplasms 83 (12.9) 34 (19.9) 117 (14.4) 
 Multiple myeloma 81 (12.6) 21 (12.3) 102 (12.5) 
 Colorectal 
Neoplasms 
83 (12.9) 15 (8.8) 98 (12.0) 
 Prostatic neoplasms 58 (9.0) 19 (11.1) 77 (9.4) 
(continued)             
  
91 
 
  
Early phase 
[b] 
Late phase 
[b] Total 
Cancer typed, N (%) 
Continued 
    
 Pancreatic 
Neoplasms 
38 (5.9) 10 (5.8) 48 (5.9) 
 Ovarian neoplasms 30 (4.7) 8 (4.7) 38 (4.7) 
 Head and neck 
Neoplasms 
24 (3.7) 1 (0.6) 25 (3.1) 
 Stomach neoplasms 15 (2.3) 3 (1.8) 18 (2.2) 
 Neoplasms, solid 14 (2.2) 0 14 (1.7) 
 Anal neoplasms 11 (1.7) 0 11 (1.3) 
 Gastrointestinal 
Neoplasms 
6 (0.9) 4 (2.3) 10 (1.2) 
 Otherc 122 (18.9) 12 (4.4) 134 (16.4) 
     
 Multiple conditions 23 (8.0) 1 (1.1) 24 (6.3) 
 
Genders included in 
study, N (%) 
    
 Males only 34 (11.9) 11 (11.6) 45 (11.8) 
 Females only 33 (11.5) 20 (21.1) 53 (13.9) 
 All 218 (76.0) 62 (65.3) 280 (73.5) 
 Not reported 1 (0.4) 2 (2.1) 3 (0.8) 
Region enrolled     
 Ex-United States 
only 
52 (18.2) 35 (36.8) 87 (22.8) 
 United States only 159 (55.6) 3 (3.2) 162 (42.5) 
 U.S. and ex-U.S. 67 (23.4) 54 (56.8) 121 (31.8) 
 Not reported 8 (2.8) 3 (3.2) 11 (2.9) a. Participant	data	within	studies	was	aggregated.	b. Study	phase	of	less	than	III	as	well	as	seamless	studies	of	Phase	II/III	were	considered	early.		c. Maximum	age	was	often	not	specified	indicating	that	adults	of	any	age	could	be	included	in	the	study.	Some	studies	reported	extreme	age	values	such	as	105,	rather	than	leaving	the	field	blank,	still	indicating	that	adults	of	any	age	could	enroll	in	the	study.	d. A	complete	list	of	disease	conditions	can	be	found	in	Appendix	XX.	Overall	counts	within	a	classification	of	less	than	10	were	combined	into	the	‘Other’	category.	
 
Characteristics of the Included Studies 
As a result of the criteria to be included in this study, most studies were reported 
by researchers to be interventional (Early: 99.7%; Late: 97.9%) of which most were drug 
treatment studies (Early: 96.2%; Late: 94.7%). Of the early phase studies, 23.1% were 
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identified as using adaptive methods and 41.1% of late phase studies used adaptive 
methods. Of the drug treatment studies, protein kinase inhibitors were primarily used in 
both phases of studies (Early: 17.4%; Late: 17.5%). Early phase studies tended to be 
single arm studies (54.9%) where late phase studies tended to have two treatment arms 
(79.0%). Primary funding for early phase studies came from industry (50.0%) and from 
other sources (41.3%), whereas late phase studies got most of their primary funding from 
industry (88.4%). Most of the studies were initiated from 2011 through 2014, but this was 
also likely related to the randomization sequencing where a greater weight of selection 
was placed on more recently initiated studies to increase the likelihood of the inclusion of 
adaptive studies as noted by other researchers (Hatfield et al., 2016). A description of 
study initiation by design method (early versus late) is shown in Figure 4. Figure 5 
includes the study design by year of initiation. Most studies were completed (57.5%) or 
active and not recruiting (24.9%) for both study phases (early versus late).  
For studies included in the analysis, if an early or late study was stopped 
prematurely, the primary reason was due to futility or safety (Early: 52.8%; Late: 40.0%). 
As expected, late phase studies had greater duration in comparison to early phase studies, 
though the median difference was only 2 months (28.0 versus 30.0 months respectively). 
The time until results were entered in the Clinical Trials database was comparable as well 
(Early: 13.0 months; Late: 12.0 months), though the Clinical Trials database result 
reporting guideline is likely the driving factor for the similarities of time until results 
availability. Results were favorable for 59.1% of early phase studies and 52.6% of late 
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stage studies, of which most clinical study results included were not reported to be 
published regardless of study stage (Early: 90.9%, Late: 89.5%, Overall: 90.6%).  
As expected, late stage studies median study size were substantially larger than 
early phase studies (Median sample size Early: 22; Late: 158). Masking, data monitoring 
committees and treatment randomization was more often used in late stage studies, in 
comparison to early studies. Most studies regardless of early or late phase had a surrogate 
clinical primary endpoint. Regardless of phase, most studies also included biomarker 
assessments as a study endpoint. Median duration between early and late phase studies 
was 27.2 months (range: 10.8 to 50.0). Additional study characteristics are shown in 
Table 12.  
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Table 12 
Summary of Study Characteristics Included in Analysis 
 Early phasea Late phasea Total 
Number of studies, N (%) 286 (75.1) 95 (24.9) 381 (100.0) 
Phasea (N, %)    
Pilot/NA 6 (2.1) 0 6 (0.2) 
Early Phase I 3 (1.1) 0 3 (0.8) 
I 28 (9.8) 0 28 (7.3) 
II 199 (69.2) 0 198 (52.0) 
III 0 88 (92.6) 88 (23.1) 
IV 0 7 (7.4) 7 (1.8) 
Combined phases 51 (17.8) 0 51 (13.4) 
0/I 0 0 0 
I/II 46 (16.1) 0 46 (12.1) 
II/III 5 (1.8) 0 4 (1.1) 
Not reported 0 0 0 
    
Study type (N, %) 0 0 0 
Expanded access    
Interventional 285 (99.7) 93 (97.9) 378 (99.2) 
Observational 0 0 0 
Observational – patient registry 0 0 0 
Not reported  1 (0.4) 2 (2.1) 3 (0.8) 
    
Treatment classificationb  (N, %)    
Drug 275 (96.2) 90 (94.7) 365 (95.8) 
Device 6 (2.1) 1 (1.1) 7 (1.8) 
Biological/vaccine 0 0 0 
Procedure/surgery 24 (8.4) 0 24 (6.3) 
Radiation 17 (5.9) 4 (4.2) 21 (5.5) 
Other 30 (10.5) 4 (4.2) 34 (8.9) 
Combination treatment 145 (50.7) 49 (51.6) 194 (50.9) 
    
Drug treatmentcd (N, %)    
Cisplatin 26 (4.0) 1 (0.6) 27 (3.3) 
Paclitaxel 16 (2.5) 11 (6.4) 27 (3.3) 
Cyclophosphamide 25 (3.9) 0 25 (3.1) 
Trastuzumab 14 (2.2) 10 (5.8) 24 (2.9) 
Docetaxel 14 (2.2) 8 (4.7) 22 (2.7) 
Gemcitabine 18 (2.8) 4 (2.3) 22 (2.7) 
Carboplatin 16 (2.5) 5 (2.9) 21 (2.6) 
Fluorouracil 16 (2.5) 4 (2.3) 20 (2.5) 
Dexamethasone 14 (2.2) 5 (2.9) 19 (2.3) 
Prednisone 11 (1.7) 5 (2.9) 16 (2.0) 
Bortezomib 11 (1.7) 3 (1.8) 14 (1.7) 
Capecitabine 12 (1.9) 2 (1.2) 14 (1.7) 
Oxaliplatin 14 (2.2) 0 14 (1.7) 
Aldesleukin 13 (2.0) 0 13 (1.6) 
(continued)
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Table 12 Continued 
 Early phasea Late phasea Total 
Drug treatment continued    
Bevacizumab 8 (1.2) 5 (2.9) 13 (1.6) 
Fludarabine 13 (2.0) 0 13 (1.6) 
Irinotecan 11 (1.7) 2 (1.2) 13 (1.6) 
Lenalidomide 10 (1.6) 3 (1.8) 13 (1.6) 
Erlotinib 10 (1.6) 2 (1.2) 12 (1.5) 
Leucovorin 9 (1.4) 2 (1.2) 11 (1.3) 
Abiraterone 9 (1.4) 1 (0.6) 10 (1.2) 
Pertuzumab 7 (1.1) 3 (1.8) 10 (1.2) 
Otherd 338 (52.5) 93 (83.0) 431 (52.9) 
    
Drug classificationcd (N, %)    
Protein kinase inhibitors 112 (17.4) 30 (17.5) 142 (17.4) 
Monoclonal antibodies 77 (12.0) 29 (17.0) 106 (13.0) 
Taxanes 43 (6.7) 21 (12.3) 64 (7.9) 
Platinum compounds 57 (8.9) 6 (3.5) 63 (7.7) 
Pyrimidine analogues 50 (7.8) 10 (5.8) 60 (7.4) 
Other antineoplastic agents 40 (6.2) 13 (7.6) 53 (6.5) 
Nitrogen mustard analogues 32 (5.0) 1 (0.6) 33 (4.0) 
Other 24 (3.7) 2 (1.2) 26 (3.2) 
Corticosteroids 16 (2.5) 6 (3.5) 22 (2.7) 
Anti-androgens 13 (2.0) 7 (4.1) 20 (2.5) 
Other immunosuppressants 14 (2.2) 4 (2.3) 18 (2.2) 
Folic acid metabolite 13 (2.0) 3 (1.8) 16 (2.0) 
Glucocorticoids 11 (1.7) 5 (2.9) 16 (2.0) 
Drug classification continued    
Interleukins 14 (2.2) 0 14 (1.7) 
Purine analogues 13 (2.0) 0 13 (1.6) 
Other hormone antagonists and related 
agents 
9 (1.4) 1 (0.6) 10 (1.2) 
Otherd 106 (16.5) 33 (19.3) 139 (17.1) 
    
Number of treatment arms (N, %)    
1 157 (54.9) 11 (11.6) 168 (44.1) 
2 80 (28.0) 75 (79.0) 155 (40.7) 
3 27 (9.4) 4 (4.2) 31 (8.1) 
4 9 (3.2) 2 (2.1) 11 (2.9) 
> 5 12 (4.2) 1 (1.1) 13 (3.4) 
Not reported 1 (0.4) 2 (2.1) 3 (0.8) 
    
Primary funding source    
Industry 143 (50.0) 84 (88.4)  227 (59.6) 
Public 23 (8.0) 1 (1.1) 24 (6.3) 
Both 0 0 0 
Other 118 (41.3) 8 (8.4) 126 (33.1) 
Not reported  2 (0.7) 2 (2.1) 4 (1.1) 
   (continued) 
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Table 12 Continued 
 Early phasea Late phasea Total 
Additional funding source    
Industry 42 (14.7) 1 (1.1) 43 (11.3) 
Public 16 (5.6) 3 (3.2) 19 (5.0) 
Other 2 (0.7) 4 (4.2) 6 (1.6) 
More than one 5 (1.8) 1 (1.1) 6 (1.6) 
Not reported/none 221 (77.3) 86 (90.5) 307 (80.6) 
    
Year study registered     
1999 1 (0.4) 2 (2.1) 3 (0.8) 
2005 2 (0.7) 2 (2.1) 4 (1.1) 
2006 2 (0.7) 4 (4.2) 6 (1.6) 
2007 8 (2.8) 6 (6.3) 14 (3.7) 
2008 6 (2.1) 1 (1.1) 7 (1.8) 
2009 8 (2.8) 0 8 (2.1) 
2010 9 (3.2) 0 9 (2.4) 
2011 32 (11.2) 8 (8.4) 40 (10.5) 
2012 94 (32.9) 25 (26.3) 119 (31.2) 
2013 68 (23.8) 22 (23.2) 90 (23.6) 
2014 35 (12.2) 21 (22.1) 56 (14.7) 
2015 14 (4.9) 2 (2.1) 16 (4.2) 
2016 7 (2.5) 2 (2.1) 9 (2.4) 
    
Study status (n, %)    
Active, not recruiting 54 (18.8) 41 (43.2) 95 (24.9) 
Completed 177 (61.9) 42 (44.2) 219 (57.5) 
Suspended 0 0 0 
Unknown 2 (0.7) 2 (2.1) 4 (1.0) 
Terminated 53 (18.5) 10 (10.5) 63 (16.5) 
Reason stopped    
Accrual problem 6 (11.3) 2 (20.0) 8 (2.1) 
Business decision 7 (13.2) 1 (10.0) 8 (2.1) 
Complete 1 (1.9) 0 1 (0.3) 
Funding problem 1 (1.9) 0 1 ( 0.3) 
Futility or safety concerns 28 (52.8) 4 (40.0) 32 (8.4) 
Other reason 3 (5.7) 2 (20.0) 5 (1.3) 
Not reported 7 (13.2) 1 (10.0) 8 (2.1) 
    
Duration of study (months)     
Median 28.0 30.0 28.0 
(Min, max, STD, N) (3, 185, 18.0, 
282) 
(9, 261, 35.5, 
93) 
(3, 261, 23.8, 
375) 
    
Time until results entered in database 
(months)  
   
Median 13.0 12.0 13.0 
(Min, max, STD, N) (1, 125, 20.8, 
285) 
(3, 87, 14.3, 94) (1, 125, 19.5, 
379) 
(continued)
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Table 12 Continued 
 Early phasea Late phasea Total 
Outcome of study    
Favorable 169 (59.1) 50 (52.6) 219 (57.5) 
Equivalent 4 (1.4) 7 (7.4) 11 (2.9) 
Unfavorable 113 (39.5) 38 (40.0) 151 (39.6) 
    
Journal publication    
Yes 43 (15.0) 10 (10.5) 53 (13.9) 
No 241 (84.3) 83 (87.4) 324 (85.0) 
Unknown 2 (0.7) 2 (2.1) 4 (1.1) 
 
Results publishede 
   
Yes 24 (8.4) 8 (8.4) 32 (8.4) 
No 260 (90.9) 85 (89.5) 345 (90.6) 
   Unknown 2 (0.7) 2 (2.1) 4 (1.1) 
    
Design characteristics    
Actual – median  22 158  36.0 
(Min, max, STD, N) (1, 343, 47.9, 
284) 
(8, 2091, 275.5, 
94) 
(1, 2091, 167.9, 
378) 
    
Study primary purpose    
Basic science 0 0 0 
Diagnostic 0 0 0 
Health services 0 0 0 
Research    
Other 0 0 0 
Prevention 0 0 0 
Screening 0 0 0 
    
Study primary purpose continued    
Supportive care 0 0 0 
Treatment 285 (99.3) 93 (97.9) 378 (97.7) 
Not reported 2 (0.7) 2 (2.1) 4 (1.0) 
    
Study design    
Adaptive 66 (23.1) 39 (41.1) 106 (27.6) 
Traditional 220 (76.9) 56 (59.0) 276 (72.4) 
    
Masking    
No 258 (90.2) 57 (60.0) 315 (82.7) 
Yes 26 (9.1) 36 (37.9) 62 (16.3) 
Type of masking    
Single 3 (11.5) 1 (2.8) 4 (6.5) 
Double 10 (38.5) 14 (38.9) 24 (38.7) 
Triple 4 (15.4) 3 (8.3) 7 (11.3) 
Quadruple 9 (34.6) 18 (50.0) 27 (43.6) 
Not reported 2 (0.7) 2 (2.1) 4 (1.1) 
Subject 25 (96.2) 34 (94.4) 59 (95.2) 
Caregiver 13 (50.0) 21 (58.3) 34 (54.8) 
Investigator 22 (84.6) 33 (91.7) 55 (88.7) 
Outcome assessor 11 (42.3) 20 (55.6) 31 (50.0) 
(continued)
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Table 12 Continued 
 Early phasea Late phasea Total 
Randomization    
Nonrandomized 52 (18.2) 2 (2.1) 54 (14.2) 
Randomized 80 (28.0) 80 (84.2) 160 (42.0) 
Not reported 154 (53.9) 13 (13.7) 167 (43.8) 
    
Intervention model     
Crossover 2 (0.70) 1 (1.1) 3 (0.8) 
Factorial 1 (0.4) 0 1 (0.3) 
Parallel  92 (32.2) 78 (82.1) 170 (44.6) 
Sequential 3 (1.1) 1 (1.1) 4 (1.1) 
Single group 184 (64.3) 11 (11.6) 195 (51.2) 
Not reported 4 (1.4) 4 (4.2) 8 (2.1) 
    
Data monitoring committee (DMC)    
Yes 126 (44.0) 54 (56.8) 180 (47.2) 
    
Type of primary endpointe    
Surrogate 271 (94.8) 73 (76.8) 344 (90.3) 
Clinical 286 (99.7) 95 (100) 380 (99.7) 
Clinical and surrogate 269 (94.1) 73 (76.8) 342 (89.8) 
    
Biomarker endpoint includede    
No 1 (0.40) 4 (4.2) 5 (1.3) 
Yes 285 (99.6) 91 (95.8) 376 (98.7) 
    
Time between late-and early-phase studies 
(months)f 
   
Median (Q1, Q3) 
(Min, Max, STD, N) 
- - 27.2 (10.8, 50.0) 
(0.2, 111.6, 
26.3, 251) a. Study	phase	of	less	than	III	as	well	as	seamless	studies	of	phase	II/III	were	considered	early	since	they	included	an	early	phase	component.		b. A	single	study	could	be	classified	in	multiple	treatment	interventions,	thus	percentages	will	add	up	to	greater	than	100%.	c. Overall	counts	within	a	treatment	classification	of	less	than	10	were	combined	into	the	‘Other’	category.	A	complete	list	of	experimental	treatments	and	drug	classifications	can	be	found	in	the	Appendix	C.		d. As	study	treatments	could	include	combination	therapy,	a	single	study	could	be	represented	in	multiple	rows.	e. Results	could	be	published	in	a	journal,	or	presented	at	a	conference	etc.	f. A	surrogate	endpoint	is	defined	to	be	a	primary	endpoint	that	is	not	overall	survival.	Clinical	endpoint	is	defined	to	be	the	primary	endpoint	that	measures	the	clinical	benefit	of	the	treatment	such	as	response	or	progression	free	survival.	A	biomarker	endpoint	is	defined	to	be	a	biological	measure	that	predicts	a	clinical	outcome	(primary	or	secondary).	g. Only	positive	time	between	studies	(early	phase	study	is	initiated	before	the	results	of	late	phase	study)	are	summarized.	
 
  
99 
 
Figure 4. Study phase (early versus late) by year. 
 
 
 
Figure 5. Study design (traditional versus adaptive) by year. 
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Changes in Data Analysis Plan 
While the study outcome was collected in three categories (favorable, equivalent 
and nonfavorable), there were limited equivalence studies (N = 11) identified in the 
random analysis sample. In equivalency studies, a favorable result would be equivalence 
(as noted in Chapter 3, Research Design and Rationale Section). As a result, studies with 
outcomes that were deemed equivalent will be included as favorable in this analysis.  
Due to lack of variability in the analysis dataset with respect to treatment 
classification, a modification was made to the third planned hypothesis of assessing the 
influence of treatment classification. The majority of studies (95%) were drug treatment 
studies and frequencies of device (1.8%), procedure/surgery (6.3%) or radiation (5.5%) 
studies reported were quite low. As a result, drug classification (include the proportions 
in each category) was assessed in the model rather than treatment classification. 
The clinical trials database includes disease condition or conditions, with the 
Medical Subject Heading (MeSh) terms that were included within the same database 
field. However, programmatic identification of the disease condition was inconsistent for 
approximately 26% of the studies included in the analysis. This issue was identified at 
analysis, after the random sample of the Clinical Trials database was determined. As a 
result, the planned stratified random sample based on the disease conditions being 
correctly identified, were no longer balanced. Programmatic extraction was also difficult 
when there were multiple conditions within a single study due to the multiple MeSH 
terms. Though not in the original analysis plan, all programmatically identified disease 
conditions included in the random sample, I manually reviewed and verified.  
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In addition, a greater rate of studies that were reported to have results, were 
actually incomplete studies. The primary reason for these studies being incomplete was 
due to lack of accrual. Even with a random sample expanded to 537 rather than the 
planned 450, only 381 studies were included in this study with complete results. As 
shown in Table 13, a reduced sample size and varying percentage between the groups of 
interest (traditional versus adaptive), led to varying power than originally computed. 
Nonetheless, all randomly identified studies with available complete results were 
included in the analysis. See Figure 3, Tables 8 and 9 for power estimates as well as a 
summary of studies included and excluded from the analysis. 
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Table 13 
 
Actual Sample Size with Assumptions for Proportion Positive Outcome, Power and Type I 
Error 
  Proportion positive outcomes Sample size 
Power (%) Type 1 Traditional Adaptive Traditional  Adaptive 
94 0.05 0.22 0.46 220 66 
80 0.05 0.30 0.50 220 66 
40 0.05 0.25 0.37 220 66 
32 0.05 0.22 0.32 220 66 
29 0.05 0.27 0.37 220 66 
      
81 0.05 0.22 0.46 154 42 
60 0.05 0.30 0.50 154 42 
28 0.05 0.25 0.37 154 42 
22 0.05 0.22 0.32 154 42 
19 0.05 0.27 0.37 154 42 
      
50 0.05 0.22 0.46 94 22 
33 0.05 0.30 0.50 94 22 
14 0.05 0.25 0.37 94 22 
11 0.05 0.22 0.32 94 22 
10 0.05 0.27 0.37 94 22 
      
85 0.05 0.22 0.46 185 47 
66 0.05 0.30 0.50 185 47 
31 0.05 0.25 0.37 185 47 
24 0.05 0.22 0.32 185 47 
21 0.05 0.27 0.37 185 47 
 
The initial data analysis plan was to include studies that were initiated January 1, 
2000 to December 31, 2016. In the end, studies included, were any oncology intervention 
studies that had results available at extraction regardless of initiation date. The 
intervention studies included in this analysis were initiated after November 1, 1999 to 
December 31, 2016. 
The random forest analysis of the time between the early and late stage study was 
not conducted, as the procedure within SAS Enterprise Miner was not available. As a 
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result, the quartiles of the duration of time were computed and included in the analysis 
model. 
Univariate Analysis of Covariates  
The univariate analyses included the following variables: experimental treatment, 
cancer type, experimental drug classification, duration between studies (months), study 
funding, type of endpoint, sample size and biomarker endpoint. Due to sparse or lack of 
variability in the data, robust estimates could not be computed for some independent 
variables included in the model. Of the univariate analyses, the only covariate, duration 
of time between studies was found to be overall statistically significant with late phase 
outcome as the dependent variable (p value=0.03). There were lower odds of having a 
favorable outcome for older studies (greater than Q3) in comparison to more recent 
studies (less than Q1) (OR: 0.33; 0.14, 0.77). This indicates that there were higher odds 
of less favorable outcomes for studies greater than Q3 in comparison to studies less than 
Q1 (OR: 0.33; 95% CI: 0.14, 0.77). Table 14 provides additional details of the univariate 
covariate analysis with late phase results outcome. Figure 6 also provides a visual of the 
odds ratio for the univariate analyses conducted. 
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Table 14  
Univariate Covariate Analysis with Late Stage Results as Outcome 
Univariate covariate DF Estimate 
Standard 
error 
(SE) 
Odds ratio (OR) 
and 95% 
confidence 
interval 
Overall p 
value/ 
p value 
Phase      
NA/Phase 1 1 -0.48 0.46 0.62 (0.25, 1.53) 0.30 
Phase I / Phase II 1 0.43 0.34 1.54 (0.79, 3.01) 0.21 
Phase II (ref) 1 --- --- --- --- 
Experimental treatment 
classification  
--- NE NE NE Most studies 
were drug 
trials, so 
limited 
variability for 
this analysis. 
      
Adaptive  1 -0.17 0.18 0.71 (0.36, 1.42) 0.33 
Cancer type      0.19 
Breast  1 -0.31 0.36 0.43 (0.08, 2.38) 0.39 
Colorectal 1 0.29 0.49 0.78 (0.12, 5.02) 0.55 
Head and neck 1 0.14 0.67 0.67 (0.08, 5.54) 0.84 
Lung  1 -0.56 0.35 0.33 (0.06, 1.84) 0.12 
Multiple myeloma 1 1.12 0.61 1.79 (0.24, 13.4) 0.06 
Neoplasms, solid 1 0.54 0.64 1.00 (0.13, 7.89) 0.39 
Ovarian 1 0.04 0.40 0.61 (0.10, 3.53) 0.92 
Pancreatic 1 -0.56 1.28 0.33 (0.01, 8.18) 0.67 
Prostatic 1 -1.25 0.59 0.17 (0.02, 1.23) 0.03 
Other (ref) --- --- --- --- --- 
      
Experimental drug 
classification 
     
Anthracyclines and related 
substances 
--- NE NE NE 0.97 
Anti-androgens --- NE NE NE 0.99 
Corticosteroids --- NE NE NE 0.97 
Folic acid metabolite --- NE NE NE 0.99 
Glucocorticoids --- NE NE NE 0.98 
Monoclonal antibodies --- NE NE NE 0.99 
Nitrogen mustard analogues --- NE NE NE 0.98 
Other alkylating agents --- NE NE NE 0.99 
Other antineoplastic agents --- NE NE NE 0.97 
Other hormone antagonists 
and related agents 
--- NE NE NE 0.98 
Other immunosuppressants --- NE NE NE 0.98 
Platinum compounds --- NE NE NE 0.99 
Protein kinase inhibitors --- NE NE NE 0.98 
Pyrimidine analogues --- NE NE NE 0.99 
Taxanes --- NE NE NE 0.99 
Other (ref) --- --- --- --- --- 
(continued) 
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Table 14 Continued 
Univariate covariate DF Estimate 
Standard 
error 
(SE) 
Odds ratio (OR) 
and 95% 
confidence 
interval 
Overall p 
value/ 
p value 
Duration between studies 
(months) 
    0.03 
Greater than Q3 -0.60 1 -0.60 0.25 0.02 
Between Q2-Q3 0.34 1 0.34 0.27 0.21 
Between Q1-Q2 -0.24 1 -0.24 0.25 0.34 
Less than Q1 (ref) --- --- --- --- --- 
      
Study funding      0.36 
Industry -0.28 1 -0.28 0.43 0.52 
NIH 0.13 1 0.13 0.82 0.87 
Other (ref) --- --- --- --- --- 
      
Sensitivity variables      
Type of endpoint      
Surrogate NE --- NE NE NE 
Clinical NE --- NE NE NE 
      
Sample size     0.44 
 --- 1 -0.004 0.004 0.44 
 0.004     
      
Biomarker     .056 
Yes 0.21 1 0.21 0.35 0.56 
No (ref) --- --- --- --- --- 
a. Reference groups for the odds ratio and p value comparison are identified by (ref). 
Favorable/unfavorable: 120/76 
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Figure 6. Odds ratio and corresponding 95% CI for univariate analyses.  
Table 15 assesses the relationship between the early phase adaptive classification, 
the covariate and the late stage study outcome. Due to lack of variability some statistical 
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classification and type of endpoint. Estimates and significance of the covariates were 
similar in value and direction as what was seen in Table 14 (univariate analysis with late 
stage results as outcome). 
Table 15  
 
Influence of Specified Covariate on Adaptive Design Estimates in a Bivariate Model with 
Late Stage Results as Outcome 
Univariate covariate DF Estimate 
Standard 
error 
(SE) 
Odds ratiob (OR) 
and 95% 
confidence 
interval (CI) p value 
Phase 1 -0.38 0.37 0.69 (0.33, 1.41) 0.31 
Experimental treatment 
classificationa 
 
1 -0.31 0.36 0.73 (0.38, 1.50) 0.40 
      
Cancer type  1 -0.35 0.40 0.71 (0.32, 1.54) 0.38 
      
Experimental drug 
classification 
1 -0.21 0.43 0.81 (0.35, 1.87) 0.62 
Duration between studies 
(months) 
1 -0.37 0.37 0.69 (0.34, 1.42) 0.31 
Study funding  1 -0.49 0.37 0.62 (0.30, 1.27) 0.19 
      
Sensitivity variables      
Sample size 
 
1 -0.33 0.35 0.72 (0.36, 1.44) 0.35 
Type of endpoint      
Surrogatea 1 -0.34 0.35 0.71 (0.36, 1.42) 0.33 
Clinicala 1 -0.34 0.35 0.71 (0.36, 1.42) 0.33 
Sample size 1 -0.33 0.35 0.72 (0.36, 1.44) 0.35 
Biomarker  1 -0.32 0.35 0.73 (0.36, 1.46) 0.37 
a. Not fully adjusted as the model was over-parameterized by the included covariate. 
b. Odds ratio of adaptive design methods versus traditional, adjusted for specified covariate. 
Favorable/unfavorable: 120/76 
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Figure 7. Odds ratio and corresponding 95% CI for univariate analyses adjusting for 
covariate adaptive design.  
Bayesian Analysis 
 For all hypotheses driven logistic regression analyses conducted, a 
noninformative prior was utilized with a Gamerman sampling algorithm. Noninformative 
priors were selected as no similar studies had been conducted, thus no prior knowledge of 
the distribution or estimates were available. The Gamerman algorithm is known for its 
good performance in generalized linear models (Stokes, Chen and Gunes, 2014). A burn-
in size of 2000 was used to reduce the chances of bias with initial estimates that may not 
be representative of the posterior distribution and Markov chain samples of 20,000 was 
used, unless otherwise specified. Thinning Markov chains to reduce the autocorrelation, 
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which may lead to biased estimates, was generally not used if the chain converged unless 
deemed necessary. Convergence assessment through multiple statistical tests were 
utilized including the effective sample sizes (ESS), Gelman-Rubin statistic, Geweke, 
Heidelberger-Welch, Raftery-Lewis statistics were used. Trace plots were used to 
visually assess good sample mixing and whether autocorrelation was acceptable for all 
parameters. 
Results 
Association between Adaptive Design in Early Phase sStudies and Outcome of Late 
Phase Studies (Hypothesis 1) 
Early and late phase studies were merged based on the treatment of which 196 
unique matched pairs (unique early and late study combinations based on treatment) were 
used in the analysis. Cancer type was not matched as researchers commonly share and 
use results of previously approved studies with common treatment to make decisions on 
the possibility of new indications (Institute of Medicine (US) Forum on Drug Discovery, 
2010). Redundant combination studies with multiple populations were filtered for the 
analysis. Confounding variables in the initial model included study design, phase of 
study, duration between studies, type of endpoint and, primary funding source. The 
association between early phase design methods and late phase outcomes were assessed 
using Bayesian logistic regression methods with a noninformative prior.  
The initial model was over-parameterized likely due to the lack of variability in 
some of the variables. The variables sample size, surrogate endpoint and clinical endpoint 
were dropped from the model due to over-parameterization and lack of variability. Study 
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funding was reduced from three levels to two as the category, NIH only had a frequency 
of 3. As evidenced by the initial trace plots and the evidence of possible nonconvergence, 
the burn-in was increased from 2000 to 3000 while the number of simulations remained 
the same (N = 20,000). The final trace plots looks satisfactory as well as the convergence 
test.   
The Gelman-Rubin and Geweke convergence tests were re-assessed with 3000 
burn-in simulations and moderate test statistics for the intercept and the adaptive 
parameter indicating that convergence of the Markov chain has been satisfied. The 
Raftery-Lewis test was also conducted and both the dependence factors for the intercept 
as well as the adaptive design variable and other confounding variables were the 
appropriate level, indicating that there is no concern with respect to correlation between 
samples. The Heidelberger-Welch stationarity and half-width diagnostics were conducted 
and all outcomes were satisfactory, indicating that correlation of samples was not a 
concern and the simulation sample size was appropriately large. The Effective Sample 
Size (ESS) was also assessed. The ESS was identified to be large enough for the 
intercept, adaptive design covariate and other confounding variables indicated good 
mixing. Additional details are shown in Table 16.  
The trace plots diagnostics for the intercept, adaptive variable and the 
confounding variables were assessed. Convergence was further assessed via the trace 
plots and good mixing is apparent (Figure 8). The posterior autocorrelation was also 
assessed, by reviewing the trace plots and the drop off is rapid, indicating there is 
adequate mixing of the Markov chain. For additional details, see Figure 8. All diagnostics 
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of the model indicate that the model is stable and the posterior estimates can be assessed. 
Details of all hypotheses model fit are in Table 16. 
Table 16  
 
Assessment Statistics for the First Hypothesis Model: Early Phase Adaptive Design 
Utilization and the Association with Late Phase Study Outcome (Burn-in=3000, MCMC 
simulations=20,000) 
Model assessment test Adaptive parameter Other parametersa 
Gelman-Rubin  
(estimate, 97.5% bound) 
1.00 
 
1.00 
 
 
Geweke Z (p-value) -0.11 (0.92) -1.11 (0.27) 
Heidelberger-Welch 
(stationarity test, half-width test) 
 
Pass; Pass 
 
Pass;Pass for all 
 
Raftery-Lewis  
(dependence factor) 
 
 
2.71 
 
1.65 
Effective sample sizes (range) 8405 (6907, 8186) 
a. Confounding variables include: Duration between studies, primary funding source, type of endpoint 
(biomarker, surrogate, clinical) and phase of study. 
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Figure 8. Trace plots for the Bayesian logistic regression analysis of the early phase 
covariate adaptive and the late phase study outcome for the intercepta and adaptive 
covariateb. 
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The odds ratio estimate was computed using PROC PLM along with the 95% 
highest posterior density (HPD), the Bayesian equivalent of the frequentist confidence 
intervals. The odds ratio was 0.66 with a 95% HPD of 0.20 to 1.21 for adaptive design 
controlling for the other confounding variables in the model. In the adjusted model, while 
the estimate was not significant (95% HPD includes 1), there does appear to be a lower 
odds of a positive outcome in late stage studies when adaptive methods are utilized in 
early phase studies. Additional details can be found in Table 18. 
Table 17  
Fit Statistics Related to All Three Hypotheses 
   Fit statistics 
Model Seed Description DIC pD 
Hypothesis 1a 1234 Outcome (+/-) = Design Method (Adaptive/Traditional) 265.2 9.12 
Hypothesis 2b  1234 Outcome(+/-) = Design Method (Adaptive/Traditional) 
+ Condition + interaction 
123.8 4.8 
Hypothesis 3c 1234 Outcome(+/-) = Design Method (Adaptive/Traditional) 
+ Drug Class + interaction 
292.0 6.9 a. Adjusting	for	confounding	variables:	phase	of	study,	biomarker	endpoint,	duration	between	studies	and	primary	funding	source.	b. Adjusting	for	confounding	variables:	disease	condition	and	interaction	term	(adaptive	*	disease	condition)	c. Adjusting	for	confounding	variables:	drug	classification	and	interaction	term	(adaptive	*	drug	classification)		
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Table 18  
 
Posterior Estimate Summaries for Hypothesis 1: Early Phase Adaptive Design Utilization 
and the Association with Late Phase Study Outcome (Burn-in=3000, MCMC 
simulations=20,000) 
Parameter Mean 
Standard 
deviation HPD Interval OR (95% HPD) 
Intercept 1.36 0.44 0.5020 2.2321 --- 
Adaptive -0.51 0.42 -1.3120 0.3162 0.66 (0.20, 1.21) 
Duration between studies      
Between Q1-Q2 -0.23 0.48 -1.1709 0.7018 0.89 (0.21, 1.78) 
Between Q2-Q3 -0.89 0.45 -1.7513 0.0326 0.45 (0.12, 0.88) 
Greater than or equal to Q3 -1.17 0.48 -2.1171 -0.2479 0.35 (0.08, 0.68) 
Funding source - Industry -0.27 0.37 -0.9431 0.4932 0.82 (0.30, 1.45) 
Biomarker endpoint 0.22 0.86 -1.5080 1.8718 1.82 (0.09, 5.29) 
Study phase      
NA/Phase1 -0.77 0.51 -1.7486 0.2357 0.53 (0.13, 1.09) 
Phase 1/Phase 2 0.25 0.39 -0.5353 1.0158 1.39 (0.46, 2.54) 
Favorable/unfavorable: 120/76 
 
Figure 9. Odds ratio of favorable versus unfavorable results, when adaptive methods 
versus traditional design are adopted and corresponding 95% HPD controlling for 
confounding variables.  
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Association of Adaptive Design and Study Outcomes across Cancer Types 
(Hypothesis 2) 
The second hypothesis of this study was to assess the association between early 
phase oncology design methods and the outcome of late stage clinical trials adjusting for 
specific cancer types and the interaction between adaptive design and cancer type. For 
this analysis, 116 unique early phase and late phase study combinations were identified 
that were matched on treatment and cancer type. Due to model over-parameterization and 
low frequencies for some cancer types, cancer types were limited to breast, lung and all 
other cancer types were combined in the ‘other’ category based on frequencies. 
Confounding variables in the initial model included study design, phase of study, 
duration between, type of endpoint, primary funding source, whether the study was 
combination treatment or not and the time between late and early phase studies. 
Combination treatment was included in the model as different treatments could be 
represented by the same study. All confounding variables were removed in the final 
model due to over-parameterization and lack of convergence. The interaction terms 
between adaption and cancer types were included in the model, and it was noted that the 
estimated parameter was in the positive direction, unlike the adaptive parameter estimate, 
which was negative, though not significant. The convergence tests appeared to be 
acceptable, though the trace plots indicated that autocorrelation remained a concern at 
lags greater than 10. The number of Monte Carlo simulations was increased to 35,000 
and the burn in time was also increased to 5,000, which lead to more stable convergence 
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indicators. The final model included the variables adaptive, disease condition and the 
interaction term between the variables. Details can be found in Table 19.  
Table 19  
 
Assessment Statistics of the Model for the Second Hypothesis Model: Early Phase 
Adaptive Design Utilization and the Association with Late Phase Study Outcome 
Controlling for Disease Condition 
Model assessment test 
Adaptive 
parameter Cancer type Interaction termsa 
Gelman-Rubin  
(estimate, 97.5% bound) 
1.00 
(1.00) 
1.00 
(1.00) 
1.00 
(1.00) 
Geweke Z (p-value) -0.42 (0.68) < 1.42 (>0.16) >0.41  
(>0.67) 
Heidelberger-Welch 
(stationarity test, half-width test) 
Passed/Passed  Passed/failedb Passed for all 
Raftery-Lewis  
(dependence factor) 
5.42 <16.80 <12.83 
Effective sample size 1210 <2478 <1211 a. All	individual	parameters	have	assessment	statistics	and	can	be	found	in	Appendix	D.	The	worst	represented	parameter	statistic	is	displayed	in	the	table.	b. Disease	condition=”Other”	did	not	pass	the	Heidelberger-Welch	half-width	test.	
The cancer type (lung versus breast cancer) in the model was significant in the 
model (β=-2.21, 95% HPD interval: -3.56, 0.89), indicating that the variable contributes 
to the association between early phase design methods and late stage outcome.  Odds 
ratios were not computed for each individual term in the model due to the interaction 
term. Lung cancer and other cancer studies have a higher odds of positive outcome when 
adaptive designs are used in comparison to traditional methods, though not significant 
(Lung - OR: 3.29, 95% HPD: 0.13, 9.97; Other - OR: 7.65, 95% HPD: 0.15, 27.90).   
Breast cancer also had reduced odds of a positive outcome when adaptive methods are 
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used in comparison to traditional methods, though the results were once again not 
significant and with very wide HPD (OR: 0.04, 95% HPD: 0.0, >50). Additional details 
can be found in Table 20.   
Table 20  
 
Model Estimates for Hypothesis 2: Early Phase Adaptive Design Utilization and the 
Association with Late Phase Study Outcome Controlling for Disease Condition 
Parameter Mean 
Standard 
deviation HPD intervals 
Odds ratio 
(OR) OR HPD 
Intercept 1.47 0.43 0.63, 2.27 --- --- 
Adaptive -449 352 -1143, 0.6146 --- --- 
Cancer typea      
Lung -2.21 0.70 -3.56, -0.89 --- --- 
Other 0.05 0.58 -1.07, 1.24 --- --- 
Interaction      
Adaptive (yes) x Lung 450 351.7 -1.22, 1142 --- --- 
Adaptive (yes) x Other  451 351.7 0.03, 1144 --- --- 
Adjusted estimates for adaptive versus 
traditional by cancer type 
    
Lung cancerb 0.74 0.95 -1.21, 2.50 3.29 (0.13, 9.97) 
Other cancerb 1.36 1.15 -0.79, 3.60 7.65 (0.15, 27.90) 
Breast cancerb -499.4 351.7 -1143, 0.61 0.04 (0.0, >50) Favorable/unfavorable:	85/31;		a. Reference	groups:	Combination	treatment	–	No;	Cancer	type	–	Breast	cancer;		b. Reference	group:	traditional	design;	
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Figure 10. Odds ratio of favorable versus unfavorable results when adaptive versus 
traditional methods are adopted and corresponding 95% HPD. 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lung cancer 
Other cancer 
Breast cancer 
>50 
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Drug Treatment Classification (Hypothesis 3) 
As previously noted, the random dataset primarily included drug treatments 
(95.8%). Unfortunately very few studies in early phase and late phase reported device use 
(Early: 2.1%; Late: 1.1%), procedures or surgery (Early: 8.4%; Late: 0.0%) or radiation 
therapy (Early: 5.9%; Late 4.2%). Due to these low frequencies a model could not be 
conducted to assess the relationship between treatment classifications, early phase 
treatment design and late phase outcome. 
The analysis by treatment classification was limited as most of the studies 
included in this analysis were drug treatment. As such, the analysis of drug classification 
was conducted. For this analysis, 232 unique early phase studies combined with late 
phase studies were identified that were matched on treatment and drug classification. 
Drug classifications that had a frequency less than 20 were combined to avoid model 
over-parameterization. The final model included the drug classifications protein kinase 
inhibitors, monoclonal antibodies, taxanes and other to allow for parameter estimates. 
Confounding variables in the initial model included combination treatment (yes/no), 
duration between studies, primary funding agency, number of subjects included in the 
actual study, study endpoint (biomarker, surrogate, clinical) and study phase. Due to the 
lack of variability in the model and over-parameterization, the confounding variables 
(clinical (100%) and surrogate endpoint (100%) were also excluded from the model. 
Over-parameterization continued after multiple steps of modeling.  As a result, 
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combination treatment, time between studies, primary funding, number of patients 
enrolled, biomarker and phase of the study were dropped from the model in order to 
assess the potential interaction of drug treatment classification and the relationship with 
study design method.  Convergence was attained, however, autocorrelation between 
samples was elevated, indicating that mixing may be a concern (Minimum Geweke 
parameter p-value: 0.038) thus the burn in period was increased to 8,000 and the model 
was rerun. The trace plots of this model were assessed and the autocorrelation between 
samples did appear to drop off appropriately indicating convergence was attained. 
Thinning was also increased to 2 to reduce autocorrelation. The sampling method was 
also assessed to determine if Gibbs or Metropolis sampling algorithm would improve 
convergence and autocorrelation, but none performed as well as the Gamerman 
algorithm.  The intercept was also removed from the model, as stationarity was not 
attained as indicated by the Heidelberger-Welch Half-width diagnostic test. In	the	final	model,	the	monoclonal-adaptive	and	taxane-adaptive	interaction	terms,	did	not	pass	the	Heidelberger-Welch	half-width	diagnostic	test,	however,	all	other	convergence	tests	were	satisfactory.	As	noted	by	researchers,	Heidelberger-Welch can	be	significant,	even	when	the	trace	plots	appear	acceptable.	However,	minor	departures	from	stationarity	should	not	be	a	concern,	particularly	when	multiple	convergence	tests	are	being	used	to	assess	the	quality	of	the	model	(Modlin,	2018).	Table 21 provides additional details on the convergence statistics for this model. 
In the final model, the covariate protein kinase was determined to be significant.  
Odds ratios for each individual covariate were not computed as a result of the interaction 
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term.  Additional model details can be found in Table 22. The odds ratio for monoclonal  
antibody(MA), taxanes (TX) and other (OT) were positive, of which taxanes and other 
were significant (MA OR: 1.15, 95% HPD: 0.55, 1.79; TX OR: 2.75, 95% HPD: 1.01, 
5.16; OT, OR: 3.23, 95% HPD: 1.58, 5.46). Protein kinase inhibitors (PK) had lower 
odds of a positive study when adaptive methods were used, though 95% HPD were very 
wide, thus indicating questionable robustness of the estimates (PK OR: 0.0005, 95% 
HPD: 0, >50).  Details are included in Table 22 and Figure 11.  
Table 21  
 
Assessment of the Model for the Third Hypothesis Model: Early Phase Adaptive Design 
Utilization and the Association with Late Phase Study Outcome Controlling for Drug 
Classification 
Model assessment test 
Adaptive 
parameter 
Drug 
classification 
All other 
parametersa 
Gelman-Rubin  
(estimate, 97.5% bound) 
1.00 
(1.00) 
1.00 
(1.00) 
1.00 
(1.00) 
Geweke Z (p-value) >-1.63(>0.10) <1.22 (> 0.36) >-0.51 (>0.61) 
Heidelberger-Welch 
(stationarity test, half-width test) 
Pass/Pass Pass/Pass Pass/Passed for 
mostb 
Raftery-Lewis  
(dependence factor) 
<3.07 <25.8 <7.75 
Effective sample size <4267 <4478 <4958 a. All	parameters	have	assessment	statistics	and	can	be	found	in	Appendix	E.	The	most	significant	parameter	statistic	is	displayed	in	the	table.	b. The	Heidelberger-Welch	diagnostic	stationarity	test	passed	for	all	variables.		The	half-width	test	did	not	pass	for	the	monoclonal-adaptive	and	taxane-adaptive	interactions.	
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Table 22  
 
Model Estimates for Hypothesis 3: Early Phase Adaptive Design Utilization and the 
Association with Late Phase Study Outcome Controlling for Drug Classification 
Parameter Mean 
Standard 
deviation HPD interval 
Odds 
ratio 
(OR) 
OR 95% 
HPD 
Adaptive (yes) 1.15 0.58 0.10, 2.32 --- --- 
Drug classificationa      
Monoclonal antibody -0.90 0.41 -1.67, 0.09 --- --- 
Protein kinase inhibitor -2.65 0.85 -4.43, -1.11 --- --- 
Taxanes -0.18 0.39 -0.98, 0.58 --- --- 
Interaction      
Adaptive (yes) x Monoclonal antibody -0.26 0.85 -1.90, 1.33 --- --- 
Adaptive (yes) x Protein kinase inhibitor -779 601 -1952, 1.88 --- --- 
   Adaptive (yes) x Taxanes -0.03 1.00 -1.93, 2.04 --- --- 
Adjusted adaptive versus traditional estimates by 
drug classificationb 
    
Monoclonal antibody 0.09 0.29 -0.47, 0.65 1.15 0.55, 1.79 
Protein kinase inhibitor -391.2 300.7 -977.1, -0.66 0.0005 0, >50  
Taxanes 0.93 0.40 0.16, 1.72 2.75 1.01, 5.16 
Other 1.12 0.32 0.50, 1.73 3.23 1.58, 5.46 
Posterior summaries (simulations = 40,000) 
Favorable/unfavorable: 150/82 
a. Reference groups: Drug classification: Other;  
b. Reference group: traditional design. 
 
Monoclonal antibody 
Protein kinase inhibitor 
Taxane 
Other 
>50 
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Figure 11. Odds ratio and corresponding 95% HPD for multivariate analyses including 
drug classification.  
Sensitivity and Additional Analyses 
Due to lack of variability in the data, full model analyses were limited and leading 
to over-parameterization. As such, a full model was conducted to assess the three 
hypotheses already assessed. Once again, studies that only had a positive difference in 
time so that the early phase studies occurred prior to the late stage studies were included 
in the analysis. Studies were merged and filtered by cancer type and treatment and 116 
matched studies were included in the analysis. Clinical, surrogate and biomarker 
variables were removed from the model, as estimates for these variables could not be 
computed due to lack of variability thus model estimates were not computed.  
In addition, a forward stepwise model was conducted to confirm any assessments 
that were made for the three hypotheses of this study. Akaike Information Criteria correct 
for bias (AICC) was used to determine which variable should be removed from the 
model. Finally, a forward stepwise model was conducted that included key study 
variables specifically adaptive design of the early phase study, drug class and cancer 
type. Once again, the AICC criterion was used to determine which variables should be 
included in the model. 
The full analysis model was:  
Phase III study results = early phase design (adaptive/traditional) + early phase + 
type of cancer + drug classification + duration between early and late phase studies + 
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(months) + study funding + actual sample size + biomarker endpoint in study + surrogate 
primary endpoint + combination treatment 
Forward Stepwise Analysis 
All Covariates Could be Excluded from the Model 
A forward stepwise model was conducted that added one variable at a time 
automatically through SAS programming procedures (PROC HPGENSELECT). 
Variables were included based on the Schwartz Bayesian criterion (SBC) is used for the 
selection criteria which is a bias-corrected version of the Akaike’s information criteria 
(AICC) (Schwarz, 1978). Cancer type and biomarker were entered into the model based 
on the AICC fit statistic, however, only cancer type was retained in the final model. Table 
23 provides the final model and estimates.  
As was found in the assessment of hypothesis 2 (Table 20), lung cancer was 
significant in the model (p-value=0.003) with an odds ratio of 0.18 (95% CI: 0.06, 0.56), 
which is in the same direction and a similar magnitude that was previously identified in 
the model that included adaptive methods. These estimates indicate that there is a reduced 
odd ratio of a positive study for lung cancer studies in comparison to breast cancer. There 
was also a reduced odds ratio of a positive study for studies that include ‘other’ cancers in 
comparison to breast cancer, though not significant. These results are also consistent with 
the results were identified in hypothesis 2 when study design was included in the model 
(Table 20). A summary of the analysis can be found in Table 23.  
A similar forward stepwise analysis was conducted where key variables including 
adaptive design, disease condition and drug classification were forced to remain in the 
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final model. Similar results to all hypotheses and sensitivity analyses were noted and 
reported in Table 24. 
Table 23  
Forward Stepwise Model - Parameter Estimates 
Parameter DF Estimate 
Standard 
error 
95% 
confidence 
limits (CL) 
Odds 
ratio 
(OR) 
95%  
OR CL Chi-Square Pr > ChiSq 
Intercept 1 1.29 0.40 0.51 2.07 -- -- -- 10.40 0.0013 
Condition –  
lung 
neoplasms 
1 -1.73 0.58 -2.88 -0.58 0.18 0.06 0.56 8.75 0.0031 
Condition – 
other  
1 0.37 0.54 -0.69 1.42 1.45 0.50 4.14 0.46 0.50 
 
Table 24  
 
Forward Stepwise Model Including Key Variables (adaptive, cancer type, drug 
classification) - Parameter Estimates 
Parameter DF 
Esti-
mate 
Standard 
error 
95% confidence 
limits (CL) 
Odds ratio 
(OR) 
95% 
OR CL 
Chi-
square 
Pr > 
ChiSq 
Intercept 1 2.27 0.91 0.50 4.04 -- -- -- 6.29 0.01 
Adaptive 1 0.66 0.70 -0.70 2.03 1.93 0.50 7.61 0.90 0.34 
Drug classification           
Monoclonal 
antibodies 
1 -1.13 0.90 -2.90 0.64 0.32 0.06 1.90 1.57 0.21 
Platinum compounds 1 -0.61 1.07 -2.72 1.50 0.54 0.07 4.48 0.32 0.57 
Pyrimidine 
analogues 
1 0.91 1.12 -1.28 3.11 2.48 0.28 22.42 0.66 0.42 
Taxanes 1 -0.69 0.83 -2.32 0.94 0.50 0.10 2.56 0.69 0.41 
Cancer type           
Lung neoplasms 1 -2.47 0.89 -4.22 -0.72 0.08 0.01 0.49 7.63 0.01 
Other 1 -0.82 0.94 -2.67 1.02 0.44 0.07 2.77 0.76 0.38 
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Table 25  
Fit Statistics for Sensitivity Analysis Models 
Model AICC fit statistic 
Forward stepwise model 125.0 
Forward stepwise model including key variables (adaptive, 
cancer type, drug classification) 
133.0 
 
Summary 
The clinical trial database was used to assess the association between design 
methods in early phase studies and the possible association with late phase outcomes in 
oncology studies. The association was also examined in categories of cancer type and 
drug classification. Five hundred thirty seven randomly selected studies where included 
in this analysis and were classified on their design methods as well as the final outcome 
of the study. Most early phase studies where phase II (69.2%) and most late phase studies 
were phase III (92.6%). The most common cancers included in early stage studies were 
lung (12.9%), colorectal (12.9%), breast neoplasms (12.4%) and multiple myeloma 
(12.6%). Multiple cancer types were included in 8.0 percent of early phase studies. Most 
studies were intervention (99.2%), drug studies (95.8%) and industry sponsored (59.6%). 
A variety of drug treatments were used of which protein kinase inhibitors were found to 
be the most frequent (17.4%). Of the early phase studies, 76.9% and 23.1% were 
classified as using traditional and adaptive design methods respectively. Most of the 
studies in early and late stage had a favorable or equivalent outcome (Early: 60.5%; Late: 
60.0%).  
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Univariate analyses were conducted and adaptive design was not found to be 
associated with late stage outcome (p value=0.33). The only variable that was associated 
with late stage outcome was duration between studies. Studies that were greater than the 
Q3 apart in duration between studies had a reduced odds of a positive outcome in 
comparison to more recent studies (Q1 or less). No other variables were found to have an 
association with the late stage outcome, though specific cancer subtypes (multiple 
myeloma and prostatic) were found to be significant in comparison to other cancer types 
(p-values were less or equal to 0.05).  
Bayesian logistic regression analyses methods were used to assess the association 
between early phase design methods (adaptive versus traditional) and the outcome of the 
late phase studies. Convergence statistics were assessed and no concerns were noted. 
There was no statistical association (OR: 0.66, 95% HPD: 0.20, 1.21) between early 
phase adaptive design studies and the outcome of late phase studies, adjusting for the 
potential confounding factors duration between studies, primary funding source, 
biomarker endpoint and study phase. 
The association between early phase design studies and late phase outcome were 
assessed controlling for disease condition. In this model, while no cancer type was 
significant, lung cancer and other cancer had higher odds of positive outcome when 
adaptive methods were used in comparison to traditional (Lung - OR: 3.29, 95% HPD: 
0.13, 9.97; Other - OR: 7.65, 95% HPD: 0.15, 27.90). Breast had reduced odds of a 
positive outcome when adaptive methods were used in comparison to traditional 
methods, though not significant (OR: 0.04, 95% HPD: 0.0, >50). 
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Similarly, a Bayesian logistic analysis was conducted assessing the association of 
early phase design and late stage outcome controlling for drug classification. Drug 
classifications taxanes and other drug classification were found to be marginally 
significant, with a higher odds of positive results when adaptive methods were adopted. 
The odds ratio for protein kinase inhibitors was close to 0 though the 95% HPD was quite 
wide, indicating questionable robustness of the estimate. Sensitivity and additional 
analyses were conducted and results were consistent with the primary analysis. 
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Chapter 5: Discussion, Conclusions and Recommendations 
This quantitative observational study was used to investigate the potential 
association of early phase study design research outcomes that utilize traditional versus 
adaptive methods on late stage results in oncology clinical trials. As drug development 
and approval are based on cancer type and treatment classifications (Barabási et al., 2011; 
U. S. Food and Drug Administration, n.d.-b; Siddiqui & Rajkumar, 2012), these potential 
effect modifiers were examined to determine whether the association between use of 
adaptive versus traditional methods (i.e. 3+3) in early phase studies and the results 
outcome of the late stage study, was different in subgroups defined according to levels of 
these factors. 
When controlling for cancer type as well as drug class including confounding 
variables, a nonstatistically significant difference in the odds of a positive study using 
adaptive design methods versus traditional was identified. Lung and other cancers appear 
to have a greater odds of positive results when adaptive methods are used versus 
traditional design methods. Breast cancer studies that used adaptive methods appeared to 
have reduced odds of a positive study when adaptive methods were used in comparison to 
traditional methods. Drug classifications, specification monoclonal antibodies, taxane and 
other appeared to have marginal impact increasing the odds of a positive study when 
adaptive methods were used in comparison to traditional methods, as odds ratios were 
greater than 1 for these drug classifications. While significant for taxanes and other, 
estimates should be interpreted with caution for both. Taxanes were estimated to be 
marginally significant as the lower 95% HPD is 1.01, just slightly higher than 1.  In 
  
130 
addition, the other category was artificially created due to over-parameterization, thus 
likely heterogeneous. 
This chapter includes a discussion and interpretation of the study results in 
conjunction with findings reported in the literature. Advantages and disadvantages related 
to limitations of this study are described. Recommendations for future research are also 
included. 
Interpretation of the Findings 
The purpose of the study was to investigate the potential associate of early phase 
study designs (adaptive versus traditional) and late stage results in oncology clinical 
trials. The association of cancer type and drug classification with design methods used for 
early phase oncology studies and the outcome of the late stage clinical trial was assessed 
using statistical modeling. A summary and interpretation of the findings can be found 
below. 
Adaptive Design Methods 
The association of adaptive design in early phase studies with the outcome of late 
phase studies adjusting for confounding variables including duration between studies, 
funding source, study endpoint and phase was assessed. There was no statistically 
significant association between adaptive design methods in early phase studies with the 
outcome of late phase studies. The odds ratio indicated that there was a reduced 
probability of positive late stage study when adaptive methods were used in comparison 
to traditional methods. While these results are not statistically significant, simulations 
indicated that adaptive methods were effective in treatment identification 
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(Ananthakrishnan et al., 2017). Further research in larger studies or targeted populations 
should be considered. 
Drug Classification 
While my initial intent was to assess treatment classifications in this study, the 
lack of heterogeneity in the data did not allow for this analysis. Drug classifications were 
assessed and within each classification, there was a marginal association between the 
study design method and study outcome. While this study marginally showed that early 
phase study design, late phase study outcome and drug classification were associated, 
oncology clinical trial development should be considered an iterative process of study 
development from early phase to late phase as indicated by the Framework for Design 
and Evaluation of Complex Interventions (DECI). This study did not definitively find an 
association between the variables of interest, perhaps a larger study or a study within a 
specific population may find a relationship between the study design and the study 
outcome.  
Drug classification is just one component of the treatment development in 
oncology studies. Other confounding variables included in the initial model included type 
of endpoint, duration between studies, treatment classification and phase of study. Each 
identified and incorporated component indicates the complexity of oncology treatment 
development as well as the theoretical foundation of systems theory used to construct this 
study. While the change in drug treatment indicated marginal statistically significant 
difference when assessing the use of adaptive methods in early phase studies and the 
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influence on late stage results, the association of one component of clinical trial research 
with other components should not be ignored. 
 
Cancer Type  
By comparing adaptive versus traditional methods and the downstream clinical 
trial outcome, the possible benefits related to late stage study success were determined 
indicating that success in late stage studies may lead to improved treatment options for 
some cancers. Among breast cancer studies, there appeared to be lower odds of positive 
outcomes when adaptive methods were adopted in comparison to traditional methods.  
Lung and other cancers appear to have higher odds of positive outcomes when adaptive 
methods are used, though the results were not statistically significant. Using the study 
design and cancer type from early phase studies and assessing whether there is an 
association with the outcome of late phase studies is an indication of the complexities of 
oncology clinical trial development as well as the multiple considerations that must be 
addressed during treatment development.  The complexity of the cancer type, phase of 
study and study endpoint should be considered to develop a quality study. 
While the results of each hypothesis of this study were not statistically significant, 
further research should be conducted to assess the relationships. Further analyses of a 
larger sample size, a variety of cancer types and treatment plans would aid in identifying 
possible scenarios where adaptive methods are most effective. Using these results related 
to the first hypothesis of this study, in combination to the results of the second and third 
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hypothesis, additional research needs to be conducted to further understand the 
relationship of adaptive design method utilization and study outcome in oncology studies.  
 
 
Limitations of the Study 
All studies have limitations. However, the limitations may lead to future research, 
as more needs to be learned and addressed on the specific topic. The Clinical Trials 
database that I used in this research is quite extensive in the number of studies as well as 
the number of data points per study. However, limitations are evident in any archival 
data, specifically what was and what was not collected in the database as well as the 
format of the collected variables. For example, as has been reported by other researchers 
(Bothwell et al., 2018; Hatfield et al., 2016), the identification of adaptive studies in the 
Clinical Trial database is challenging and requires extensive manual review.  
Clinical Trials Database 
Many fields in the Clinical Trials database are free text format, thus varying text 
with the same message are frequently reported. The lack of consistent text made 
classification within variables difficult. As a result, in this research project, the 
classification of the study design methods, the study outcome, as well as basic study 
characteristics, such as phase of study and reason for termination were often 
supplemented with study publications or investigator contact for clarification when 
necessary. As such, while the database is informative on a study by study basis, 
aggregation and analysis of the database was very labor intensive as a result of formatting 
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and inconsistencies in text across studies. As a result of the key variables being labor 
intensive, a random sample of 381 studies were included in this analysis, rather than the 
3040 oncology studies that were reported to have results. Increased power and the ability 
to assess the influence of early phase adaptive design utilization on late phase outcomes 
may be more feasible with a larger sample size.  
As previous researchers have noted, overall the quality of the database is quite 
high (Hartung et al., 2014), however the capture of study design characteristics are 
inconsistently reported and limited with descriptive information (Anderson et al., 2015). 
Utilization of the clinical trials database as well as other databases collecting study details 
such as TrialTrove (Informa, n.d.) which was used in a recent publication by the Drug 
Information Association’s Adaptive Design Scientific Working Group (ADSWG) in 
order to summarize adaptive design clinical trial utilization (Hartford et al., 2018). A 
larger sample size using systematic rather than random study identification may be 
incorporated in future research when multiple registration databases are used, which 
could simplify the labor-intensive process of study classification. 
Delays in reporting of results in the Clinical Trials database have been noted 
(Anderson et al., 2015). In the current research, if a study did not have results, the study 
was automatically excluded from the analysis. Time until expected results were not 
assessed or summarized in this analysis for all studies. This exclusion criterion may have 
led to a biased sample. 
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Random Sample  
This study included the analysis a random subset of archival ClinicalTrials.gov 
data. As the entire database was not used, however, when using a random sample, the 
underlying expectation is that the sample will be representative of the entire database and 
of clinical trials as a whole. However, the sample included a reduced percentage of 
adaptive studies in comparison to other similar analyses (Bothwell et al., 2018; Hatfield 
et al., 2016; Lin et al., 2016). Researchers have previously noted that between 37% to 
42% of studies included in their analyses were adaptive (Bothwell et al., 2018; Hatfield et 
al., 2016).  The random sample included in this analysis included a lower rate of adaptive 
studies (27.6%). However, unlike the other studies, this study includes phase I studies 
and strictly oncology research, which likely contributed to the lower rate of adaptive 
studies identified.  
In addition, the random sample included a high percentage of positive outcome 
studies, which may indicate that bias may have been introduced when incomplete studies 
were removed from the analysis. Ideally, all oncology studies would be included in the 
analysis; however, due to the programmatic and manual data review, the sample size had 
to be limited for a timely analysis.  
Model Development and Assumptions 
One of the known benefits of adaptive studies is their ability to identify 
ineffective treatments earlier in comparison to traditional studies(Christopher S Coffey et 
al., 2012). To be included in the modeling of this analysis, early phase studies had to be 
matched on study characteristics, specifically treatment and/or disease condition 
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dependent on the hypothesis being assessed. As such, this study was conditional on 
treatments being available in late stage clinical trials, though not powered for this 
condition. This conditional sampling may be an area of future studies. The effectiveness 
of adaptive methods has been conducted in simulations (Bornkamp et al., 2007; Morgan 
et al., 2014) but a similar analysis has not been conducted on real data, as the feasibility is 
questionable. 
A further limitation of this study is that the late stage outcome was strictly based 
on the primary endpoint. While the primary endpoint was negative, significant clinical 
secondary endpoints may have been statistically or clinically significant thus impacting 
future studies. Secondary endpoints were not a consideration of this study and may have 
blurred study impact on future development, regardless of the primary endpoint outcome. 
Once again, this may be an area where additional analyses should be conducted. 
Recommendations 
Considerations and Documentation of Design Methods 
No study can address every issue related to a problem. Regardless of the study, 
further research is needed as a result of unanswered questions or questions raised during 
the study. With the increasing costs of healthcare and drug development, as well as the 
notable lag in the development of oncology clinical trials, adaptive design research 
should at a minimum be considered during the development phase of every clinical trial. 
While the design methods may not be appropriate for every situation, justification for not 
considering nontraditional designs should be considered and justification supporting or 
refuting the design should be well documented in trial records.  
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In addition, careful documentation and reporting of design methods (traditional 
versus adaptive) should be incorporated within the Clinical Trial database. With the 
definition of adaptive studies evolving over time, specifically when considering the 
recently released draft FDA adaptive design guidelines (U. S. Food and Drug 
Administration, 2018a) as well as the FDA master protocol guidelines for oncology 
studies (U. S. Food and Drug Administration, 2018b), documentation of the adaptive 
design definition that was utilized should also be reported in the database. With clearer 
documentation, further research could be conducted on the entire database and within 
diseases other than oncology. These additional analyses could aid in improving the 
understanding of the impact of adaptive methods as well as fully quantify their 
frequencies, benefits and limitations.  
The possible inaccuracies introduced when self-reporting design methods need to 
be addressed. Additional collaboration with perhaps the NIH, AACT-CTTI and the 
subject matter experts such as the DIA Adaptive Design Scientific Working group (Drug 
Information Association, n.d.), should aid in appropriate and consistent classification of 
all studies within the database. In order to truly assess the impact of adaptive studies and 
the influence on treatment development, consistent classification of studies with input 
from the experts in the field is needed. In addition, classification within the database 
would reduce redundant work classifying studies by CT.gov users and researchers.  
Study Endpoints 
Further research is also needed to assess effective quality endpoints including 
composites in adaptive and tradition settings. While overall survival is considered the 
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gold standard in oncology, other endpoints may be more reflective of treatment efficacy 
for the population of interest. In this study, only the primary outcome was assessed and 
utilized in the analysis, regardless of what endpoint or type of endpoint was used in the 
study. However, study designs such as gatekeeper methods, mixed or composite 
endpoints or multiple primaries should also be considered when assessing the impact of 
adaptive methods on study outcomes. In addition, incorporating secondary endpoints in 
the analysis should be considered, as they may impact the future of the treatment, 
regardless of what the results of the primary endpoint is particularly in early phase 
studies. 
Continued Education 
A longitudinal qualitative study or a survey on clinical trial researchers should be 
conducted in the future to assess the researcher’s perceived barriers on the adoption of 
adaptive methods. While this type of research has been conducted at a single point in 
time (Morgan et al., 2014), extended follow up would allow an assessment of perceived 
evolution of adaptive design barriers over time. Recently the Drug Information 
Association’s Adaptive Design Scientific Working Group (ADSWG) published a survey 
about adaptive method use and changes (Hartford et al., 2018). The survey included 
questions about adaptive design use and perceived barriers.  
In addition, as new researchers enter the field, this research could aid in 
illuminating similarities and differences within and across cohorts of interest, which 
would aid in future education development planning. The study could also lead to the 
development of appropriate adaptive design training developed for the specific audience 
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of interest, improving general knowledge on the topic at the university as well as 
continuing education programs. Using the research from the ADSWG on identified 
barriers would aid in training development. 
Implications 
Sharing of Results and the Data 
In order to continue making progress in oncology clinical trials as well as 
reducing the incidence of similar treatment failures in targeted populations, quality meta-
analyses, publicly available data of past studies need to be conducted on a regular basis 
and those results need to be shared. The Clinical Trials database as well as journal 
requirements for study registration has increased the opportunity for design, data and 
results sharing reducing the possible impact of publication bias. While individual clinical 
trials are important, appropriate meta-analyses need to be conducted in order to assess 
study trends with respect to safety, efficacy and noted trends and that have been reported. 
Additional information may be gleaned from the combined studies with the availability of 
increased information, sample size and power.  
Sharing of information within programs is critical. However, sharing of 
information across programs, including with competitors is also important to continue 
moving the field forward and reduce the number of patients exposed to ineffective 
treatment. Researchers have reported results that furthered the treatment of oncology 
patients. The Clinical Trials results database should improve in sharing of results and 
information, however all studies should be required to share results to aid in future meta-
analyses in all indications. These combined results should aid in moving the field forward 
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in oncology and allow for greater assessment of short term and long term efficacy and 
safety in the patient population or targeted treatment. Sharing of positive or negative 
results in a timely manner may reduce the rate of repeated study failures thus improve 
patient treatment options in the future. 
Consideration of Adaptive Design Methods 
While this analysis is only the beginning of assessing populations and treatments 
where adaptive methods can be used, further analyses are needed. In addition, researchers 
must continue to learn about new treatments, patient risks and predictive factors, but also 
newer design methods should be assessed. In order for treatment options to continue to be 
developed for the patient population, each component of the research field must be 
evaluated. The overall assessment and the adoption of possible new methods may lead to 
progress in every component of clinical research, including analysis and design methods. 
The quality of clinical research needs to continue to improve in order to increase the odds 
effective treatment options for the patient population. 
Conclusion 
This study assessed the possible relationship between early stage design methods 
and the outcome of late stage studies. The influence of cancer disease type and drug 
classification was also incorporated into the study and was found that there was a varying 
odds of a positive (lung and other cancer) and negative (breast) outcome in the late stage 
study when adaptive methods were utilized, though not significant or with wide credible 
intervals indicating estimates may not be robust. Drug classification appeared to have 
minimal influence on the relationship between early phase adaptive design utilization and 
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late stage study outcomes. These results indicate that further research in assessing design 
methods should be conducted. However, improved and consistent design reporting is 
needed to aid in the continued area of research. 
Continuing to expand the Clinical Trials database as well as other databases by 
ex-United States regulatory bodies leads to shared information and additional analyses 
increasing knowledge. Meta-analyses and data sharing should increase patient and 
treatment related expertise in the field and hopefully improved treatment options for 
oncology patients as well as patients with other disease types as well. These types of 
analyses also utilized limited financial resources particularly in comparison to clinical 
research themselves and still continue to move the field forward with the aggregated 
analyses. However, registry database administrators should continue to assess the quality 
of their database as well as methods to improve the quality and accessibility to allow for 
expanded research. 
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Appendix A: Definition of Acronyms 
  
Acronym Definition 
AACR American Association for Cancer Research 
AACT Aggregate Analysis of ClinicalTrials.gov 
ADSWG Adaptive Design Scientific Working Group 
AIC Akaike information criteria 
AICC Akaike information criteria corrected for bias 
ATC Anatomical-Therapeutic-Chemical 
BIO Biotechnology Innovation Organization 
CBER Center for Biologics Evaluation and Research 
CDER Center for Drug Evaluation and Research 
CHMP Committee for Medicinal Products for Human Use 
CL Confidence limits 
CRB Central Review Boards 
CRM Continual Reassessment Method 
CT Clinical Trials 
CTTI Clinical Trials Transformation Initiative 
DECI Design and Evaluation of Complex Interventions 
Df Degrees of freedom 
DIA Drug Information Association 
DIC Deviance Information Criterion 
DLT Dose limiting toxicities 
DMC Data monitoring committee 
ESS Effective Sample Size 
FDAAA Food and Drug Administration Amendment Act 
FDA Food and Drug Administration 
FDAMA Food and Drug Modernization Act 
HER2 Human epidermal growth factor receptor 2 
HHS United States Department of Health and Human Services 
HPD Highest posterior density 
IRB Internal Review Boards 
I-SPY Investigation of Serial Studies to Predict Your Therapeutic 
Response with Imaging and moLecular Analysis 
MCMC Monte Carlo Markov Chain 
MeSh Medical Subject Heading 
MTA Molecularly targeted agents 
MTD Maximum tolerated dose 
NCI United States National Cancer Institute 
NE Not estimable 
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NIH United States National Institute of Health 
OECD Organisation for Economic Co-operation and Development 
OR Odds ratio 
OS Overall survival 
PFS Progression free survival 
PhRMA Pharmaceutical Research and Manufacturers of America 
PLM Postfitting analysis for very general linear models 
Q1 First quartile 
Q3 Third quartile 
RCT Randomized clinical trials 
Ref Reference group 
RP2D Recommended phase two dose 
RR Relative risk 
SOC Standard of care 
SPP Survival post progression 
SSR Sample Size Reassessment 
US United States 
WHO World Health Organization 
WHOCC World Health Organization Collaboration Center 
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Disease condition Frequency Percent 
Anal Neoplasms 11 1.35 
Appendiceal Neoplasms 2 0.25 
Biliary Tract Neoplasms 4 0.49 
Brain Neoplasms 3 0.37 
Breast Neoplasms 123 15.09 
Cervical Neoplasms 5 0.61 
Cholangiocarcinoma 1 0.12 
Colorectal Neoplasms 98 12.02 
Digestive System Neoplasms 1 0.12 
Endometrial Neoplasms 3 0.37 
Esophageal Neoplasms 3 0.37 
Fallopian Tube Neoplasms 6 0.74 
Gastrointestinal Neoplasms 10 1.23 
Head and Neck Neoplasms 25 3.07 
Liver Neoplasms 4 0.49 
Lung Neoplasms 117 14.36 
Lymphoma 1 0.12 
Lymphoma, NonHodgkin 4 0.49 
Melanoma 6 0.74 
Mouth Neoplasms 1 0.12 
Multiple Myeloma 102 12.52 
Neoplasm Metastasis 2 0.25 
Neoplasms 3 0.37 
Neoplasms, Glandular and Epithelial 3 0.37 
Neoplasms, Second Primary 3 0.37 
Neoplasms, Solid 14 1.72 
Nervous System Neoplasms 1 0.12 
Neuroendocrine Tumors 2 0.25 
Neuroendocrine Tumour 2 0.25 
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Disease condition Frequency Percent 
Oropharyngeal Neoplasms 9 1.10 
Ovarian Neoplasms 38 4.66 
Pancreatic Neoplasms 48 5.89 
Penile Neoplasms 8 0.98 
Peritoneal Neoplasms 4 0.49 
Prostatic Neoplasms 77 9.45 
Salivary Gland Neoplasms 1 0.12 
Skin Neoplasms 5 0.61 
Stomach Neoplasms 18 2.21 
Testicular Germ Cell Tumor 5 0.61 
Thyroid Neoplasms 4 0.49 
Urethral Neoplasms 2 0.25 
Urinary Bladder Neoplasms 9 1.10 
Urogenital Neoplasms 2 0.25 
Urologic Neoplasms 2 0.25 
Uterine Cervical Neoplasms 8 0.98 
Uterine Neoplasms 5 0.61 
Uveal Neoplasms 2 0.25 
Vaginal Neoplasms 8 0.98 
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Treatment Classification Frequency Percent 
Anti-Hpv-16 4 0.49 
852a 4 0.49 
Abemaciclib 4 0.49 
Abiraterone 10 1.23 
Adavosertib 1 0.12 
Afatinib 2 0.25 
Aflibercept 9 1.10 
Aldesleukin 13 1.60 
Alectinib 4 0.49 
Alisertib 3 0.37 
Alpharadin 3 0.37 
Anastrozole 3 0.37 
Androgen 1 0.12 
Anti-Hpv-16 1 0.12 
Apatinib 1 0.12 
Apatorsen 1 0.12 
Atezolizumab 7 0.86 
Axitinib 1 0.12 
Azacitidine 2 0.25 
Azd4547 1 0.12 
Azd4877 1 0.12 
Bendamustine 2 0.25 
Bevacizumab 13 1.60 
Bicalutamide 1 0.12 
Binimetinib 1 0.12 
Birinapant 3 0.37 
Bortezomib 14 1.72 
Buparlisib 3 0.37 
Burixafor 2 0.25 
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Treatment Classification Frequency Percent 
Cabazitaxel 7 0.86 
Cabozantinib 5 0.61 
Camptothecin 6 0.74 
Capecitabine 14 1.72 
Capivasertib 3 0.37 
Carboplatin 21 2.58 
Carfilzomib 8 0.98 
Carmustine 1 0.12 
Carotuximab 1 0.12 
Cediranib 1 0.12 
Celecoxib 1 0.12 
Ceritinib 2 0.25 
Cetuximab 7 0.86 
Cisplatin 27 3.31 
Clarithromycin 1 0.12 
Crizotinib 3 0.37 
Custirsen 1 0.12 
Cyclophosphamide 25 3.07 
Cytarabine 1 0.12 
Dabrafenib 1 0.12 
Dacarbazine 1 0.12 
Dacomitinib 2 0.25 
Dactolisib 2 0.25 
Daratumumab 4 0.49 
Denosumab 2 0.25 
Dexamethasone 19 2.33 
Dkn-01 3 0.37 
Docetaxel 22 2.70 
Dovitinib 4 0.49 
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Treatment Classification Frequency Percent 
Doxorubicin 8 0.98 
Durvalumab 1 0.12 
Dutasteride 1 0.12 
Elotuzumab 2 0.25 
Enzalutamide 9 1.10 
Epacadostat 1 0.12 
Eribulin 4 0.49 
Erlotinib 12 1.47 
Etoposide 5 0.61 
Everolimus 3 0.37 
Evofosfamide 2 0.25 
Exemestane 2 0.25 
Figitumumab 2 0.25 
Filgrastim 8 0.98 
Fludarabine 13 1.60 
Fluorothymidine 5 0.61 
Fluorouracil 20 2.45 
Flutamide 1 0.12 
Fosbretabulin Tromethamine 3 0.37 
Fulvestrant 4 0.49 
Ganetespib 3 0.37 
Gedatolisib 1 0.12 
Gefitinib 3 0.37 
Gemcitabine 22 2.70 
Glidescope 1 0.12 
Glufosfamide 1 0.12 
Goserelin 2 0.25 
Hydroxychloroquine 1 0.12 
Ibandronate 1 0.12 
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Treatment Classification Frequency Percent 
Ifosfamide 2 0.25 
Imalumab 1 0.12 
Imatinib 1 0.12 
Indusatumab Vedotin 1 0.12 
Inebilizumab 1 0.12 
Ipilimumab 1 0.12 
Irinotecan 13 1.60 
Isis 183750 1 0.12 
Ixazomib 2 0.25 
Krn330 2 0.25 
Kw-2478 1 0.12 
Lapatinib 5 0.61 
Lcl161 1 0.12 
Lenalidomide 13 1.60 
Lenvatinib 1 0.12 
Letrozole 5 0.61 
Leucovorin 11 1.35 
Leuprolide 6 0.74 
Levocetirizine 1 0.12 
Levofolinate 2 0.25 
Linsitinib 1 0.12 
Loratadine 1 0.12 
Luminespib 1 0.12 
Lutetium Lu 177 Dotatate 2 0.25 
Lymphocyte Depleting Prep Regimen 1 0.12 
Melatonin 1 0.12 
Melitac 12.1 Peptide Vaccine 1 0.12 
Melphalan 3 0.37 
Mitomycin 3 0.37 
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Treatment Classification Frequency Percent 
Mk2206 7 0.86 
Mln0264 1 0.12 
Mm-111 1 0.12 
Nab-Paclitaxel 8 0.98 
Nadofaragene firadenovec 1 0.12 
Naproxen 1 0.12 
Necitumumab 3 0.37 
Neratinib 1 0.12 
Nilotinib 2 0.25 
Nintedanib 4 0.49 
Nivolumab 5 0.61 
Nsaid 1 0.12 
Octreotide 2 0.25 
Olaparib 4 0.49 
Orteronel 3 0.37 
Osimertinib 4 0.49 
Other 11 1.35 
Oxaliplatin 14 1.72 
Paclitaxel 27 3.31 
Pacritinib 1 0.12 
Palbociclib 5 0.61 
Panobinostat 1 0.12 
Patritumab 1 0.12 
Pazopanib 1 0.12 
Pegfilgrastim 1 0.12 
Pembrolizumab 4 0.49 
Pemetrexed 5 0.61 
Pertuzumab 10 1.23 
Pictilisib 1 0.12 
  
177 
Treatment Classification Frequency Percent 
Plerixafor 2 0.25 
Pomalidomide 3 0.37 
Ponatinib 1 0.12 
Prednisolone 1 0.12 
Prednisone 16 1.96 
Psma Adc 2 0.25 
Ramucirumab 7 0.86 
Regorafenib 3 0.37 
Relugolix 1 0.12 
Ribociclib 1 0.12 
Rocuronium 1 0.12 
Roflumilast 1 0.12 
Rosuvastatin 1 0.12 
Ruxolitinib 7 0.86 
Surgery 1 0.12 
Satraplatin 1 0.12 
Saw Palmetto 1 0.12 
Selinexor 1 0.12 
Selumetinib 6 0.74 
Serabelisib 1 0.12 
Siltuximab 1 0.12 
Sodium Deoxyribonucleate 1 0.12 
Sonidegib 1 0.12 
Sorafenib 2 0.25 
Sotrastaurin 1 0.12 
Sulfasalazine 1 0.12 
Sunitinib 6 0.74 
Surgery 1 0.12 
Talazoparib 2 0.25 
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Treatment Classification Frequency Percent 
Tamoxifen 1 0.12 
Tasquinimod 1 0.12 
Tavokinogene Telseplasmid 1 0.12 
Tecemotide 1 0.12 
Tegafur/Gimeracil/oteracil 1 0.12 
Temozolomide 3 0.37 
Temsirolimus 2 0.25 
Testosterone Cypionate 1 0.12 
Thalidomide 2 0.25 
Tigatuzumab 1 0.12 
Tivantinib 1 0.12 
Tivozanib 2 0.25 
Topotecan 1 0.12 
Trabectedin 1 0.12 
Trametinib 4 0.49 
Trastuzumab 24 2.94 
Triptorelin 2 0.25 
Vandetanib 2 0.25 
Veliparib 5 0.61 
Vemurafenib 2 0.25 
Vinorelbine 3 0.37 
Vismodegib 1 0.12 
Visualase Thermal Therapy 1 0.12 
Vorinostat 3 0.37 
Young Tumor-Infiltrating Lymphocytes 5 0.61 
Young Tumor-infiltrating lymphocytes 1 0.12 
Zilver Stent 1 0.12 
Zoledronic Acid 1 0.12 
[6r] 5,10-Methylenetetrahydrofolate 1 0.12 
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Appendix D: Hypothesis 2 Additional Analyses 
 
 
 
Influence on Adaptive Design Estimates in a Bivariate Analysis of Specified Covariate with Late Stage 
Results as Outcome 
Favorable/Unfavorable 120/76 
Univariate Covariate DF Estimate Standard 
Error 
(SE) 
Odds Ratio (OR) 
and 95% 
Confidence 
Interval (CI) 
Overall P-
value/ 
P-value 
Experimental treatment classification  
 
1 NE NE NE Most studies 
were drug 
trials, so 
limited 
variability for 
this analysis. 
      
Cancer type      0.21 
 Breast  1 -0.34 0.36 0.44 (0.32,1.54) 0.34 
 Colorectal 1 0.34 0.49 0.87 (0.08, 2.43) 0.49 
 Head and neck 1 0.08 0.67 0.67 (0.13, 5.71) 0.91 
 Lung  1 -0.48 0.36 0.38 (0.07, 2.17) 0.19 
 Multiple myeloma 1 1.22 0.62 2.08 (0.27, 16.26) 0.05 
 Neoplasms, Solid 1 0.48 0.64 1.00 (0.13, 7.89) 0.45 
 Ovarian 1 0.04 0.40 0.64 (0.11, 3.76) 0.92 
 Pancreatic 1 -0.62 1.29 0.33 (0.01, 8.18) 0.63 
 Prostatic 1 -1.20 0.60 0.19 (0.03, 1.40) 0.04 
 Other --- --- --- --- --- 
Experimental drug classification  
 
    
0.32 
 Anthracyclines and related 
substances 
--- NE NE NE NE 
 Anti-androgens --- NE NE NE NE 
 Corticosteroids --- NE NE NE NE 
 Folic acid metabolite --- NE NE NE NE 
 Glucocorticoids --- NE NE NE NE 
 Monoclonal antibodies --- NE NE NE NE 
 Nitrogen mustard analogues --- NE NE NE NE 
 Other alkylating agents --- NE NE NE NE 
 Other antineoplastic 
agents 
--- NE NE NE NE 
 Other hormone antagonists 
and related agents 
--- NE NE NE NE 
 
 
Other  
immunosuppressants 
--- NE NE NE NE 
 Platinum compounds --- NE NE NE NE 
 
 
Protein kinase  
inhibitors 
--- NE NE NE NE 
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Influence on Adaptive Design Estimates in a Bivariate Analysis of Specified Covariate with Late Stage 
Results as Outcome 
Favorable/Unfavorable 120/76 
 Pyrimidine analogues --- NE NE NE NE 
 Taxanes  NE NE NE NE 
 Other --- --- --- --- --- 
Duration between studies (months)     0.03 
Quartile 4 1 -0.62 0.25 0.33 (0.14, 0.78) 0.01 
Quartile 3 1 0.37 0.27 0.90 (0.37, 2.2 0.17 
Quartile 2 1 -0.23 0.25 0.49 (0.21, 1.15) 0.36 
Quartile 1 (reference) --- --- --- --- --- 
      
Study funding      0.25 
Industry 1 -0.29 0.44 0.59 (0.32, 1.10) 0.51 
NIH 1 0.05 0.83 0.83 (0.07, 9.71) 0.95 
Other --- --- --- --- --- 
      
Sensitivity Variables      
Type of endpoint      
 
--- 
Surrogate --- NE NE NE NE 
Clinical --- NE NE NE NE 
      
Sample size     0.48 
 1 -0.003 0.004 1.00 (0.99, 1.01) 0.46 
 
Biomarker      0.64 
Yes 1 0.17 0.3556 1.40 (0.35, 5.64) 0.64 
No --- --- --- --- --- 
 
 
Table A4 
Full Analysis of Hypothesis Two 
 
 
  
Output 15: Logistic Analysis: outcome= intercept adaptive_n + covar=condition_fn 
adaptive_n*condition_fn (Hypothesis 2: Adaptive  versus Traditional Full Model - Disease condition and 
interaction) 
Thin=2, nbi=5000, nmc=50000 
 
The FREQ Procedure 
 
 
09:30  Saturday, May 18, 2019  1 
Table of outcome_n by condition_fn 
outcome_n condition_fn 
Frequency 
Percent 
Row Pct 
Col Pct 
Breast 
Neoplasms 
Lung 
Neoplasms Other Total 
0 8 
6.90 
25.81 
21.62 
14 
12.07 
45.16 
60.87 
9 
7.76 
29.03 
16.07 
31 
26.72 
 
 
1 29 
25.00 
34.12 
78.38 
9 
7.76 
10.59 
39.13 
47 
40.52 
55.29 
83.93 
85 
73.28 
 
 
Total 37 
31.90 
23 
19.83 
56 
48.28 
116 
100.00 
 
 
biomarker 
biomarker Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
0 1 0.86 1 0.86 
1 115 99.14 116 100.00 
 
 
surrogate 
surrogate Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
1 116 100.00 116 100.00 
 
 
clinical 
clinical Frequency Percent 
Cumulative 
Frequency 
Cumulative 
Percent 
1 116 100.00 116 100.00 
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Appendix E: Hypothesis 3 – Additional Analyses  
Table A5 
Full Analysis of Hypothesis Three 
 
 
  
Output 15: Logistic Analysis # 15: outcome= intercept adaptive_n + covar=drug_class_cat2 (Hypothesis 3: 
Adaptive  versus Traditional Full Model - Drug class) 
Burn in=8000, MCMC simulations=50000 
 
The FREQ Procedure 
 
 
05:58  Sunday, May 19, 2019  1 
Table of outcome_n by drug_class_cat2 
outcome_n drug_class_cat2 
Frequency 
Percent 
Row Pct 
Col Pct 
Monoclonal 
antibodies Other 
Protein 
kinase 
inhibitors Taxanes Total 
0 28 
12.07 
34.15 
46.67 
23 
9.91 
28.05 
25.27 
11 
4.74 
13.41 
84.62 
20 
8.62 
24.39 
29.41 
82 
35.34 
 
 
1 32 
13.79 
21.33 
53.33 
68 
29.31 
45.33 
74.73 
2 
0.86 
1.33 
15.38 
48 
20.69 
32.00 
70.59 
150 
64.66 
 
 
Total 60 
25.86 
91 
39.22 
13 
5.60 
68 
29.31 
232 
100.00 
 
 
Table of outcome_n by adaptive_n 
outcome_n adaptive_n 
Frequency 
Percent 
Row Pct 
Col Pct 0 1 Total 
0 63 
27.16 
76.83 
34.05 
19 
8.19 
23.17 
40.43 
82 
35.34 
 
 
1 122 
52.59 
81.33 
65.95 
28 
12.07 
18.67 
59.57 
150 
64.66 
 
 
Total 185 
79.74 
47 
20.26 
232 
100.00 
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Appendix F: Framework Figure Permission for Reprint from Author  
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